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SUMMARY
Aberrant calcium handling in cardiomyocytes, linked to ryanodine receptor (RyR) dysfunction, 
causes cardiac arrhythmias underlying catecholaminergic polymorphic ventricular tachycardia 
(CPVT) and heart failure. CPVT links to point mutations in specific domains of the cardiac 
ryanodine receptor (RyR2). Similar mutational clusters in RyR1 (skeletal muscle) cause malignant 
hyperthermia and central core disease suggesting common mechanisms of dysfunction underlying 
cardiac and skeletal muscle pathologies, leading to the domain interaction hypothesis. Peptides 
complimentary to N-terminus and central domain mutational clusters activate RyR by disrupting 
interaction. RyR1/2 is regulated by calcium, ATP, magnesium, phosphorylation and the accessory 
protein FKBP12/12.6. Previous work, on RyR1/2 modulation, assessing phosphorylation in relation 
to FKBP12/12.6 stabilisation of channel activity, indicates convergent regulation involving control of 
domain interaction sites by phosphorylation, FKBP12/12.6 and other modulators. This study used a 
central domain peptide (DP4) and its mutant form (DP4M) to investigate the relationship between 
FKBP12, phosphorylation, and other modulators to identify this region of convergent regulation. 
Native RyR1 channels, stripped of endogenous FKBP12 and phosphorylated or dephosphorylated, 
were shown, by [3H]ryanodine binding, to be fully functional and to be activated by calcium and 
ATP. FKBP12 and magnesium were each shown to inhibit channel activity, and phosphorylation 
reversed magnesium inhibition. DP4, peptide, synthesised from two sources, activated RyR1 2-fold 
in the presence of pM calcium, less than the activity observed with ATP. Magnesium and FKBP12 
inhibited RyR1 activation by DP4. In contrast to previous studies, DP4M was not an inactive control 
peptide. To investigate this discrepancy, recombinant GST-tagged (R-)DP4M and (R-)DP4 were 
generated and neither showed an activatory effect. However, once cleaved of GST, the R-DP4 was 
as potent as synthetic DP4 at 10 pM. Experiments with RyR2 demonstrated similar results for 
calcium and ATP activation with inhibition by FKBP12.6. The RyR2 central domain peptide (DPc10) 
has been cloned and the protein produced.
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CHAPTER 1; General Introduction
Aberrant calcium handling in skeletal myocytes, manifesting as the condition malignant 
hyperthermia (MH), results in patients responding to volatile anaesthetics with skeletal muscle 
rigidity, tachycardia, and rising blood pressure which may eventually lead to death if not treated 
quickly (MacLennan and Phillips 1992). A number of mutations have identified the ryanodine 
receptor type 1 gene (RyR1)  as the causal gene for this condition and also central core disease 
(CCD), which is a congenital myopathy (MacLennan, Duff et al. 1990; McCarthy, Healy et al. 1990; 
Zhang, Chen et al. 1993). CCD symptoms involve hypotonia (decreased muscle tone) and muscle 
weakness that is present in infancy and leads to a delay in achieving motor milestones. Patients 
with CCD are at high risk of suffering MH during anaesthesia (Zhang, Chen et al. 1993). RyR1 
mutations in MH/CCD have been found to result in abnormal calcium channel gating that alters the 
channels ability to inactivate and hence induces potentially fatal arrhythmia (Denborough 1998).
In 2001, the first report of a disease linked mutation in RyR2 was published (Priori, Napolitano et al. 
2001). Many more have been discovered since, in analogous regions to those in RyR1 found to 
cause MH/CCD (Marks, Priori et al. 2002). In RyR2 these mutations manifest as arrhythmogenic 
right ventricular dysplasia (ARVD) or catecholaminergic polymorphic ventricular tachycardia 
(CPVT) (Priori, Napolitano et al. 2001). CPVT patients exhibit no abnormal phenotype at rest, 
however, may suffer lethal arrhythmia triggered by physical or emotional stress (Priori, Napolitano 
et al. 2002).
The pathological role of CPVT-linked RyR2 mutations has been evaluated and shown to result in 
similar channel hyperactivity to that seen in MH. The nature of the arrhythmias common to CPVT 
and MH are also a common feature of heart failure (HF) (Yano, Yamamoto et al. 2005) and thus 
modulation of RyR1/2 functionality has been the subject of extensive medical research since the 
discovery that this calcium channel is a crucial factor in cardiac disease and sudden cardiac death 
(SCD) (Phrommintikul and Chattipakorn 2006).
2
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1.1 What is the ryanodine receptor?
The RyR was first discovered in 1985 by Fleischer et al. when the plant alkaloid ryanodine, used 
commonly as an insecticide as it lead to irreversible muscle contractures, was suspected of 
influencing the calcium handling of contractile cells (Fleischer, Ogunbunmi et al. 1985). At the time 
of discovery little was known about the mechanism involved in calcium release from the cellular 
calcium store, the sarcoplasmic reticulum (SR) in the process of muscle contraction. Ryanodine at 
nM concentrations was found to block the ability of ruthenium red to inhibit calcium release and 
was able to stabilise and maintain calcium release from the SR, using purified fractions of SR from 
rabbit skeletal muscle (twitch muscle). These were analysed and radiolabelled [3H]ryanodine used 
to isolate the binding region to the terminal cisternae of the SR. Further work by this group lead to 
the identification of the ‘ryanodine receptor’ as a calcium release channel and designated the ‘foot 
structure’, which could be seen in electron microscopy sections of skeletal muscle, located across 
the triad junction, as the protein through which the calcium signal passed (Figure 1.1). The foot 
structure was noted to respond directly to the signal from transverse tubules and to cause the 
release of calcium from the junctional face membrane of the SR (Inui, Saito et al. 1987).
Figure 1.1 Electron micrograph showing a central t-tubule in a triad 
junction section. The tubule is flanked on either side by a terminal 
cisternae element o f the SR. Arrows indicate the electron dense 
junctional feet spanning the junctional gap (Franzini.C 1970).
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The RyR was first purified from the SR by Makoto Inui using a CHAPS detergent supplemented 
with phospholipid to solubilise the membrane and was visualized using electron microscopy (Inui, 
Saito et al. 1987). The size of the RyR polypeptide was estimated by northern blot analysis to be 
about 550 kilodaltons (kDa) (Marks, Tempst et al. 1989), but the mass of the receptor was found to 
be 2.3 ± 0.3 megadaltons using scanning electron microscopy of unstained receptors, making it the 
largest channel known (Fleischer 2008). Once the full amino acid sequence became available for 
skeletal muscle RyR, the size was confirmed as 565.233 kDa (Takeshima, Nishimura et al. 1989). 
This difference was reconciled by the suggestion that dividing 565,000 into 2.3 million meant that 
the RyR existed as a homotetramer, consisting of four identical subunits. Further evidence for the 
existence of the RyR homotetramer was found by Lai et al in 1988 who successfully purified the 
receptor from native tissue using sucrose density gradient centrifugation and used zwitterionic 
detergent to generate RyR monomers (Lai, Erickson et al. 1988). The RyR from the heart was also 
purified and the mass found to be similar to that for skeletal muscle (Otsu, Willard et al. 1990).
Three different isoforms of the RyR have been cloned. These have been designated as skeletal 
(RyR1) (Takeshima, Nishimura et al. 1989), cardiac (RyR2) (Otsu, Willard et al. 1990; Tunwell, 
Wickenden et al. 1996) and brain (RyR3) (Jeyakumar, Copello et al. 1998), although combinations 
of different isoforms do exist in specific tissue, these are the tissues from which the isotypes were 
originally cloned. The amino acid sequences of all three isoforms share a high degree of sequence 
homology (66-70%). Major variations occur in three regions known as divergent regions 1, 2 and 3. 
-90%  of the RyR polypeptide chain forms the cytoplasmic domain that modulates channel function. 
The remaining 10% of the channel sequence (C-terminal region) forms the transmembrane and 
pore regions (Sorrentino and Volpe 1993).
1.2 Excitation- contraction coupling in muscle
Excitation-contraction coupling (ECC) is the process by which an electrical excitation of a 
contractile cell (myocyte) results in a physical movement of the muscle tissue (Bers 2002). This is a 
particularly important cycle when considering cardiac muscle, which results in the rhythmical 
contraction of the heart to propel blood around the body. Calcium is an essential messenger in
4
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ECC as it is the direct activator of the myofillaments, actin and myosin, which cause the cellular 
contraction (Bers 2004)
1.3 Compartmentalisation
Skeletal and cardiac myocytes have a highly organised and typical intracellular architecture. This 
organisation is vitally important to the process of ECC (Bers 2004). The mammalian skeletal 
muscle fibre (myofibre) consists of hundreds of myofibrils which extend the full length of the 
myofibre (possibly many centimetres long and -100 pm diameter). Myofibrils consist of linear 
arrays of sarcomeres, the fundamental units of muscle contraction. Thick myosin filaments slide 
between thin filaments, which consist of actin and regulatory subunits such as troponin or 
tropomyosin, to result in the shortening of the sarcomere during muscular contraction (Fleischer 
2008). In spite of the large size of the myofibre, the depolarization is rapidly transferred 
longitudinally along the full length of the fibre, as well as transversely along the transverse tubules, 
to within the muscle fibre. Transverse tubules are invaginations of the plasma membrane 
(sarcolemma) and are associated with the SR, forming a network system (Brette and Orchard 
2003). The transverse tubules are junctionally associated with the terminal cisternae of the SR to 
form an intracellular junction or triad junction (Saito, Seiler et al. 1984). The ‘foot’ region of the RyR 
sits between these two membranes, with its transmembrane region passing through the SR 
membrane so that the luminal portion is immersed in the cellular calcium store (Franzini-Armstrong, 
Protasi et al. 1999). Skeletal muscle contraction does not require external calcium for activation 
(depolarisation induced calcium release), however the cardiac muscle of the heart is dependent on 
calcium influx via the voltage gated L-type calcium channel (LCC) in the sarcolemma to trigger 
further calcium release from the SR (calcium induced calcium release- CICR) via RyR2, a term first 
proposed by Fabiato et al in 1979 (Fabiato and Fabiato 1979). Skeletal muscle RyR(1) is 
mechanically linked to the LCC, via allosteric interaction, meaning that activation of the LCC opens 
the RyR directly (Cheng, Altafaj et al. 2005).
5
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Figure 1.2 Structure of a skeletal myocyte. T-tubules enable the
sarcolemma to connect to the ends of each myofibril. Inset: Structure ol
the ‘foot’ region (Garrett and Grisham 1998).
Cardiac myocytes are smaller in size than skeletal myocytes, about 10-20 pm in diameter and 
-100 pm long. In heart tissue, the cardiomyocytes are connected to one another at their 
longitudinal ends by junctions referred to as intercalated discs. The signal for depolarisation is
transferred from one cardiomyocyte to another via gap junctions, in the intercalated discs. This
assembly enables the action potential to pass from one cardiomyocyte to another, resulting in one 
signal being effective over long distances. In mammalian skeletal muscle, the triads are found at 
the junction between the A and the I band of the sarcomere (Figure 1.2B), whereas cardiomyocytes 
form diads rather than triads between the t-tubules and the SR at the Z lines, which are the borders 
which separate and link sarcomeres within a myocyte (Fleischer 2008).
Cardiomyocytes obtain their energy from mitochondrial oxidative phosphorylation. Mitochondria 
make up approximately 35% of the total cell mass of the myocyte. They are also known to have the 
capacity to bind and take up large amounts of cytosolic calcium and therefore play a role in the
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buffering of cytosolic calcium, helping to protect the myocyte from the potential arrhythmogenic 
effects of calcium overload (Walker and Spinale 1999; Bers 2002).
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Figure 1.3 Structural representation of a section through a myocyte.
The invaginations from the plasma membrane form the t-tubules. These 
enter the myofibrils at the Z-disks, connecting the terminal cisternae ol 
the SR, forming the triad junctions. The SR tubules, which store calcium, 
form a network over the A band (Lodish, Berk et al. 2000).
1.4 RyR macromolecular complex
RyRs form 2D arrays at the terminal cisternae of the junctional SR with clusters of up to 100 
molecules in each array (Franzini-Armstrong, Protasi et al. 1999). These form a couplon together 
with the LCC and sodium/calcium exchange protein (NCX) (Stern, Song et al. 1999) and this 
functional calcium release unit may actually be centred on up to 10 neighbouring RyR molecules at 
any one junction (Cheng, Lederer et al. 1993). RyR has an important role as a scaffolding protein, 
producing a huge macromolecular complex with many regulatory proteins. It associates with FK506 
binding protein (FKBP12/12.6), protein kinase A (PKA), protein phosphatases 1 (PP1) and 2A 
(PP2A), calmodulin, calmodulin kinase II (CaMKII) and the phosphodiesterase PDE4D3. Junctin 
and triadin anchor calsequestrin and bind to the luminal side of RyR2. PKA and PP1 and 2A are
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bound to the RyR through anchoring proteins. The spatial association of the RyR with the LCC and 
its modulatory proteins form a key functional unit in cardiac ECC (Bers 2004).
FOOT STRUCTURE
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Figure 1.4 RyR2 as a scaffolding protein. The primary polypeptide 
chain or RyR2 is shown with its associated satellite proteins. On the 
cytoplasmic region, calmodulin, FKBP12.6, PKA, phosphatase I and 
phosphatase 2A are shown to bind. Junctin and triadin bind to the 
interluminal region, where they anchor calsequestrin to the RyR molecule 
in a calcium-dependent manner. The three major non-homologous 
(divergent) regions are indicated, DR1, DR2, DR3 (Yano 2008).
1.5 Calcium induced calcium release
During the cardiac action potential, calcium enters the myocyte through the voltage-gated LCC 
situated in the T-tubules of the sarcolemma at the cell surface. A small amount of ‘trigger’ calcium, 
approximately 10% of that required for contraction of the myofilaments, passes across the diadic 
cleft to the RyR2 where calcium entry triggers the opening of RyR2 and additional calcium is 
released from the SR calcium store, the process of CICR (Fabiato and Fabiato 1979). The 
combination of calcium influx and release raises the free intracellular calcium concentration from 
100 nm to about 1 pM, allowing calcium to bind to the myofilament protein troponin C, which then 
switches on the contractile machinery (Bers 2002). Relaxation, during which calcium dissociates 
from troponin C, occurs because calcium release from the SR ceases. Calcium is transported out of
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the cytosol and the SR calcium ATPase (SERCA) sequesters calcium back into the SR calcium 
store. The sarcolemmal NCX removes calcium from the cytosol to the extracellular space, as does 
the SERCA, but to a lesser extent. The mitochondrial calcium uniport can also take up calcium 
(Bers 2002). The perfect balance between calcium influx and calcium efflux must be maintained in 
order to maintain calcium homeostasis for a regular heart rate.
Sarcolemma
Myofilaments
\  Contraction
200 ms
Figure 1.5 Calcium transport in ventricular myocytes. Calcium entry 
via LCCs (yellow) results in calcium release from the SR through RyR.
This rise in intracellular calcium causes cellular contraction through
myofilament activation. Relaxation is achieved through the reduction ol 
cytosolic calcium via calcium-ATPase and NCX on the cell membrane, 
along with the SERCA and mitochondrial calcium uni port. Inset: Cardiac 
action potential (AP), intracellular calcium concentration ([Ca]) and 
myocyte contraction (Bers 2002).
1.6 Calcium homeostasis
High SR calcium content means that more calcium is available for release and therefore the
fraction of total SR calcium released in response to the inward ‘trigger’ calcium is also increased.
High SR (luminal) calcium has a stimulatory effect on the RyR, and hence increases the RyR open 
probability. This enhanced sensitivity of the RyR means that when the SR calcium content is high, 
a process often termed ‘spontaneous SR calcium release’ or calcium ‘leak’ may occur. This is the 
basis of aftercontractions, transient inward currents and delayed after depolarisations (DADs)
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which can trigger arrhythmia. RyR2 must close to maintain the fidelity of the heart beat but the 
underlying mechanisms leading to closure have been difficult to ascertain, primarily because of the 
many factors affecting calcium currents within the cell (Bers 2002). However likely causes of RyR2 
closure include decreased luminal calcium, detection of high calcium in the dyadic cleft and 
potential inherent properties of the RyR acting to modify channel gating, as discussed in section 
1.10.
When the calcium content of the SR is comparatively low, the inward calcium trigger may be 
unable to elicit SR calcium release (Bassani, Yuan et al. 1995). This assists calcium reuptake into 
the SR upon its relative depletion. A reduction in SR calcium release enables greater calcium influx 
through inward LCCs, due to reduced calcium-dependent inhibition, and through a shift in the 
action of the NCX away from calcium efflux. A reduction, even locally, in SR calcium load may 
result in inhibition of CICR. The total calcium content of the SR may be increased as a result of a 
rise in the calcium influx or a reduction in calcium efflux. It may also be achieved through more 
efficient SR calcium uptake as a direct result of p-adrenergic receptor (P-AR) stimulation, greater 
frequency of stimulation, increased action potential duration and raised intracellular calcium or 
sodium (Bers 2002).
1.7 Regulation of ECC bv adrenergic drive (Flight or fight response)
Physical or emotional stresses result in activation of the p-AR/PKA signalling pathway. p-AR 
stimulation results in both a positive inotropic and a positive lusitropic response. Inotropy is the 
measure of the strength of muscular contraction and an increase is associated with faster 
contractile events. Lusitropy, the measure of muscular relaxation, is increased to return the 
myocyte to a ground state enabling further contractions. Stimulation of P-AR, on the surface of the 
myocyte (Figure 1.4), by norepinephrine or epinephrine (Epi/Norepi) results in activation of the 
receptor-coupled G-protein (a, p and y complex) and subsequent release of the GTP-bound Gs 
subunit. This subunit binds to and activates adenylyl cyclase (AC), which in turn produces the PKA 
activator cyclic adenosine monophosphate (cAMP). The now active PKA is able to phosphorylate 
many of the ECC-related proteins including phospholamban (PLB), LCC (/Ca), troponin I, myosin 
binding protein C and RyR (Bers 2002).
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Phosphorylation of PLB and troponin I mediates the positive lusitropic response, with 
phosphorylated PLB, the more dominant effector of lusitropy, increasing calcium re-uptake, and 
phosphorylated troponin I accelerating calcium dissociation from the myofilaments (Li, Desantiago 
et al. 2000).
Epi/Nofepi
Sarcolemma
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Figure 1.6 p-adrenergic receptor activation. Stimulation of /3-AR by 
epi/norepinephrine results in an increase in the developed contractions 
(Inotropy) and an acceleration of relaxation (Lusitropy). This change is 
bought about through cAMP-mediated PKA activation (Bers 2002).
The increase in both the inward calcium trigger, due to phosphorylation of the LCC, and the 
availability of calcium within the SR, due to phosphorylated PLB -mediated calcium re-uptake, 
results in much larger calcium transients resulting from a given inward calcium trigger. These larger 
calcium transients provide the positive inotropic response, greatly outweighing the negative 
inotropic response provided by the accelerated calcium dissociation from the myofilaments via 
phosphorylated troponin I (Kentish, McCloskey et al. 2001).
PKA has also been shown to modulate the open probability of RyRs, although there is a great deal 
of controversy surrounding the extent and nature of this modulation. It has been proposed that 
chronic PKA hyperphosphorylation of RyR2 can result in incomplete channel closure and a calcium 
‘leak’ during diastole, which causes depletion of the SR calcium store and reduced calcium release 
upon receptor activation. Marx et al have found that PKA phosphorylation enhanced the steady-
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state open probability of single RyRs in bilayers, and suggested this to be a result of FKBP12.6 
dissociation from RyR2 (Marx, Reiken et al. 2000). They attributed the reduced SR calcium, as 
seen in HF, to the finding that RyRs were hyperphosphorylated. However, alternative experimental 
models involving permeabilised myocytes have shown no change in resting SR calcium leak in 
relation to PKA-dependent RyR2 phosphorylation where the SR calcium load remained stable (Li, 
Kranias et al. 2002).
SR calcium release, in response to the inward calcium trigger signal, may also be altered by the 
level of RyR phosphorylation, but results concerning this are disparate, and thus the level of control 
exerted by phosphorylation remains elusive (Song, Wang et al. 2001; Ginsburg and Bers 2005). 
The finer details of calcium handling with respect to the RyR are particularly challenging to 
measure in intact cells, because both a rise in intracellular calcium and an increase in SR calcium 
uptake make isolation of intrinsic RyR effects a significant challenge (Bers 2002).
Local signalling, assisted by the macromolecular complex of the RyR, is also important in the p- 
adrenergic cascade. LCC form an assembly with p-AR, G-proteins, AC, PKA and PP2A and the 
close physical proximity of these proteins may be functionally essential to enable rapid cellular 
signalling (Bers and Ziolo 2001; Marx, Reiken et al. 2001).
Catecholaminergic stimulation of the heart as part of the sympathetic nervous system activation 
during stress (fight or flight response) has been linked to PKA phosphorylation of RyR2 at S2808 
(Wehrens, Lehnart et al. 2006) and S2030 (Xiao, Jiang et al. 2005; Xiao, Tian et al. 2007). The 
relative importance of these two sites with regard to the role of RyR regulation during ECC, and 
particularly in pathology (Jiang, Lokuta et al. 2002; Xiao, Sutherland et al. 2004; Xiao, Tian et al. 
2007), is disputed.
1.8 Calcium/calmodulin-dependent protein kinase II (CaMKII)
The RyR complex also associates with CaMKII, potentially through mutual binding to calcineurin 
(Wehrens, Lehnart et al. 2004), although the specific interacting site of CamKII with RyR has not 
yet been identified. CaMKII phosphorylation has been suggested to increase single channel RyR2
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open probability but to a smaller extent than PKA phosphorylation (Wehrens, Lehnart et al. 2004). 
Mutagenesis studies have confirmed S2814 as a CaMKII site (Marx, Reiken et al. 2001), although 
there are potentially more sites for this kinase, as discussed in section 1.10.1. CaMKII is activated 
by increased levels of calcium or calmodulin, for example when intracellular calcium is increased 
upon (3-AR regulation (Zhang, Khoo et al. 2005). This kinase features three subunits featuring three 
key domains. The association domain directs assembly, the regulatory domain controls enzyme 
activation and auto-inhibition and the catalytic domain performs the kinase function of CaMKII. 
Upon binding of calcium or calmodulin, the kinase undergoes a conformational change whereby 
the regulatory domain inhibition of the kinase domain is relieved (Hudmon and Schulman 2002; 
Rosenberg, Deindl et al. 2005). This enables enzyme activation, however, in sustained calcium or 
calmodulin presence, the enzyme is able to self phosphorylate at a site which prevents 
reassociation of the regulatory domain with the kinase region, preventing autoinhibition. This self 
phosphorylation results in calcium/calmodulin independent activity and enables CaMKII to sustain 
its kinase activity which may result in excessive phosphorylation coincident with disease pathology 
(Hudmon and Schulman 2002).
1.9 Ryanodine receptor dysfunction in skeletal muscle and cardiac diseases
The involvement of RyR in cardiac disease has been recognised by its association with 
arrhythmogenesis in HF, ventricular outflow tract tachycardia and CPVT. This arrhythmia is defined 
as DADs, or ‘triggered arrhythmia’ which may be fatal and hence result in SCD.
Waves of calcium release have been shown to activate DADs. Calcium waves occur during 
diastole, if calcium release from the SR occurs in the absence of an inward calcium trigger. 
Diastolic calcium release activates NCX, which depolarises the cell and the resulting inward current 
can trigger a DAD (Scoote and Williams 2002; Pogwizd and Bers 2004). The initial cause for this 
SR calcium release, or leak, is an overloaded SR store, which occurs due to an imbalance between 
calcium entry into the cell and efflux out of the cell (Trafford, Diaz et al. 2001). Increased SR 
calcium content increases the open probability of the RyR and decreases the threshold for calcium 
release (Cheng, Lederer et al. 1996), enhancing the likelihood of a calcium wave and hence 
arrhythmia.
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Experimental models with myocytes have used caffeine, in addition to a |3-adrenergic stimulant, to 
increase RyR open probability, which results in initial production of calcium waves, and DADs, 
which become progressively smaller and then disappear. It has been observed that before adding 
the caffeine, the calcium content of the SR is constant from beat to beat, suggesting a perfect 
balance between influx and efflux. However, the waves of calcium efflux generated by caffeine 
result in a net loss of calcium, meaning that there is an overall decline in SR calcium compared 
with the control. At the end of a calcium wave, the decrease in SR content has been shown to be 
equal to the amount of calcium removed during that wave, indicating an inability to replenish the 
calcium store (Venetucci, Trafford et al. 2007).
The idea of an SR calcium store threshold, which must be overcome before calcium efflux from the 
SR will occur, has been backed by many experiments, and has resulted in the term store overload 
induced calcium release (SOICR) (Jiang, Wang et al. 2005). This threshold for calcium release has 
been attributed to the properties of the RyR, where an increased open potential of the RyR 
decreases the threshold for calcium release (Xiao, Tian et al. 2007). Conversely, decreasing the 
open probability of the RyR with tetracaine, a channel blocker, increases the threshold for calcium 
release (Venetucci, Trafford et al. 2006). In addition to this, DADs are known to be prevented by 
ryanodine, which is a specific blocker of the open state RyR (Song and Belardinelli 1994).
1.9.1 Calcium and arrhythmias in Heart Failure
Persistent pathological stress on the heart, such as HF, results in long term compensation and 
remodelling of cardiac ECC as SR calcium content is reduced, and intracellular free calcium 
increases. Reduced calcium pumping by SERCA and increased SR calcium leak via RyR2 result in 
this reduced SR calcium content and raised intracellular calcium, hence there is a loss of calcium 
homeostasis. There is good evidence that DADs contribute significantly to many ventricular 
arrhythmias seen in HF (Pogwizd and Bers 2004). A study on a small group of patients with dilated 
cardiomyopathy suggested that arrhythmias are caused by a focal mechanism involving triggered 
activity and DADs (Pogwizd, McKenzie et al. 1998).
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A paradox exists in HF, where decreased SR calcium content (resulting in smaller contractions) is 
observed, yet an increased prevalence of arrhythmia (linked to SR calcium overload) is also 
apparent. A potential explanation for this is that the threshold for SR calcium release is reduced as 
a consequence of HF, which may be due to a change in the properties of RyR. It has been reported 
that RyR2 becomes excessively phosphorylated (hyperphosphorylated) in HF, which may result in 
dissociation of the stabilising protein FKBP12.6 from RyR2 and lead to reduced threshold for SR 
calcium (Marx, Reiken et al. 2000; Wehrens, Lehnart et al. 2006).
Spontaneous calcium release has been shown to be increased in rats with HF, suggesting a 
reduced threshold for SOICR (Obayashi, Xiao et al. 2006). This is consistent with the finding of 
increased sensitivity to luminal calcium in single RyR2 channels isolated from failing canine hearts 
(Li and Chen 2001). The Chen group hypothesize that RyR2 sensitivity to luminal calcium is the 
primary determinant of SOICR threshold and that PKA phosphorylation (due to p-AR stimulation) of 
RyR2 reduces the threshold for SOICR (Figure 1.7). This elicits no calcium leak in normal cells, 
because this reduced SOICR threshold is still higher than the increased SR calcium store level. 
However, in abnormal (HF) SR, the threshold for SOICR is already reduced, due to cellular 
remodelling over time, so that during stressful conditions, the PKA phosphorylation of PLB 
activating SERCA results in abrupt overloading of the SR with calcium. Hence DADs occur and 
triggered arrhythmia (Xiao, Tian et al. 2007). Treatment by p-AR antagonists (p-blockers) is able to 
restore the SR calcium level as they prevent the stress-related PKA phosphorylation response.
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Figure 1.7 The proposed mode of action of PKA in stress-induced 
arrhythmia in patients with CPVT and HF mutations. As explained in 
section 1.9.1 (Xiao, Tian et al. 2007).
Ventricular outflow tract tachycardia accounts for -70% of all ventricular tachycardias in patients 
with structural heart disease. It is caused by abnormalities in metabolism of cAMP (the main 
intracellular messenger of p-AR stimulation), this generates cellular calcium overload and thence, 
by the same mechanism as described, DADs (Eisner, Kashimura et al. 2009).
1.9.2 Catecholaminergic polymorphic ventricular tachycardia
CPVT is an inherited syndrome, characterised by ventricular tachycardias, linked to DADs, 
developing under conditions of physical or emotional stress, when circulating catecholamines (such 
as adrenaline) are increased (Leenhardt, Lucet et al. 1995), hence the p-AR pathway is activated. 
CPVT was first associated with mutations in RyR2, which is an autosomal dominant form of the 
disease (Priori, Napolitano et al. 2001). There is no structural manifestation of the disease and 
patients have a normal resting sinus rhythm and electrocardiogram. More recently, a recessive 
form has been described, in which the underlying mutations occur in the SR calcium buffer- 
calsequestrin (CSQ) (George, Higgs et al. 2003; Wehrens, Lehnart et al. 2003). Work on isolated
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RyRs has shown that the probability they are open at low cytosolic calcium concentrations is 
greater than for wildtype RyRs (Wehrens, Lehnart et al. 2003) (Jiang, Xiao et al. 2004) and that 
DADs are also more likely to occur in cells expressing mutant forms of RyR or CSQ (Liu, Colombi 
et al. 2006). That this condition is only unveiled under conditions of stress places direct focus on 
the importance of PKA phosphorylation as a trigger for the resultant arrhythmias, therefore the 
mechanism involved in CPVT arrhythmia may be linked to that of HF.
1.9.3 Drug therapy for CPVT
(3-blockers were the first therapeutic option for CPVT because of the link between stress and 
arrhythmic symptoms. Initial clinical observations suggested this drug was effective in preventing 
arrhythmic events in CPVT patients (Leenhardt, Lucet et al. 1995), however, longer term follow up 
studies have suggested cardiac arrhythmias do still occur in patients, and one study has reported 
mortality rates in CPVT patients as high as 19%, for those using (3-blocker therapy (Sumitomo, 
Harada et al. 2003). Implantable cardioverter defibrillator therapy (ICD) has been used as an 
alternative for patients not responsive to (3-blockers, this device delivers a small series of shocks 
upon detection of arrhythmia, but death has been shown to occur despite the device being in place 
in a few documented cases (Uwais, Michael et al. 2006).
The experimental drug K201, a derivative of the benzothiazepine class of voltage-gated channel 
blockers, has been proposed to stabilise the binding of FKBP12.6 to RyR2 and hence result in 
normalised channel function (Yano, Kobayashi et al. 2002; Wehrens, Lehnart et al. 2004). 
However, the validity of FKBP12.6 dissociation linked to CPVT has been questioned, with some 
studies suggesting the mode of action of K201 is independent of FKBP12.6 (Hunt 2007; Blayney, 
Jones et al. 2010). One knock in mouse model has shown that mutations in the N-terminal and 
central RyR domains, regions where CPVT mutations reside, result in defective domain 
interactions which result in channel destabilisation (see domain interaction hypothesis section 
1.10.3). The effect of these mutations can be corrected by the K201 drug (Tateishi, Yano et al. 
2009). Previous studies in this group have shown K201 to stabilise RyR2 in [3H]ryanodine binding 
studies, in spite of an absence of FKBP12.6 as RyR channels were stripped of FKBP12.6 prior to 
the experiment. In parallel surface plasmon resonance (SPR) experiments assessing the binding
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affinity of FKBP12.6 for RyR2, the affinity was found to be reduced in the presence of K201. The 
lack of an additive effect seen in the [3H]ryanodine binding studies has lead to the suggestion of a 
common site of regulation for both K201 and FKBP12.6 (Blayney, Jones et al. 2010).
K201 has also been shown to have an inhibitory effect on the SERCA, suggesting there may be 
more than one site of action for the drug (Loughrey, Otani et al. 2007), indeed, K201 lacks 
specificity for the RyR2 channel, so its beneficial effects may be a result of this broader range of 
action.
Some studies have provided evidence against the use of K201 as an anti-arrhythmic drug. In one 
knock in mouse model featuring a CPVT mutation, K201 had no protective effect on 
catecholamine- induced DADs (Liu, Colombi et al. 2006). A more recent study has also suggested 
that the effects of K201 may only be beneficial to certain mutations, given that aberrant domain- 
domain interaction incurred by a mutation in the l-domain was not corrected by K201 (Tateishi, 
Yano et al. 2009).
Another drug from the same family as K201, S107 is thought to have higher specificity for RyR2 as 
it prevented arrhythmias in an alternative knock in mouse CPVT model, also by apparently 
encouraging FKBP12.6 binding (Lehnart, Mongillo et al. 2008). This drug has shown promising 
results so far in experiments, however has not been fully tested as yet (Bellinger, Reiken et al. 
2009).
Some studies have suggested Verapamil to be a suitable alternative treatment option for CPVT. 
This has already been used in combination with (3-blockers to treat CPVT (Rafael, Jonathan et al. 
2007). Verapamil is classed as an LCC blocker, therefore effects seen are considered to be 
indirectly linked to RyR2 due to a reduction in the trigger calcium during an action potential. In spite 
of this, the drug has actually been shown to bind directly to the RyR2 channel, reducing open 
probability (Valdivia, Valdivia et al. 1990). In cases where the combination of Verapamil and (3- 
blockers are ineffective, the anaesthetic Flecainide has been proposed as an alternative. This drug 
is a cardiac sodium channel antagonist, which is now also thought to block RyR2 (Watanabe,
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Chopra et al. 2009). Single channel experiments have demonstrated the ability of Flecainide to 
increase the frequency of closing events, and in a CSQ mutant model of CPVT, it decreased the 
frequency of arrhythmogenic calcium waves without altering the SR calcium load, suggesting this 
drug does not act by altering the balance of SR calcium flux. This drug has also been shown to 
induce a subconductance channel state of the RyR, which occurs when the channel is open, 
implying a direct physical blocking mechanism of action (Hilliard, Steele et al. 2010). The effects of 
Flecainide need to be further investigated, partly due to its non-specific mode of action, and also 
because of potential pro-arrhythmic effects in HF patients with ventricular tachycardia (Echt, 
Liebson et al. 1991). This drug has also been withdrawn from one study, due to increased loss of 
consciousness in CPVT patients (Sumitomo, Harada et al. 2003).
Dantrolene is another candidate drug for CPVT treatment. This drug is commonly used to treat MH, 
and binds at a site in the N-terminus region of the RyR1, but is known to also bind to RyR2. 
Dantrolene has been shown to stabilise channel domain interaction in one model of HF, using 
isolated SR and cardiomyocytes from either normal or rapidly paced dogs treated with CPVT 
mimicking domain peptides capable of disrupting natural domain interaction (Kobayashi, Yano et 
al. 2009). It has also recently been used in fluorescence resonance energy transfer (FRET) studies 
assessing labelled N-terminal and central domain interaction which generated FRET on mutual 
interaction. Dantrolene was shown to stabilise the RyR2 domain in the presence of activatory 
peptides, restoring ‘zipping’ between subunits and thus generating FRET (Liu, Wang et al. 2010).
1.9.4 Malignant Hyperthermia
MH and CCD are disorders linked to the skeletal muscle isoform (RyR1). MH mutations cluster into 
three distinct regions or ‘hot-spots’ of the coding sequence, corresponding to those in RyR2 linked 
to CPVT. Thus it has been suggested that these C-terminal, N-terminal and central domains may 
represent modulatory regions, proposed to interact and stabilise channel function (Yamamoto, El- 
Hayek et al. 2000). MH mutations were identified a decade earlier than those causing CPVT in 
RyR2 (MacLennan, Duff et al. 1990) but the corresponding nature of MH triggered by anaesthetics 
and of DADs triggered by stress in CPVT leads to the belief of many groups that these mutational 
clusters are related to a common mechanism of RyR regulation and pathology (Yamamoto, El-
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Hayek et al. 2000). An abundance of disease-linked RyR1 and RyR2 mutations have been 
recognised to date, these include over 120 substitutions, one insertion, one deletion and two 
genomic rearrangements, resulting in deletion of an entire exon (Thomas, Maxwell et al. 2010). 
Figure 1.8 demonstrates the analogous mutation clusters in the two RyR isoforms.
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Figure 1.8 Mutational clusters on N-, C- and central domains ol 
RyR1 and RyR2. The high correlation of mutation sites that cause the 
isoform-specific diseases is shown (Yano 2008).
1.10 Molecular Mechanisms of RyR2 dysfunction
1.10.1 Phosphorylation
Consequences of RyR2 phosphorylation have not yet been well established and remain 
controversial in terms of the site of action and the exact kinases involved in channel modulation 
pertinent to disease and aberrant RyR function. There are two main kinases suggested to be 
involved; PKA, which is immediately highlighted by its direct upregulation as a result of p-AR 
stimulation (Bers 2002) and CaMKII, (Currie, Loughrey et al. 2004) (Grimm and Brown 2010). PKA 
dependent phosphorylation at S2808 has been proposed by one group as increasing the open 
probability of RyR2 and to result in channel destabilisation. This has been attributed to dissociation 
of the FK506 binding protein FKBP12.6 from the RyR2 (Marx, Reiken et al. 2000). However, 
CaMKII has also been proposed to phosphorylate at this same serine residue, and S2815, with no 
increased RyR open probability or evidence of subconductance states (Witcher, Kovacs et al.
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1991; Wehrens, Lehnart et al. 2003). Insertion of a permanently phosphorylated mutation at the 
site in question was then found to increase open probability coincident with FKBP12.6 dissociation, 
suggesting an alternative kinase may be acting on this site. RyR2 channels featuring recombinantly 
expressed mutations were then shown by this group to have reduced affinity for FKBP12.6 
following PKA phosphorylation, suggesting this kinase to be the most important (Wehrens, Lehnart 
et al. 2003).
An alternative site for PKA phosphorylation at S2030 has been proposed and this site was shown 
to be phosphorylated after p-AR stimulation of rat cardiac myocytes but not before, whereas the 
S2808 site remained unchanged (Xiao, Tian et al. 2007). It was proposed that phosphorylation at 
S2808 did not affect FKBP12.6 binding and that FKBP12.6 dissociation was not concurrent with 
mutant RyR2 dysfunction. Single channel studies have also implicated S2030 mutants as reducing 
the activating effect of PKA, where S2808 had no effect, adding to the idea that this may be the 
more relevant site of phosphorylation (Xiao, Tian et al. 2007). In addition to this, RyR2 
phosphorylation at both sites was suggested to be unchanged in failing and non-failing canine 
hearts, placing the hyperphosphorylation theory into question (Wehrens, Lehnart et al. 2006). 
Knock in mouse models of CPVT have further complicated the phosphorylation story. Two of three 
models studied have shown similar wildtype (WT) and mutant RyR2-FKBP12.6 interaction and 
S2808 phosphorylation both before and after p-AR stimulation (Kannankeril, Mitchell et al. 2006; 
Liu, Colombi et al. 2006; Fernandez-Velasco, Rueda et al. 2009). A more recent model then 
showed dramatic differences in the WT and mutant, suggesting the effect of mutations may be 
more complicated than originally thought and there may be specific mechanisms linked to mutant 
heterogeneity (Thomas, George et al. 2004; Lehnart, Mongillo et al. 2008).
It has been suggested that the hyperphosphorylation observed in HF may actually be due to 
CaMKII, hence the discrepancies in experimental findings linked to PKA phosphorylation (Xiao, 
Tian et al. 2007).
Wehrens et al have found another site of CaMKII phosphorylation at S2814 (Wehrens, Lehnart et 
al. 2004) and CaMKII activation has been increasingly related to sympathetic adrenergic drive, with
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other possible sites of action suggested in the literature (Rodriguez, Bhogal et al. 2003). S2814 
phosphorylation of RyR has been shown to potently activate the channel and evidence suggests 
that abnormal phosphorylation by CaMKII may be a key factor in aberrant RyR function (Ai, Curran 
et al. 2005; Ferrero, Said et al. 2007). It may be the case that PKA and CaMKII activity are not 
independent of one another, and that PKA activation, due to p-AR stimulation, and thus increased 
calcium transients, may then affect activation of CaMKII (Ferrero, Said et al. 2007). Alternatively, 
there may be PKA independent activation of CaMKII via a cAMP-activated protein named Epac. 
CaMKII activation via Epac has been shown to result in S2814 phosphorylation and this protein has 
also been linked to increased SR calcium leak in adult rat cardiomyocytes in the presence of 
phosphorylation by CaMKII (Pereira, MAOtrich et al. 2007). As yet, little is known of the importance 
of CaMKII linked with CPVT and further research is required to elucidate the exact mechanism for 
activation and the effect of this kinase.
In addition to these findings, work within this group has shown a reduced affinity of RyR2 for 
FKBP12.6 caused by PKA phosphorylation of isolated RyR channels, which was not translated into 
increased open probability of channels in [3H]ryanodine binding (Blayney, Jones et al. 2010). This 
finding points to a conformational change of RyR incurred by PKA phosphorylation at a level 
difficult to detect in many experimental models, which would explain the lack of PKA effect 
suggested by several groups.
1.10.2 Redox effects
Catecholamine induction stimulates the release of reactive oxygen species (ROS) which may have 
an effect on mutant RyR2 function in patients exhibiting heightened sensitivity to these (Zhang, 
Kimura et al. 2005). Oxidative stress is measured as the number of free thiols, or reduced cysteine 
residues present on the RyR. Redox modification of RyR2 has been linked to calcium leak from the 
SR in HF, even though the level of redox sensitivity of FKBP12.6 bound to RyR2 remained 
unchanged in WT and mutant channels (Zhang, Kimura et al. 2005; Mochizuki, Yano et al. 2007; 
Zissimofolilos, Thomas et al. 2009). Carvedilol (CV) is a (3-blocker with an antioxidant effect, which 
was shown to prevent HF in dogs subjected to chronic pacing. CV treated failing hearts have 
shown heightened free thiol levels compared with untreated failing hearts, suggesting this drug
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may be valid for restoring normal RyR2 oxidation levels in mutant channels. An oxidative agent 
SIN-1 was able to reduce the number of free thiols of RyR2, but when added in conjunction with 
CV, free thiols were increased. This suggests that the stabilising effect of CV can be attributed to 
its prevention of RyR2 oxidation. CV was also shown to reduce calcium leak triggered by SIN-1, 
however, the addition of the DPc10 domain peptide, proposed to disrupt interdomain interaction of 
RyR2, completely abolished this CV effect. This would suggest that benefits of CV link to 
restoration of the defective domain interaction proposed in failing cardiomyocytes by reducing the 
oxidative stress level of RyR2 (Mochizuki, Yano et al. 2007).
CaMKII activation has also been linked to oxidation, implying that stabilising effects of CV may also 
be linked to reduced phosphorylation levels. Oxidation of methionine residues in the regulatory 
domain of CaMKII induces sustained kinase activity in the absence of calcium or calmodulin, and it 
is suggested that oxidation can directly modify the autoinhibitory region of CaMKII, in a mechanism 
analogous to autophosphorylation which enables this calcium/calmodulin independent activity 
(Erickson, Joiner et al. 2008).
1.10.3 Cytosolic and luminal calcium sensitivity
As calcium is the primary agonist of RyR2, it makes sense that fluctuations in calcium 
concentration will directly affect channel functionality. Recent mouse models have placed focus on 
increased calcium sensitivity as a common feature of mutant dysfunction. This is reflected in an 
increased level of [3H]ryanodine binding, and increased spark frequency in permeabilised myocytes 
(Fernandez-Velasco, Rueda et al. 2009).
As mentioned previously, low doses of caffeine result in DADs in cardiomyocytes in the presence 
of |3-AR stimulation due to increased calcium sensitivity, suggesting a direct link to arrhythmia 
(Venetucci, Trafford et al. 2006). It is well known that RyR is regulated by calcium at both a luminal 
and a cytosolic site and increased luminal (SR) calcium sensitivity has been reported for most of 
the characterised CPVT mutants (Jiang, Xiao et al. 2004; Jiang, Wang et al. 2005). Some of these 
mutants exhibit diastolic leak, with an increased open probability at sub-activatory trigger (cytosolic) 
calcium levels compared to WT channels, in the absence of any phosphorylation treatment (Jiang,
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Xiao et al. 2004). However, other mutants have reduced sensitivity to trigger calcium and 
subsequent CICR, suggesting that these mutations affect deactivation of the channel, rather than 
activation (Thomas, Lai et al. 2005).
The recessive form of CPVT, linked to a cardiac CSQ mutation, has been shown to result in 
aberrant luminal calcium sensitivity (Viatchenko-Karpinski, Terentyev et al. 2004). CSQ is an RyR 
accessory protein which has a low affinity for calcium and therefore may serve to monitor and 
buffer luminal calcium levels to maintain homeostasis (Mitchell, Simmerman et al. 1988). Calcium 
release from the SR has been shown to rise at a faster rate as calcium concentration within the SR 
increases. This would correlate with potential saturation of SR buffering proteins, such as CSQ 
(Shannon, Ginsburg et al. 2000). Certain CSQ mutations have been suggested to modify the 
calcium buffering or the RyR2 interaction ability of CSQ. Interactions with other accessory proteins, 
such as triadin are also altered in CSQ mutants but have not been tested in the RyR2 CPVT 
mutants. Triadin may act in complex with CSQ, along with junctin, another luminal protein (Gyorke, 
Hester et al. 2004). Mouse models suggest that all types of disease-linked CSQ mutant affect the 
ability to restore RyR2 calcium release to its normal state, thus preventing aberrant calcium release 
which may cause arrhythmia. CSQ knock-out mice have also shown increased SR volume, 
demonstrating a possible compensation for its loss (Knollmann, Chopra et al. 2006).
There may also be a link between luminal calcium activation and phosphorylation, as mentioned 
earlier, so that PKA only stimulates channel open probability in the presence of luminal activation 
(SR calcium beyond threshold level) (Xiao, Tian et al. 2007). The specific effects of luminal or 
cytosolic calcium are difficult to determine
1.10.4 Channel inter-domain interaction
Peptide studies have shown that interacting domains of RyR1 and RyR2 can be disrupted by single 
base mutations specific to MH (RyR1) or CPVT (RyR2), leading to channel instability and diastolic 
leak, indicating that these interactions are essential to channel closure and may be involved in a 
conformational change which is implicated in RyR calcium release (Yamamoto and Ikemoto 2002; 
Yang, Ikemoto et al. 2006). Domain peptides corresponding to portions of the N-terminal (590-639)
24
Chapter 1
and central domain (2460-2495) (Dpc10) of RyR2 have been shown to enhance [3H]ryanodine 
binding to cardiac SR preparations suggesting an increased open probability. Increased calcium 
release from the SR has also been shown in the presence of these peptides, with increased 
sensitivity to both luminal and cytosolic calcium evident in permeabilised cardiomyocytes, 
suggesting a replication of mechanisms involved in CPVT (Yang, Ikemoto et al. 2006). These 
findings have lead to the interdomain interaction hypothesis by the Ikemoto group. They suggest 
that competitive binding of central domain peptide to the N-terminal of the channel, and conversely, 
binding of the N-terminal domain peptide to the central domain of the channel, disrupt the natural 
intramolecular interactions that would normally stabilise the channel in its resting state. Introduction 
of a CPVT mutation (R2474S) into the central domain peptide was shown to eliminate the 
activating effect, indicating that the mutation was sufficient to disturb interaction with the N-terminus 
and thus disrupt channel regulation. It was therefore proposed that defective interaction between 
these two domains, caused by a single point mutation, could represent a mechanism underlying 
RyR dysfunction in arrhythmia (Yamamoto and Ikemoto 2002).
Use of peptides has been extended to other RyR2 domains and cross linking studies have 
confirmed the region of peptide binding on the RyR1 isoform as being between the N-terminus and 
central domains (Hamada, Bannister et al. 2007). The DPc10 equivalent for RyR1 is DP4, the 
mutant of which features an MH specific mutation of the central domain. The DP4 peptide has been 
shown to activate RyR1 in a similar fashion to DPc10 in RyR2 studies (Yamamoto, El-Hayek et al.
2000), which are discussed in more detail in chapter 6. One group has used a fluorescence quench 
study to assess potential disruption of domain interaction in the presence of peptides from three 
different regions of RyR2, including DPc10. A quenching molecule only had access to the 
fluorescent label if the bound domain regions were unzipped (Tateishi, Yano et al. 2009). All three 
peptides were thus shown to disrupt inter-domain interaction and to increase SR calcium leak, as 
well as increasing ryanodine binding of SR vesicles. It would seem that the level of instability 
induced by these peptides may be variable however, given that one peptide used in the previously 
mentioned study, corresponding to the l-domain of RyR2 and proposed to bind to the 
transmembrane cytoplasmic loop (George, Jundi et al. 2004), did not exhibit a reversible effect on 
wash out (Tateishi, Yano et al. 2009). This suggests that mutations in this region do not result in
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the same outcome with regard to RyR dysfunction even though they would appear to induce 
conformational and calcium release instability, in accordance with alternative peptide studies 
(George, Jundi et al. 2004). This heterogeneity in response has implications for drug therapy, 
where a single solution may not be valid and the therapy may need to be suited more specifically to 
the individual case (Thomas, Maxwell et al. 2010).
wild-type: inter-domain 
interaction stabilizes channel 
in closed state.
central domain mutation: 
domains partially 
‘unzipped’, inducing channel 
instability/ 'hyperactivation'.
peptide conta ining 
central domain mutation: 
does not compete at 
wild-type binding sites.
peptide containing
competes for N-terminal 
binding site, inducing 
instability/ 'hyperactivation,.
during physiological activation, 
Ca* domain unzipping is recognised
activation as a CICR activation signal, 
signal Hence, partial unzipping
(by mutation or peptide) 
facilitates unzipping by Ca2* 
activation.
Figure 1.9 Inter-domain interaction hypothesis. Shows the presented 
theory that complex folding brings the N-terminal and central domain 
together allowing them to bind, regulating the RyR channel state. The 
mode o f action of the wild-type and mutant peptides is also indicated 
(Yang, Ikemoto et al. 2006).
1.11 Modulation of the RyR
1.11.1 Calcium, ATP and Magnesium
Calcium is the key modulator of the RyR channel, and it is now well known from single channel and 
ryanodine binding experiments that RyR open probability shows a biphasic response to 
cytoplasmic calcium concentrations, with a threshold for activation at nM range of free calcium and 
maximal activation at pM free calcium. This activation then declines as free calcium rises until 
maximal inhibition occurs at 1 mM free calcium (RyR1) and -10 mM free calcium (RyR2).
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(Nagasaki and Kasai 1983) (Kirino, Osakabe et al. 1983) (Meissner, Rousseau et al. 1988) (Lai, 
Misra et al. 1989; Mickelson, Litterer et al. 1990) However, maximal activation of the channel is 
only obtained in the presence of ~1 mM ATP (Xu, Mann et al. 1996; Kermode, Williams et al. 1998) 
and it has been widely reported that magnesium at mM concentrations will completely inhibit the 
open probability of the channel. Magnesium and ATP are therefore also key regulators of the RyR 
channel and it is generally believed that magnesium competes with calcium for the activating sites 
(A-site), or that magnesium can bind to low-affinity, inhibitory, non ion-selective sites (l-site) that 
can also mediate calcium inhibition of the channel (Kirino, Osakabe et al. 1983; Nagasaki and 
Kasai 1983; Meissner 1986) Intracellular free magnesium is normally 0.5-1 mM in cardiac 
myocytes, however at physiological ATP- 5 mM, magnesium only modestly inhibits RyR2 gating at 
2 mM concentration. Since ATP and magnesium do not change rapidly during ECC these levels 
may set the physiological calcium sensitivity of the RyR (Xu, Mann et al. 1996). However, during 
ischemia, a common feature of tachycardia, free intracellular magnesium increases several fold as 
ATP falls, because ATP is a major magnesium buffer, this has been suggested to reduce RyR 
sensitivity to calcium (Murphy, Steenbergen et al. 1989).
Reduced magnesium inhibition and increased calcium sensitivity were found in MH (Meissner 
2002). It has been reported that ATP can open the RyR from skeletal muscle even under 
conditions where almost no free calcium is present. (Dias, Szegedi et al. 2006) The biphasic 
response to calcium may be explained by the presence of activating calcium sites on RyR with a 
high calcium affinity, as well as low affinity, inhibitory calcium binding sites. Dias et al show a total 
of eight nucleotide binding sites are located on RyR1 from skeletal muscle and they propose that 
ATP binding at all eight sites on the RyR tetramer stabilizes an open channel conformation or 
primes the channel for opening events, while binding of ATP to only four of the sites correlates to 
closed channel conditions, suggesting there may conformational change of RyR linked to ATP 
binding (Dias, Szegedi et al. 2006). Magnesium and ATP binding site locations are not yet known.
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1.11.2 Accessory protein modulation 
FK506 binding protein
As previously mentioned, dissociation of the FK506 binding protein FKBP12.6 from RyR2 has been 
implicated in HF and RyR2 linked arrhythmias (Marx, Reiken et al. 2000; Yano, Ono et al. 2000). 
Although the cause of this dissociation has been the subject of much controversy, it is known that 
FKBP12.6 dissociation results in excess calcium release from the SR (McCall, Li et al. 1996). It has 
also been shown by our group that FKBP12.6 reduces ryanodine binding by approximately 50%, 
suggesting a reduction in RyR2 open probability, and a reduced affinity for the channel in its open 
conformation (Blayney, Jones et al. 2010). FKBP12.6 has been suggested to coordinate the 
opening of neighbouring RyR2 channels, from single channel studies (Marx, Gaburjakova et al.
2001). Although it is established that one FKBP12.6 binds to each subunit of RyR2, it is unknown 
exactly where this protein binds (Meissner 2002). The RyR1 equivalent, from the same family, is 
named FKBP12 and has been suggested to have similar stabilising effects on this RyR1 isoform 
(Avila, Lee et al. 2003).
Calsequestrin
The role of CSQ as a luminal regulatory protein has already been discussed in section 1.10.2. It 
has been suggested that CSQ communicates with the RyR through interaction with triadin and 
junctin, although there is evidence that CSQ may be able to bind RyR in their absence as well 
(Herzog, Szegedi et al. 2000). Binding of calcium by CSQ causes a major conformational change 
in the molecule (Mitchell, Simmerman et al. 1988) however CSQ also possesses a similar affinity 
for magnesium (Ikemoto, Nagy et al. 1974) and there is no known active transport of magnesium 
across the SR membrane therefore CSQ is an important modulator of luminal magnesium 
concentrations. The effect of luminal magnesium concentration on RyR is little known, but a recent 
study assessing sheep RyR2 in lipid bilayers, proposes that luminal magnesium does in fact play a 
key role in RyR2 calcium release by inhibiting at activatory calcium concentrations (Laver and 
Honen 2008).
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Triadin and Junctin
Triadin and junctin, which have luminal and transmembrane regions (Zhang, Kelley et al. 1997) and 
are found in many tissues where they are thought to have ubiquitous roles in calcium signalling. 
CSQ knockout mice have been shown to have suppressed expression of junctin and triadin but the 
roles of these proteins in mediating regulation of the RyR by CSQ and the response to luminal 
calcium have not been established. Overexpression of triadin has been correlated with a 
predisposition to arrhythmia in cardiomyocytes (Terentyev, Cala et al. 2005) and junctin 
overexpression has been associated with a reduced SR calcium load (Kirchhefer, Hanske et al. 
2006).
Sorcin
The calcium binding protein sorcin has been shown to bind to RyR2 with high affinity, inhibiting the 
channels activity (Farrell 2004). Shown to reduce the calcium transient amplitude without affecting 
that of the inward calcium trigger signal, this modulator appears to inhibit the ‘gain’ of calcium 
signalling usually observed in ECC. Sorcin has been localised to the dyadic cleft and, although the 
site of interaction has not been established, it has been linked with the LCC (Meyers, Pickel et al. 
1995; Meyers, Puri et al. 1998). Whether directly, or indirectly, through association with the LCC, 
the depressive effect of sorcin on RyR activity has been shown to be relieved by PKA 
phosphorylation (Lokuta, Meyers et al. 1997; Farrell, Antaramian et al. 2003).
Calmodulin
Calmodulin (CaM) binds to both RyR1 and RyR2 in a 1:1 stoichiometry at a high affinity binding site 
(Rodney, Williams et al. 2000). CaM inhibits RyR2 at all calcium concentrations, but only inhibits 
RyR1 at the pM concentrations of calcium associated with muscle contraction (Tripathy, Xu et al. 
1995; Balshaw, Xu et al. 2001). CaM binds to RyR between residues 3630-3637 and may be 
involved in calcium-RyR binding during ECC as its association enhances channel opening and 
closing (Balshaw, Xu et al. 2001).
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1.12 RvR structure and function
RyR is a homotetramer with a central calcium pore and each subunit has a molecular mass of 
-560 kDa, making RyR the largest known calcium channel protein with a total molecular mass of 
>2000 kDa. (Lai, Erickson et al. 1988)
Given the enormous size of the RyR homotetramer and its inherent stability, this protein is suitable 
for image analysis by cryo-electron microscopy and electron density maps of the molecule have 
been produced at 14 A (Samso and Wagenknecht 1998; Serysheva, Hamilton et al. 2005) and 30 
A (Radermacher, Rao et al. 1994). From these maps, a tetragonal structure, with a large 
cytoplasmic region and a transmembrane stalk, has been observed (Figure 1.10).
Sequence analysis has shown that 20% of the C-terminus is made up of hydrophobic helical 
regions. These are likely transmembrane domains (Takeshima, Nishimura et al. 1989). A 
substantial section of these domains share a high homology with the potassium channel pore loop. 
As this channel has been crystallised (Jiang, Lee et al. 2002), comparisons have been drawn 
between the two channels in an attempt to hypothesise the likely configuration of the RyR calcium 
pore (Welch, Rheault et al. 2004).
According to topology models, RyR1 and RyR2 are subjected to a conformational change involving 
domain rearrangements in the transition from the open to closed conductive state. The binding of 
FKBP12.6 has also been shown to induce a conformational change in RyR2 (Serysheva, Schatz et 
al. 1999; Sharma, Jeyakumar et al. 2006). Through domain mapping studies, it has been 
suggested that the N-terminus and the central domains, both sites of CPVT-causing mutations, are 
situated at the corners (‘clamp’ regions) of the RyR homotetramer within close proximity of one 
another (Liu, Zhang et al. 2001; Liu, Wang et al. 2005).
That so many domains, from various regions of the RyR primary sequence, have been mapped to 
this ‘clamp’ region, indicates the possibility of convoluted folding, in the tertiary structure, bringing 
together otherwise distant domains (Blayney and Lai 2009).
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Figure 1.10 Primary sequence and 3D structure of RyR1 with 
potential ligand binding sites. Left: Primary polypeptide structure 
showing the proposed transmembrane domains. Putative ligand binding 
regions are indicated (red). Right: Solid body representation (Top: 
Cytoplasmic view. Bottom: Side view) showing sequence specific 
markers (red). Arrow indicates transmembrane region correlation 
(Radermacher, R aoe ta l. 1994).
In 2009 the first successful crystallisation of the N-terminal portion of RyR1 was achieved 
(Amador, Liu et al. 2009). The structure of the first 217 amino acids (N-terminus) were obtained 
and shown to be highly homologous between RyR1 and RyR2 in further studies by Van Petegem 
et al (Lobo and Van Petegem 2009). Both studies demonstrated that the N terminal region of the 
RyR adopts a p-trefoil structure, not dissimilar to that of the IP3 receptor (Figure 1.11). This fold is 
found among proteins with very distinct functions but likely has a key role in regulatory mechanisms 
in the IP3 receptor family . The (3-trefoil is flanked by an alpha-helix (Lobo and Van Petegem 2009).
Three MH associated mutations in the RyR1 sequence were found to have no adverse affect on 
the global stability or fold of RyR, yet Van Petegem et al crystallised two RyR2 disease mutants 
which apparently caused distinct local changes in the surface of the protein and significant changes 
in RyR thermal stability (Lobo and Van Petegem 2009). These studies further add to the idea that
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there may be mutation-specific effects on calcium-handling and that these are linked to 
conformational change in the RyR molecule (Blayney, Jones et al. 2010), which may occur at 
different levels in a hierarchy of molecular movement, thus some mutation-linked changes are 
more dramatic than others.
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Figure 1.11 Structural representation of the similar structures of A)
RyR1 and B) RyR2. Disease positions are highlighted (Green) and, from 
a severe form of CPVT, a deletion (orange) of exon 3 (Lobo and Van 
Petegem 2009).
1.13 Previous work and the context of this project
Recent research has provided valuable clues toward RyR structure and is slowly helping us to 
elucidate functionality of the RyR channel and offer insights into its dysfunction. It is clear however, 
that there are still many pieces of the RyR jigsaw unsolved, such as the key regions of the channel 
involved in stabilisation and modulation. The binding sites for many of the key modulators of RyR 
activity, such as calcium, ATP, magnesium, or the protein modulators such as FKBP12/12.6 or 
calmodulin are unknown. Some phosphorylation sites have been identified for PKA and CaMKII but 
there is controversy over their relative importance in both normal regulation and their contribution to 
pathology. The point mutation clusters associated with MH and CPVT in RyR1 and RyR2 
respectively have suggested two pairs of interacting domains which may be critical to regulation of 
RyR channel gating; the N-terminus with the central domain (Yamamoto, El-Hayek et al. 2000) and 
the l-domain with the transmembrane cytoplasmic loops (George, Jundi et al. 2004).
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Previous work done by this group has centred on the interaction of RyR1/2 with FKBP12/12.6 
which had been highlighted by the suggestion that hyperphosphorylation of RyR, associated with 
HF, dissociates these modulatory proteins rendering the RyR leaky. The relationship between 
RyR1/2, FKBP12/12.6 and phosphorylation of RyR had been untested in normal physiological 
conditions. In cells, or by using SR preparations, the factors modulating RyR function are 
numerous and themselves subject to environmental influence. Our unique approach is to study 
these interactions in isolation from the cellular environment by purifying native RyR1 (from rabbit 
skeletal muscle) or RyR2 (from pig heart). In this way it has been possible to strip these 
preparations of FKBP12/12.6 and regulate RyR phosphorylation by PKA and to examine their inter­
relationship (Jones, Reynolds et al. 2005; Jones, D'Cruz et al. 2007; Blayney, Jones et al. 2010).
This work, the components of which are described more fully in each of the chapter introductions, 
has lead to a model of ‘convergent regulation’, see figure 1.12.
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Figure 1.12 Convergent regulation hypothesis. The diagram above illustrates the 
findings from previous studies by this group on the kinetics o f binding o f FKBP12/12.6 to 
RyR1/2 and the influence o f PKA phosphorylation.
Using fHJryanodine binding to determine the open state it was found that the RyR1 channel 
was closed in the presence o f EGTA (which lowers the calcium to <pCa8) and in 1 mM 
calcium. The channel could be opened by 1 pM calcium, shown by the upward arrow on the 
left. Thus the open/closed conductive state could be manipulated by changing the calcium 
buffer. Using buffers containing RyR modulators which either opened or closed the channel 
the affinity o f RyR1 for FKBP12 was determined using SPR (Biacore) to measure the 
kinetics o f interaction (Jones, Reynolds et al. 2005).
Initial experiments using physiological or pharmacological activators o f the RyR- calcium, 
ATP, caffeine and the inhibitors calcium (1 mM), EGTA or ruthenium red, showed that the 
transition from the closed to the open state altered the affinity o f RyR1 for FKBP12, such 
that the affinity was reduced four-fold when the channel was open (Jones, Reynolds et al. 
2005). PKA phosphorylation was able to reduce the affinity o f RyR1/2 for FKBP12/12.6 
whilst the channel was in the closed state. Ryanodine binding studies also showed that the 
stabilising drug K201 could reduce the affinity for FKBP12/12.6. [3H]ryanodine binding 
showed that the biphasic response to calcium was not influenced by phosphorylation but 
K201 reduced activity.
It was proposed that phosphorylation can cause a conformational change which poises the 
channel ready to open by reducing the inhibition by FKBP12/12.6. K201 also causes the 
same conformational change but can stabilise the proposed transition state. This 
mechanism may underlie the ‘flight or fight’ response and poise the RyR molecule to open 
and close faster during sympathetic upregulation o f ECC. Phosphorylation in our studies 
and others has been shown to reverse the effects o f magnesium inhibition and the masking 
and unmasking o f a magnesium inhibition site would be consistent with our data (Blayney, 
Jones et al. 2010).
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1.14 Aims and hypothesis of this study
As outlined above, circumstantial evidence points to a series of interactions that are linked to a 
conformational change in RyR2, which masks a magnesium inhibition site and reduces the affinity 
for FKBP12.6 in response to PKA phosphorylation. The experimental drug K201 appears to 
influence the same pathway. The peptide probes DP4 and DPc10, which are derived from central 
domain sequence of RyR1 and RyR2, respectively, can activate RyR1/2 in a manner postulated to 
disrupt the N-terminus/central domain interaction by causing a conformational change. Key to the 
domain interaction hypothesis was that DP4 or DPc10 with an MH or CPVT mutation respectively 
in the sequence (DP4M or DPdOM) were inactive, caused no conformational change and did not 
increase the open probability of the channel.
Identification of this region of convergent regulation is the intention of this work.
The PKA-mediated conformational change of RyR1/2, reducing the affinity for FKBP12/12.6, 
observed in previous studies, has been hypothesised to involve the central domain. Use of the 
peptide probes, DP4 and DPdO, should be able to confirm this if they alter the affinity of RyR1/2 
for FKBP12/12.6 in a similar way to phosphorylation.
The intention was to carry out preliminary experiments for proof of concept using [3H]ryanodine 
binding to establish the effect of the DP4 wildtype and mutant domain peptides on the open/closed 
activity of RyR1 due to the relative low abundance of RyR2 that can be purified from native tissue. 
This will enable further experiments on the affinity for FKBP12 using SPR technology to measure 
the kinetics of interaction in the presence of DP4. Key experiments would then be performed using 
RyR2, FKBP12.6 and DPdO.
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CHAPTER 2: General Materials and Methods
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich (Dorset, UK) and 
Fisher Scientific (Leicestershire, UK), solutions were made in dH20  and stored at 4°C and 
standard experimental protocols were based on those given in ‘Short protocols in Molecular 
Biology’, Ausobel et al 2002 and ‘Molecular Cloning: a lab manual’ by Sembrook and Russell, 
2001.
2.1 Molecular Biology
Aseptic technique was employed throughout and all surfaces swabbed with 70% v/v methanol 
before and after use. Sterile flow hoods were used for pouring plates and all culture inoculation 
steps. Sterile plasticware (culture tubes, universals, centrifuge tubes, petri dishes, spreaders 
and loops) were obtained from Fisher Scientific. All non-sterile apparatus was washed in 
detergent free water and autoclaved at 135°C, 4 bar pressure for 90 minutes. All media was 
autoclaved in the same manner before use. Restriction enzymes and their respective buffers 
were obtained from New England Biolabs (NEB, Hertfordshire, UK) and Promega, (Hampshire, 
UK) unless otherwise stated. Filter sterilisation was performed using 0.2 pm filters (Sartorius, 
Aubagne, France). Antibiotics (Ampicillin and Chloramphenicol) were purchased from 
Formedium (Norfolk, UK)
2.1.1 Analysis of DNA products
2.1.1.1 Agarose Gel Electrophoresis
DNA Loading Buffer (2x stock): TAE (2x), glycerol 50% v/v, Orange G 0.25% w/v. Glycerol 
provides the necessary weight to sink the DNA into the gel wells, whilst the orange G dye 
enables visualisation of the dye front as it migrates through the gel.
Ethidium bromide (EtBr): Stock concentration 10 mg/ml Added at 1 pl/50 ml agarose. EtBr, the 
most commonly used nucleic acid stain for agarose gel electrophoresis, increases in 
fluorescence 25-fold upon intercalating double-stranded DNA. As a result destaining the 
background is usually not required.
Tris/acetate EDTA (TAE) buffer: 50x stock made-up and diluted to give Tris/acetate 40 mM, 
EDTA 1 mM, pH 7.4 (with glacial acetic acid).
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Agarose gels were made by dissolving a w/v percentage of agarose in 1xTAE buffer by boiling 
in a microwave. Agarose was cooled to -  50°C before addition of 0.1 pg/ml EtBr and pouring 
into gel casting trays (Biorad or Hoeffer) with a comb to create loading wells and assembled as 
per manufacturers’ instructions. Once the gel had set the tray was placed into an 
electrophoresis tank. 5 pi of sample mixed with 5 pi of 2x DNA loading buffer was pipetted into 
each well. A DNA ladder (Hyperladder (Bioline, London, UK) or NEB) of a suitable kb range was 
run alongside the samples. This was used to estimate the size of the DNA sample, from the 
distance run by the marker bands of known size, and its concentration, by comparison with the 
brightness of the bands, which contained known quantities of marker DNA. The lid was placed 
on the electrophoresis tank and a voltage of 80 V (small gel) or 120 V (large gel) was applied 
until the orange dye front, which migrates coincident with DNA of -50  base pairs (bp), had 
migrated approximately three quarters of the length of the gel. The gel was then removed from 
the tank and viewed by exposure to UV light, using a XRS Gel Doc system and Quantity One 
software (Bio-Rad, Hertfordshire, UK).
2.1.1.2 Quantification of DNA by spectrophotometry
Peak absorption of DNA is at A26o and this wavelength was used to determine the quantity of 
DNA in an unknown sample by using the constant that 50 ng/pl of DNA has an absorption of 1. 
Using a quartz cuvette of pathlength 1 cm and volume 100 pi, a x100 -  x25 dilution with dH20  of 
the DNA preparation was scanned from A20o-A4oo. The A260 was used to calculate the DNA 
concentration. The ratio of A260/A28o gave an indication of its purity with respect to contaminating 
protein (which has a maximum absorbance at A280). A ratio of >2.0 indicated good purity, which 
was valuable when DNA had been extracted from bacterial lysates.
2.1.2 Cloning of DNA
2.1.2.1 Oligonucleotide primers
All primers were ordered from Sigma. These were supplied as lyophilised pellets which were 
reconstituted with sterile dH20  to give a 100 pM stock solution and solution of 10 pM was 
prepared by dilution with sterile dH20 for PCR amplification. These solutions were stored at - 
20°C. Two gene specific primers were designed for each clone required, using the full
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nucleotide sequences published in GenBank. Restriction sites, compatible with the vector 
multiple cloning site, were inserted immediately before the first nucleotide of the desired forward 
sequence and immediately before a stop codon in the reverse sequence. Primers were 
generally of 30 bp in length with a 50-60% GC content which was adjusted by calculating the 
number of individual nucleotides comprising the restriction site and compatible forward or 
reverse sequence of the primer. Any deficit was balanced within a nucleotide clamp 5’ to the 
restriction site (Figure 2.1). The primer pairs used to create specific DNA clones are given in the 
relevant chapters.
Forward primer
5 ’x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x  3 9 
Clamp ResSite cDNA
Reverse Primer
5 ’x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x  3 9 
Clamp ResSite Stop cDNA
Figure 2.1 Representation of primer design
2.1.2.2 Polymerase Chain Reaction (PCR)
Phusion High- Fidelity DNA Polymerase (Finnzvmes. Massachusetts. USA): This is a highly 
accurate thermostable polymerase. A double-strand DNA binding domain, fused with a 
polymerase, increases processivity 10-fold, reduces extension times, provides greater 
amplification yield and enables long templates to be copied more rapidly. Supplied as 2 units/pl 
stock. Storage at -20°C, in buffer Tris/HCI 20 mM, KC1100 mM, DTT 1 mM, EDTA 0.1 mM, BSA 
200 pg/ml, Glycerol 50%, Tween-20 0.5%, Nonidet P40 0.5%, pH 7.4 at 25°C.
Phusion HF buffer: Contains MgCI2 7.5 mM
Deoxvnucleotide mix (Siama): Contains 10 mM each of Ultrapure dATP, dCTP, dGTP and TTP 
sodium salts in high molecular biology grade water. Stored at -  20°C.
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Molecular biology grade dHgO (Sigma): DNase, RNase and protease free. 0.1 pm filter 
sterilised.
Table 2.1 Standard PCR reaction mix
Reagent
Final
Concentration Volume (pi)
Phusion DNA Polymerase 1 Unit 0.5
Phusion HF Buffer (5x) 1X 10
dNTPs (10 mM) 200 pM 1
DNA template (2 ng/ pi) 40 pg 1
Forward Primer (10 pM) 0.2 pM 1
Reverse Primer (10 pM) 0.2 pM 1
dH20  (molecular biology grade) 35.5
TOTAL 50
A two-step ‘extended’ PCR programme was used (Table 2.2). The first five cycles were at a 
high annealing temperature to encourage specific binding of primers to their complementary 
sequence and provide a stock of specific template DNA for the clone required. The annealing 
temperature was then lowered for the final 38 cycles as non-specific binding to the original 
template (outside of the region to be cloned) would be overwhelmed by the concentration of 
specific DNA cloned in the first five cycles.
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Table 2.2 Extended PCR cycle
Step Temperature (°C) Time No. Cycles
Denatu ration 95 5 min 1
Denatu ration 95 30 sec 10
Annealing 65 10 sec 10
Extension 72 15 sec/kb 10
Denatu ration 95 30 sec 42
Annealing 55 15 sec/kb 42
Extension 72 2 min 42
Extension 72 10 min 1
PCR reactions were set up as shown above (Table 2.1) and placed into a thermocycler 
(GeneAmp PCR system 9700, Applied Biosystems, California, USA) using the extended PCR 
program.
2.1.2.3 PCR clean-up
Two methods were used for PCR clean-up. Three of the constructs cloned were small -133 bp 
and the size limit Of the extraction medium was critical to the removal of primers, nucleotides, 
enzymes, salts, and other impurities from the cloned DNA samples.
Gel extraction kit (Qiaaen. West Sussex. UK): Enables removal of primers, nucleotides, 
enzymes, agarose and EtBr from DNA. The size limit to extract and purify DNA was 70 bp which 
made this the method of choice for small DNA constructs. PCR products were run on an 
agarose gel. Using a UV lamp for detection, bands containing the correct sized PCR product 
were excised and weighed. A specific volume, relative to gel weight, of Qiagen buffer QG was 
then added and incubated at 50°C until all agarose was dissolved. 1 gel volume of isopropanol 
was added and the mixture applied to a ‘QIAquick’ column and centrifuged for 1 minute at
10,000 fir to bind DNA to the silica-gel membrane of the column. The eluate was disposed of the 
DNA washed with another 0.5 ml of buffer QG to remove all residual traces of agarose. The 
DNA was then washed in a buffer containing ethanol and the remainder of the protocol was the
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same as for the PCR purification using the QIAquick column. DNA was eluted into a small 
volume of elution buffer to finish.
PCR clean-up kit (Qiaaen): 100 bp -  10 kb. 5 volumes of a high salt buffer were added to the 
PCR mixture which was then passed through the membrane by centrifugation at 10,000 gfor 1 
minute. Nucleic acids adsorb to the silica-gel membrane in buffer containing chaotropic salts 
which reduce the negative charge of the DNA to enable stronger interaction with the column 
membrane. The DNA was washed in 0.75 ml ethanol buffer and the column was centrifuged for 
1 minute. The eluate was discarded and a second centrifugation was used to remove all 
residual traces of ethanol which may interfere with DNA elution. The DNA was then eluted in a 
small volume of low salt buffer in a final centrifugation step for 1 minute, which increases the 
repulsion between the membrane and the DNA.
2.1.2.4 Ethanol precipitation
Where PCR fragments were too small for PCR purification, ethanol precipitation was used 
instead. This involved addition of 1/10th DNA mixture volume of sodium acetate to the DNA mix. 
In the presence of ethanol, which reduces the polarity of the solution, DNA phosphate groups 
form stable ionic bonds with any positively charged ions available (Na+) and the DNA 
precipitates out of solution. The mixture was incubated on dry ice with 3x total volume of 100% 
ethanol for 30 minutes, then centrifuged at 13,000 g for 10 minutes. The supernatant was 
carefully removed and the pellet washed with 70% ethanol. Following a second spin for 1 
minute and removal of supernatant, the pellet was resuspended in a small volume of water.
2.1.2.5 Restriction digest
Following DNA clean-up the PCR products were subjected to a restriction digest to prepare 
them for insertion into the pGEX 6P-1 cloning vector.
BamH1 enzyme (NEB): Recognition site; 5’...GGATTC...3’ 3’...CCTAGG...5’
20,000 units per ml concentration (One unit is defined as the amount of enzyme required to 
digest 1 pg of A DNA in 1 hour at 37°C in a total reaction volume of 50 pi.)
EcoR1 enzyme (NEB): Recognition site; 5’...GAATTC...3’ 3’...CTTAAG...5’
Enzymes are stored in 50% glycerol at -20°C and are sourced from Ecolab
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EcoR1 buffer (10x) (NEB): Tris-HC1100 mM, NaCI 50 mM, MgCI2 10 mM, Triton X-100 0.025%, 
pH 7.5 at 25°C
BSA (100x) (NEB): 100 pg/ml
Both restriction enzymes have 100% efficiency in the EcoR1 buffer, which enabled a double 
digest reaction to be performed. BSA is required by BamH1 and provides additional protein 
which helps to stabilise this enzyme and balance any negative effects arising as a result of 
enzyme interaction with solid surfaces and/or the air-liquid interface. To ensure glycerol levels 
were not too high in the mixture, which could result in ‘star’ activity (non-fidelity to the restriction 
sequence resulting in non-specific cuts) by the restriction enzymes the glycerol must be no 
more than 2% of the total volume. 1 pi of each enzyme is sufficient for a total reaction volume 
up to 100 pi.
Table 2.3 Standard Restriction digest recipe
Reagent Concentration Volume (pi)
Undigested DNA 5pg 10
Eco R1 enzyme 20 units 1
Bam H1 enzyme 20 units 1
Eco Rt buffer (10x) 1X 2.5
BSA (100x) 1X 0.25
dH2C> 41% 10.25
TOTAL 25
Following restriction digest (Table 2.3) the cut product was cleaned up by either gel extraction 
or PCR clean-up. The final elution step was into 30 pi of dH20 . 5 pi was run on an agarose gel 
to visualise, asses the quality and estimate the concentration of the DNA.
The cloning vector pGEX-6P-1 was also cut by the EcoR1 and BamH1 restriction enzymes to 
prepare it for ligation with the cloned and cut DNA fragments (Figure 2.2).
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pGEX-6P-1(27-4597-011 
 PreScissjorT Proteose
'Leu Glu Val Leu Phe Gln^Gty ProlLeu Gly Ser Pro Glu Phe Pro Gly Arg Leu Glu Arg Pro His 
CTG GAA GTT CTG TTC CAG GGG CCC CTG GGA TCC CCG GAA TTC CCG GGT CGA CTC GAG CGG CCG CAT
I------------------ I 1-------------- |_  L-|------------|_J L_|----------------------1
BamHI EcoRI Sma, Sail xho) Not I
Figure 2.2 The multiple cloning site of pGEX-6P-1 vector showing the protease 
cleavage site and BamHI and EcoRI restriction sites (GE Healthcare, UK).
2.1.2.6 Ligation
T4 Liqase buffer (10x): Tris-HCI 50 mM, MgCI2 10 mM, ATP 1 mM, DTT 10 mM, pH 7.5 at
25°C.
T4 Liqase (NEB): Catalyzes the formation of a phosphodiester bond between juxtaposed 5' 
phosphate and 3' hydroxyl termini in duplex DNA or RNA. This enzyme will join blunt end and 
cohesive end termini as well as repair single stranded nicks in duplex DNA, RNA or DNA/RNA 
hybrids. Recombinantly sourced, purified from E.coli. 12,000 units/mg. (One unit is defined as 
the amount of enzyme required to give 50% ligation of Hindlll fragments of A DNA in a total 
reaction volume of 20 pi in 30 minutes at 16°C in 1X T4 DNA Ligase Reaction Buffer).
Standard Ligation protocol
For efficient ligation, a ratio of insert to vector of approximately 10:1 is required.
To calculate this for each given insert, the number of ng per kb of vector is first calculated (e.g. 
100 ng/4.9 kb = 20.41 ng/kb). The number of ng insert needed for a 1:1 ratio is calculated by 
multiplying this value by the size of the insert in kb (e.g. for an insert of size 1 kb; 1 x 20.41 = 
20.41 ng insert is required)
To get the 10:1 ratio, this value is multiplied by 10.
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The following table (2.4) provides the amounts of each reagent used in the ligation experiments 
Table 2.4 Standard Ligation recipe
Reagent Stock concentration Final
concentration
Volume
Insert (X kb ) Y ng/pl Z ng/pl V
Vector pGEX 6P-1 (4.9 k b ) 100 ng/pl 20 ng/pl 1 pi
T4 DNA Ligase 7x ~1 X 2 pi
T4 Buffer 10x 1x 2 pi
dH20 - - Up to 20 pi
Total 20 pi
X = Length of insert (kb)
Y = Stock concentration of insert (ng/pl)
Z = (10X x (100/4.9))/20
V = 20/(Y/Z)
2.1.2.7 Transformation
TOP1Q E.Coli chemically competent cells: Suitable for cloning unmethylated DNA from PCR 
amplifications.
Super Optimal Broth with Catabolite repression (SOC) media, filter sterilised: Bacto-tryptone 2% 
w/v, yeast extract 0.5% w/v, NaCI 10 mM, KCI 2.5 mM, MgCI2 10 mM, glucose 20 mM, dH20 , 
pH 7.0. Stored at -20°C. Nutrient rich bacterial growth medium, results in higher transformation 
efficiency of plasmids (Sun 2009).
Lvsoaenv Broth (LB) media (broth): T rvotone 10 g/L, Yeast Extract 5 g/L, NaCI 5 g/L, dH20 . 
Autoclaved as described previously. For LB agar, 15 g/L agar was added. LB Agar was cooled 
to 50°C before adding relevant antibiotics and pouring into petri dishes to set.
Ampicillin. filter sterilised: 100 mg/ml stock made up in dH20 . Ampicillin is a broad-spectrum (3- 
lactam antibiotic. It is able to disrupt cell wall synthesis, acting as an inhibitor or transpeptidase, 
in certain Gram-positive and Gram-negative bacteria.
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Chloramphenicol, filter sterilised: 40 mg/ml stock made up in EtOH. This is a broad spectrum 
antibiotic, effective against a wide variety of Gram-positive and Gram-negative bacteria. It 
inhibits bacterial protein synthesis.
50 pi chemically competent bacteria were gently thawed on ice before adding 1-5 pi of ligation 
mix in a microcentrifuge tube. The mixture was incubated on ice for 30 minutes and then 
subjected to a 45 second heat shock in a 42°C water bath. The microcentrifuge tube was placed 
back on ice for 2 minutes and 1 ml of room temperature SOC media was added. The culture 
was incubated for 1 hour at 37°C in an Innova 4300 shaker (New Brunswick Scientific, 
Hertfordshire, UK) at 225 rpm. 150 pi of the cell mixture grown in the SOC media was plated 
onto a pre-warmed LB agar plate containing Ampicillin at 100 pg/ml. Plates were incubated for 
16-18 hours at 37°C. Colonies were screened for plasmid containing the insert either by 
preparing DNA using a mini prep kit, or by colony screening.
2.1.2.8 Colony PCR
GoTAQ® Green Master Mix (Promeaa): Contains GoTaq® Green polymerase in 2x reaction 
buffer with dNTPs (400 pM) and MgCI2 (3 mM). Enables the PCR reaction to be directly loaded 
onto an agarose gel as the reaction buffer increases sample density, serving as a loading dye.
Table 2.5 Colony screen PCR reaction recipe
Reagent Concentration Volume (pi)
GoTaq Green Master mix (2x) 1X 12.5
Forward primer 0.1-1 pM X
Reverse primer 0.1-1 pM X
DNA template/ bacteria <250 ng X
dH20 (molecular biology grade) to 25 pi
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Table 2.6 PCR cvcle used
Step Temperature (°C) Time No. Cycles
Denatu ration 95 2 min 1
Denatu ration 95 1 min
Annealing 50 30 sec 30
Extension 72 1 min/ kb insert
Extension 72 5 min 1
Defined colonies were selected for screening for vector containing the insert by scraping a small 
sample of a single colony with a sterile pipette tip and adding this to the GoTaq reaction mixture 
within a PCR tube by repeatedly pipetting up and down to disperse the cells. The PCR cycle 
incorporates an initial boiling step to enable cell lysis and DNA dispersal within the PCR 
mixture. Taq polymerase has a relatively low specificity but as there will be no template for the 
polymerase to bind to in negative colonies, any positive PCR reaction will indicate potential 
positively transformed colonies, which can be further analysed by mini-prep and sequencing.
2.1.2.9 Plasmid purification
Resuspension solution: Tris-HCI 50 mM (pH 7.5), EDTA 10 mM, RNase A 100 pg/ ml 
Lvsis solution: NaOH 0.2 M, SDS 1%
Neutralization solution: Guanidine hydrochloride 4.09 M, Potassium acetate 0.759 M, Glacial 
acetic acid 2.12 M, pH 4.2.
Column wash solution: Potassium acetate 162.8 mM, Tris-HCI 22.6 mM pH 7.5, EDTA 0.109 
mM, pH 8.0
Mini-prep kit (Promeoa): Wizard Plus SV Minipreps DNA Purification System: For small scale 
isolation of plasmid DNA. Defined colonies were selected for screening of vector-containing 
insert by picking a small colony with a sterile pipette tip and adding this to 5-10 ml LB media 
containing Ampicillin and growing overnight (Innova shaker, 37°C). Bacteria were then pelleted 
at 3000 g in an Avanti centrifuge for 5 minutes. The media was discarded and the pellet 
resuspended in 250 pi resuspension solution. 250 pi cell lysis solution was added. This contains 
SDS to solubilise the phospholipid and protein components of the cell membrane, leading to
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lysis and release of DNA. NaOH denatures chromosomal and plasmid DNA. Alkaline protease 
(10 pi) is added after lysis to inactivate endonucleases and other proteins released during 
bacterial lysis. The lysate was then neutralised by addition of potassium acetate in 
neutralization buffer (350 pi). The high salt concentration precipitates chromosomal DNA and 
proteins, as well as cellular debris but the plasmid DNA remains in solution. Precipitants were 
pelletted by centrifugation at 14,000 rpm for 20 minutes. The supernatant, containing plasmid 
DNA, was passed through a collection tube. The DNA, bound to the matrix, was washed twice 
with wash solution containing ethanol to remove any residual cell constituents, first with 750 pi, 
then with 250 pi after another centrifugation for 1 minute. A centrifugation is used to remove the 
second wash buffer, a further spin removes any residual ethanol that may prevent 
resolubilisation of DNA in elution buffer. The purified DNA was eluted in 40 pi of dH20 . 5 pi was 
screened for insert by performing a double digest, in a 20 pi reaction, with Bam H1 and EcoRI 
enzymes as above. 5 pi of the digest was then analysed by agarose gel electrophoresis. If the 
cleaved fragment of insert DNA was required for future ligation then the band was extracted 
using the gel extraction kit (Qiagen).
Plasmid maxi-prep. Qiaaen: For large scale (up to 100 pg) isolation of plasmid DNA. The 
principles behind this protocol are the same as for plasmid mini-prep, but a starting culture of 
approximately 200 ml was used to generate the DNA. Bacteria were harvested at 6000 gr for 15 
minutes at 4°C, then resuspended in 10 ml resuspension buffer. 10 ml lysis buffer was then 
added and the sample gently agitated for 5 minutes to encourage cell breakage without 
shearing of genomic DNA. A neutralization buffer (10 ml) was added and mixed immediately, 
again by gentle inverting, followed by incubation on ice for 20 minutes to enhance precipitation. 
The sample was then centrifuged at 20,000 g for 30 minutes at 4°C and the supernatant was 
applied to a 10 ml QIAGEN column to bind DNA by gravity flow. The column was washed with 2 
x 30 ml wash buffer containing ethanol, followed by elution with 15 ml water or specific elution 
buffer. DNA was then precipitated by addition of 10.5 ml room temperature isopropanol. This 
was mixed and centrifuged immediately at 15,000 g for 30 minutes at 4°C. The supernatant was 
carefully discarded and the DNA pellet washed in 5 ml of room temperature 70 % ethanol,
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followed by another centrifugation, for 10 minutes. The supernatant was removed and the pellet 
air dried. DNA was then redissolved in 400 pi molecular grade water.
2.1.2.10 Sequencing
ABI prism BIG-DYE® terminator sequencing dNTPs: Incorporation of uniquely labelled BIG-DYE 
dNTPs during the PCR cycle results in termination of the DNA extension. A successful PCR will 
contain truncated amplicons at all possible lengths. This sample is then passed through a gel- 
filled capillary tube, with a charge applied across it as in standard electrophoresis, where DNA 
migrates towards a positive charge such that smaller fragments move fastest. Simultaneous 
recording of the dNTP fluorescence passing through the capillary provides a read-out of the 
incorporated base at each length, as each of the four dNTPs is labelled with a different coloured 
dye. Hence a full sequence can be obtained for the PCR product.
DveEx 2.0 Spin kit (Qiaaen): Unincorporated dye terminators following the sequencing PCR 
reaction (above), are retained in a gel matrix to prevent interference during the sequencing 
read. A column containing the gel matrix is vortexed and centrifuged at 3000 rpm for 3 minutes 
to remove the storage buffer. The PCR reaction mixture is pipetted onto the surface of the gel. 
Subsequent centrifugation (3 minutes) passes the sample through the gel matrix and the clean 
sample can be sequenced directly.
Table 2.7 BIG DYE sequencing PCR reaction recipe
Reagent Concentration Volume (ul)
ABI BIG DYE® terminator sequencing kit (7x) 1X 2
Sequencing primer 10 pM 2
DNA template 2 ng /  pi 2
dH20 (molecular biology grade) 14
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Table 2.8 Standard sequencing PCR cycle
Step Temperature (°C) Time No. Cycles
Denatu ration 95 3 min 1
Denatu ration 95 30 sec 32
Annealing 50 15 sec 32
Extension 60 4 min 32
Extension 60 10 min 1
Mini-prep plasmid preparations were sequenced using the above protocol to confirm correct 
plasmid insert sequence. Samples were sent to CBS Cardiff University for sequencing in an ABI 
Prism 377 sequencer.
2.1.3 Quikchange® XL Site-Directed Mutagenesis
Primers, designed to be complementary to a region of intended mutation, except for the specific 
bases in which the mutation is desired, are used in a PCR reaction to produce modified DNA 
amplicons. Quikchange® enables point mutations, changes in amino acids, or 
deletions/insertions of amino acids using a thermal cycling technique in combination with Dpn1 
restriction digest. As Dpn1 is specific to methylated and hemi-methylated DNA, it will only digest 
the non-mutated parental DNA template but does not digest the mutant-synthesized DNA. The 
system uses Pfu Ultra-High Fidelity DNA polymerase. Two primers, both containing the desired 
mutation, cover the area where the mutation is to be made.
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Step 1
Plasmid Preparation
Step 2
Temperature Cycling
Mutogenlc
Step 3 
Digestion
Step 4
Transformation
Mutated plasmid 
(contain nicked 
circular strands)
Gene in plosmid with 
target site ($ ) for mutation
Denature the plasmid and anneal the 
oligonucleotide primers { / )  containing 
the desired mulotion (x )
Using the nonstrond-displacing 
action of PfuTurba DNA polymerase, 
extend and incorporate the 
mutagenic primers resulting 
in nicked circular strands
Digest the methylated, nonmutated 
parental DNA template with Dpo I
Transform the circular, nicked dsDNA 
into XL1 -Blue supercompetent cells
After transformation, the XL1 -Blue 
supercompetent cells repair the 
nicks in the mutated plosmid
LEG fNO
— Rommtal DNA plasmid
Mutagenic primer
— Mutated DNA plasmid
Figure 2.3 Quikchange® mutagenesis as shown in the manufacturers’ manual.
The protocol for site-directed mutagenesis was found to be more efficient when modified 
slightly. The manufacturer recommends addition of 1 pi Dpn1 enzyme to the PCR reaction for 1 
hour to digest parental DNA, however, 1.5 pi enzyme with a 2 hour incubation gave positive 
results, where the recommended protocol did not.
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Table 2.9 PCR reaction mix for site-directed mutagenesis (Polymerase is added after the 
mixture is made u p  to 50 ul).
Reagent Concentration Volume (pi)
reaction buffer (10x) 1x 500%
dsDNA template 10 ng X
mutant primer 1 125 ng X
mutant primer 2 125 ng X
dNTP mix 1
Quiksolution 3
dH20 Up to 50 pi
PfuTurbo DNA polymerase 2.5 units 1
Table 2.10 PCR cycle for site-directed mutagenesis
Step Temperature (°C) Time No. cycles
Denatu ration 95 1 min 1
Denaturation 95 50 sec
Annealing 60 50 sec 18
Extension 68 1 min/kb plasmid
Extension 68 7 min 1
2.2 Protein production and biochemistry
2.2.1 Protein analysis by SDS-Polyacrylamide gel electrophoresis (PAGE)
SDS Sample buffer with bromophenol blue: Tris 1M, SDS 20% w/v, glycerol 6 ml, EDTA 100 
mM, dH20  to total volume of 20 ml, pH 6.8, a small spatula of Bromophenol blue was added 
and when dissolved the solution was filtered through a micropore 0.22 pm filter and stored at 
room temperature, DTT was added at 50 mg/ml buffer immediately prior to use. The SDS (an 
anionic detergent) and DTT (which reduces thiol groups and disrupts cysteine bridges) both
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contribute to the disruption of the tertiary and secondary structure of proteins. In addition the 
SDS binds to the protein (a process aided by heating the sample with the loading buffer) and
gives each protein a uniform negative charge.
SDS running buffer: T ris 15 g/L, Glycine 72 g/L, SDS 5 g/L, (5x stock), store at room 
temperature and dilute for use
1.5 M Tris/HCI (separating gel) buffer: T ris 1.5 M, dH20 , pH 8.8, stored at 4°C 
0.5M Tris/HCI (stacking gel) buffer: Tris 0.5 M, dH20 , pH 6.8, stored at 4°C.
40% Acrvlamide/Bis solution 19:1 ratio (Biorad): Polyacrylamide gels form as a result of 
crosslinking between acrylamide and bis-acrylamide.
Ammonium persulphate: 50 mg in 0.5 ml dH2CL
TEMED: Increases the rate of production of free radicals from persulphate. These free radicals 
increase the rate of polymerisation of acrylamide by reacting with and radicalising 
unpolymerised acrylamide. This reactive acrylamide then reacts with other acrylamide 
molecules creating crosslinks which in turn creates a gel matrix.
PBS buffer 1X: NaCI 137 mM, KCI 2.7 mM, Na2H P 04 4.3 mM, KH2P 0 4 1.47 mM pH7.4
(prepared as a 10X stock and diluted prior to use).
Protein stain: SimplyBlue™ SafeStain -  coomassie based (Invitrogen, Paisley, UK).
Protein MW Markers: Kaleidoscope prestained MW range, 7-200 kDa (Biorad), Wide range MW 
markers, 7-200 kDa (Sigma) or ColourPlus prestained markers, Biorad range, 7-175 kDa 
(NEB).
Transfer buffer: Tris 48 mM, Glycine 39 mM, SDS 3.75 ml of 10% solution, 20% methanol 
(exclude methanol for RyR transfer), dH20 , stored at 4°C
Blotting buffer: (Tris-buffered saline - TBS): T ris 200 mM, NaCI 1.37 M, dH20 , pH 7.4, stored at 
room temperature as 10x stock, diluted prior to use, allowing for addition of 1 ml Tween-20 per 
500 ml buffer, re-pH to 7.4. BSA 5% w/v or non-fat milk powder 5% w/v (dependent upon the 
primary antibody) were added for all but the last two washes of the Western blot procedure (see 
below). These proteins are present to block non-specific binding of low affinity proteins and 
prevent non-specific binding of antibodies to the polyvinylidene fluoride (PVDF) membrane
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Proteins can be separated on the basis of their molecular size by electrophoresis (Laemmli 
1970). The gels are formed from acrylamide and bis acrylamide which are cross-linked in the 
presence of TEMED and ammonium persulphate (see above).
Table 2.11 Acrylamide gel composition
Reagent
Final proportion 
(separating gel)
Final proportion 
(stacking gel)
bis- acrylamide x % 2.50%
Tris pH 6.8 (pH 8.8 for stack) 25% v/v 25% v/v
SDS 10% w/v 0.5% v/v 0.5% v/v
Ammonium persulphate 10% w/v 0.5% v/v 0.5% v/v
TEMED 0.05% v/v 0.05% v/v
dH20 Up to 30 ml Up to 30 ml
X is dependent on the percentage of acrylamide required according to the size of the proteins to 
be run -  the larger the protein the smaller the percentage gel. The lower percentage and pH of 
the stacking gel concentrates the proteins into a tight band at the interface with the separating 
gel. As the proteins move through the latter their progress and resolution is dependent upon 
their mass.
SDS-PAGE mini-gel tanks and plates were supplied by Biorad and assembled following the 
manufacturers’ protocol. The appropriate percentage separating gel was poured and a layer of 
water applied over the top. When the gel was set the water layer was removed by absorption 
using a paper towel. The stacking gel and comb (0.75 mm), used to create loading wells, were 
then added. When set, the gel containing plates were clamped into the electrode assembly and 
placed in a running tank which was filled with 1x SDS running buffer. 20 pi protein samples 
were boiled with 10 pi of 3x SDS loading buffer for 1 minute. Cooled samples were then loaded 
into the gel wells using a Gilson pipette and Biorad gel tips for precision loading. Protein 
standards were run in one lane. A charge of 80 V was placed across the chamber until the dye 
front had passed through the stack of the gel. The voltage was then increased to 200 V until the
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dye front (Bromophenol blue) was at the bottom of the gel. The gel was removed from the tank 
and either stained with Coomassie or used for Western Blotting (see below).
2.2.1.1 Coomassie Staining
The gel was transferred to a flat container and washed in dH20  for 20 minutes, with 2 changes 
of water, to remove SDS from the gel. 10 ml of coomassie stain was then added to the gel and 
incubated until significant bands were visible -  usually 1 hour to overnight. The gel was then 
washed in dH20  until all the background stain had disappeared.
2.2.1.2 Western Blotting
Antibodies (Ab)s
Anti-phosphoserine 16B4, mouse monoclonal (Sigma), used at x200 dilution
Anti-RyR1 (2142), ‘in house’ rabbit polyclonal raised against a peptide to rRyR1 aa 830-835
(used atx1000),
Anti-RyR2 (1093), ‘in house’ rabbit polyclonal raised against peptide to hRyR2 4459-4478 (used 
at x1000),
Anti-FKBP (12/12.6), goat polyclonal (Santa Cruz Biotechnologies), used at x250)
Anti-GST (103T), ‘in house’ rabbit polyclonal raised against recombinant GST used at x10000. 
Anti-mouse secondary, HRP conjugate (Pierce), used at x5000 dilution 
Anti-rabbit secondary, HRP conjugate (Sigma), used at x10000 dilution.
Anti-goat secondary, HRP conjugate, (Pierce), used at x5000 dilution
PVDF membrane. Immobilon-P (Millipore. Watford. UK): 0.45 pm pore size. Prepared before 
use by soaking in methanol for 1 minute.
ECL reagents (Amersham. Buckinghamshire. UK): Enables chemiluminescent detection of 
antibody binding using horse-radish peroxidase (HRP). HRP conjugated secondary antibody 
bound to the PVDF membrane surface reacts with water in the detection reagent. This oxidises 
luminal, also in the reagents, to generate enhanced chemiluminescence. The ECL reagents are 
mixed in a 1:1 ratio to activate the oxidation reaction and any light emitted is detected on ECL 
hyperfilm upon exposure in a dark room.
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Figure 2.4 The ECL detection process from the GE Healthcare website.
Following SDS-PAGE the run gel is soaked in transfer buffer for 20 minutes. The PVDF 
membrane was washed for 30 seconds in methanol to prime before also soaking in transfer 
buffer, along with 6 sheets of blotting paper. The gel, membrane and blotting paper were then 
assembled on the bottom plate (anode) of a semi dry blotter (Trans-blot SD, semi-dry transfer 
cell, Biorad) in the following order; blotting paper x 3, PVDF membrane, gel, blotting paper x 3. 
Each layer was gently rolled onto the next using a plastic pipette as a ‘rolling pin’ to remove air 
bubbles, which would have inhibited transfer. After assembly, the lid of the semi-dry-blotter 
containing the cathode plate was placed on top. The transfer was run for 30 minutes at 400 mA 
for small MW proteins and up to 4 hours for those of very high MW (see individual chapters). 
The blotting stack was disassembled. Kaleidoscope markers were normally run on SDS-PAGE 
gels destined for Western Blot and the transfer of these was a good test of efficiency. The 
membrane was normally marked with a biro to indicate the marker bands as these would often 
fade during the antibody incubation stages. The membrane was placed in blotting buffer with 
the appropriate BSA or milk powder addition, to prevent non-specific binding, for 1 hour at room 
temperature or overnight at 4°C. At room temperature the primary Ab at the given dilution was 
then added for 1 hour. This was followed by 3 consecutive 10 minute washes with blotting 
buffer. The HRP conjugated secondary Ab was then added at the appropriate dilution for 1 
hour. Finally the membrane was washed once with blotting buffer (10 minutes) and twice with 
TBS-Tween buffer minus the BSA or milk powder.
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For detection of the specific protein bands ECL reagents were combined in a 1:1 ratio and 
washed over the membrane for 1 minute. The membrane was then placed in a cassette with a 
sheet of film (Amersham Hyperfilm™, GE Healthcare) for 1 minute in the first instance. The film 
was then removed in the dark and developed (X-ograph Imaging system, Compact X4). The 
membrane was then exposed to the film for varying time periods depending on the signal 
strength of the developed 1 minute film.
2.2.2 GST-tagged recombinant protein production
Salt buffers for protein purification and washes: NaC11 M /  300 mM / 50 mM, Tris 20 mM, EDTA 
2 mM, DTT 2 mM (added before use), pH 7.5
Rosetta™ E.colh These are bacteria engineered to expressing eukaryotic codons rarely used by 
E.coli. Rosetta provide tRNAs for these codons on a compatible chloramphenicol-resistant 
plasmid. Rosetta originate from the BL21 strain of E. coli and thereby also lack two key 
proteases which would otherwise contribute to the degradation of expressed proteins.
Isopropvl B-D-1-thioaalactQDvranoside (IPTG): 100 mM stock in dH20 , filter sterilised, stored at - 
20°C, diluted 1:1000 for use. IPTG is a non-metabolisable analogue of lactose and remains at 
constant concentration when added to bacterial culture. It is used with bacterial expression 
vectors (such as pGEX-6P-1 see below) where the lac operon drives plasmid protein 
production.
Glutathione sepharose 4B affinity chromatography medium (GE Healthcare): 60% slurry in 20% 
ethanol, washed to remove ethanol before use. This has an affinity for GST and other 
glutathione binding proteins. Total binding capacity is 10 mg recombinant GST/ml medium. 
Reduced glutathione solution: Reduced glutathione (Sigma) 10 mM was dissolved in Tris/HCI 
50 mM, pH 8.0. The solution was made immediately before use.
Lvsozvme: Catalyzes hydrolysis of bacterial cell walls (From Egg white 50000 units/mg, Merck- 
Chemicals, Nottingham, UK).
Benzonase. purity grade II (> 90%).Merck: pH 8.0, specific activity > 1.0E+06 units/mg, high 
speed activity, genetically engineered endonuclease for degrading DNA and RNA.
Vivaspin 3.000 kDa cut-off column (Sartorious): the appropriate buffer was washed through 
membrane before use to remove membrane preservatives and prime the membrane for use.
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2.2.2.1 The pGEX expression vector system
The glutathione S-Transferase (GST) Gene Fusion System was developed by GE Healthcare. 
The pGEX series of vectors are all characterised by the inclusion of a GST ‘tag’ C-terminus to 
the multiple cloning site and separated from it by a protease cleavage site. For our studies we 
have used pGEX-6P-1 (see Figure 2.4). Expression in E. coli produces a fusion protein which 
can be affinity purified from bacterial lysate by high affinity binding to glutathione sepharose 4B 
beads. If required, the fused protein can be removed from the beads by the addition of a 
reduced glutathione solution. Alternatively the precision protease site can be used to cleave the 
cloned protein from the GST tag using 3C protease, which is derived from human Rhinovirus
and is itself cloned into a pGEX vector. This enables the 3C protease and the cleaved GST
moiety to remain attached to the beads and the recombinant protein is liberated into solution for 
further purification. As well as the role in affinity purification, the GST tag can be used to track 
expression using an Anti GST Ab, it also aids solubility of the recombinant protein. pGEX 
vectors all contain a la c f  expression operon and expression can be induced by IPTG (see 
above) which combines with the lac repressor protein and de-inhibits transcription (Jacob and 
Monod 1961). pGEX vectors also carry an ampicillin resistance gene which is used for selection 
of colonies carrying the plasmid as these will grow in ampicillin containing medium.
PGEX-6 P -1 I27-4597-OU 
PreSctsswn" Proteose
leu Glu vol leu Phe Pro I leu Gly Ser Pro Glu Phe Pro Gly Arg Leu Glu Arg Pro His
CTG GAA GTT CTG TTC CAG GGG CCC CTG GGA TCC CCG GAA TTC OCG GGT CGA CTC GAG CGG CCG CATt--------------- 1 I------------£ .  U ---------- M  M  >
BomH I EcoR | | Sol I ^ho I Not I
Ml
PtOC
Pst I
pGEX
-4900 tp
Figure 2.5 pGEX-6P-1 plasmid map The glutathione sepharose transferase 
(GST) tag region is highlighted, along with the Amp resistance gene and the lac 
operon (From the GE Healthcare website).
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2.2.2.2 Optimisation of protein expression in Rosetta
Rosetta bacteria were transformed with 2 pi of protein plasmid construct (mini-prep or maxi-prep 
-known from sequencing to contain plasmid with the correctly cloned DNA) following the 
standard protocol and plated for selection on LB agar plates containing both Ampicillin and 
Chloramphenicol. A single colony was inoculated into 4 x 10 ml starter cultures for 16-18 hours 
(37°C, Innova shaker). These four clonal cultures were then combined and added to 1 litre LB 
broth containing only Ampicillin antibiotic as Chloramphenicol can reduce protein synthesis 
efficiency. The culture was incubated at 37°C in a shaking incubator (Innova shaker). Growth 
was tracked with a spectrophotometer at A.600 nm, using a 1 cm plastic cuvette and 
uninnoculated culture medium as the blank, until an optical density at A600 of -0 .6 was obtained. 
At this point the temperature was reduced to either 25°C or 30°C for 30 min to acclimatise the 
culture to the protein growth temperature. A 50 ml sample of the culture was decanted following 
which 1 ml of IPTG was added to induce protein production. The culture continued for a total of 
four hours at either 25°C or 30°C, with 50 ml samples taken every hour. The 50 ml samples 
were pelletted in a centrifuge tube at 7000 gr for 15 minutes, the supernatant was discarded and 
the pellet frozen at -20°C.
To liberate and assess the recombinant protein expression, the pellets were thawed and 
resuspended in 2 ml of 50 mM salt buffer. These were then sonicated on ice in 3 x 15 second 
bursts to lyse the bacteria. The lysate was centrifuged at 15,000 g for 10 minutes to remove 
unbroken bacteria and debris and the resultant supernatant combined with 100 pi of washed 
Glutathione sepharose beads and incubated at 4°C for 1 hour (beads and prep split between 2 
eppendorfs for each time sample). The bead and protein mix were then spun down at 1,000 g 
for 1 minute and the supernatant removed. The beads from each time sample were recombined 
and were washed rigorously by the addition of 1 ml of 1 M salt buffer and re-centrifuged. This 
was repeated three times, after which the beads were washed twice more with 50 mM salt 
buffer. The final wash buffer was removed leaving a total volume (of beads plus buffer) of 100 
pi. 50 pi of 3x SDS loading buffer was added to the sample, which was then boiled for 1 minute. 
20 pi samples were then loaded and run on pairs of SDS-PAGE gels, one of which was
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analysed by Coomassie staining, and the other by Western Blot to determine optimal induction 
time for protein production.
2.2.2.3 Making glycerol stocks of transformed Rosetta cells
A small scale culture (50 ml) was started from a colony, from a transformation of sequenced 
mini prep or maxiprep plasmid, grown on a selective ampicillin and chloramphenicol agar plate. 
The culture was grown overnight, the bacteria spun down and the media removed. 5 ml of SOC 
medium was combined with 5 ml of glycerol and 10 pi each of concentrated ampicillin and 
chloramphenicol antibiotics were added. The 10 ml mixture was filter sterilised and added to the 
bacterial pellet, which was resuspended by vortexing. 1 ml aliquots were pipetted into sterile 
tubes and stored frozen at -80°C. Whenever more protein was required, a sterile loop was 
stabbed into the glycerol stock and spread on a selective plate to grow fresh colonies.
2.2.3 Affinity Purification of GST-tagged proteins
Once optimal growth conditions were ascertained, large scale cultures were grown (1- 2 litres) 
and harvested in 1 litre buckets. Once spun down to harvest cells, pellets were resuspended in 
25 ml PBS /1  litre pellet and stored frozen at -20°C.
Frozen bacterial pellets were thawed and lysozyme (20 mg/pellet from 1 litre of culture plus 1 pi 
of DNAase (Benzonase) were added. The suspension was rolled for 4 hours at 4°C to start cell 
wall lysis. The cells were then passed through the French press four times to lyse the cells 
completely under high pressure. The cell debris was then pelleted at 15,000 gfor 10 minutes 
(Beckman Coulter Avanti at 4°C) and the resultant supernatant combined with 0.5 ml bed 
volume washed glutathione sepharose beads (per 1 litre culture). Beads and supernatant were 
incubated at 4°C over night. Beads and supernatant were then centrifuged at 500 rpm for 5 
minutes in the Allegra bench top centrifuge at 4°C. The supernatant was discarded and the 
beads were washed with 3 x 25 ml 1 M salt buffer, followed by 1 x 25 ml 50 mM salt buffer.
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2.2.3.1 GST-tagged protein liberation
The procedure was scaled according to the initial culture size. For every 1 ml of beads a bed 
volume of 5 ml of reduced glutathione solution was used. Beads were rolled with the solution at 
4°C for 4 hours. The beads and solution were transferred to a gravity feed column and the 
eluate collected. The beads were washed twice more with 5 ml of glutathione solution and the 
eluates combined. For small volumes (<200 pi) the beads were centrifuged at 1000 g for 2 
minutes and the supernatant collected. This was followed by two further 10 minute incubations 
with glutathione solution each followed by centrifugation, after which all the supernatants were 
combined. The combined supernatants were concentrated down to ~2 ml using Vivaspin 
centrifugal concentrators (Sartorius).
2.2.3.1 3C cleavage of recombinant GST protein
3C protease was produced in Rosetta E. Coli from a pGEX-3X vector, following the same 
protocol as standard GST-tagged proteins. This was stored as a harvested pellet at -20°C. 
When the cleavage of a recombinant protein from the 3C moiety was required, the pellet from 1 
litre of culture was processed and combined with 1 ml of GST-beads, which were rigorously 
washed using the methods described above. For cleavage of the required recombinant protein 
from the GST tag, the GST-3C beads were mixed with those from the affinity purification of the 
GST-recombinant protein, in a ratio of 1:6. 2 bed volumes of cleavage buffer were used and the 
beads tumbled together at 4°C overnight. The beads and solution were transferred to a gravity- 
feed column and the eluate collected. The beads were washed with 2 bed volumes of cleavage 
buffer and the eluates combined. The eluates were concentrated to 2 ml using a centrifugal 
concentrator.
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G f~  ' ' ' ' "G  protease Glutathione sepharose bead
Overnight incubation Bead capture and elution of cleaved protein
column
Figure 2.6 3C cleavage of recombinant protein for removal of the 
glutathione sepharose tag. The first stage involves incubation of GST-taggeO 
3C protease and the GST tagged recombinant protein with GST beads 
separately to enable binding. Subsequent wash steps eliminate non- 
specifically bound proteins. Both sets of protein bound to beads are then 
combined and incubated overnight to enable cleavage to occur. Beads are 
then captured on a column along with the GST-tagged 3C and any cleavea 
GST moiety. Cleaved protein is eluted with a small GPLGS tag intact.
2.2.4 Gel Filtration
Gel filtration using Fast Protein Liquid Chromatography (FPLC), AKTA Prime FPLC, GE 
Healthcare) was used to purify cleaved recombinant protein further. 2 ml of concentrated protein 
was injected onto a S75 gel filtration column using a 2 ml sample loop. The column was pre­
equilibrated with Tris/HCI 20 mM, NaCI 300 mM, 2 mM DTT (added on the day of the 
experiment). Flow rate was 0.4 ml/minute. 1 ml fractions were collected and the protein content 
analysed by SDS PAGE and Western Blot. The peak fractions containing the purified protein 
were combined, re-concentrated with a centrifugal concentrator if necessary, aliquoted and 
stored at -20 °C.
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2.2.5 Protein purification using Vivapure Ion Exchange Spin Columns (Sartorius).
Where protein was lacking an extinction coefficient, and therefore not amenable to FPLC 
purification, which relies on UV absorption for tracking and generally involves relatively large 
elution volumes, this protocol enabled purification of small volumes of protein by ion exchange 
using centrifugation. Charged molecules, such as proteins, adsorb to the membrane surface of 
an opposite charge. The isoelectric point (pi) of the protein to be purified must be known, as this 
the pH at which it has a neutral charge, therefore this determines whether there is a positive or 
negative charge at pH 7.0. A positive charge at pH 7.0 required a negatively charged column 
membrane to enable binding. The protein was then eluted by applying small volumes (2 ml) of 
increasing NaCI buffer separately, and centrifuging the column each time. Each sample was 
then tested for protein quantity using BCA assay (below) to determine the optimum salt 
concentration for protein elution. This could then be used in future purifications of this protein.
2.2.6 Protein quantification using Bicinchoninic Acid (BCA) (Micro BCA Protein Assay 
Kit, Pierce)
The basis of the BCA assay is the biuret reaction, which is the formation of a cuprous ion (Cu+) 
from (Cu2+) when it chelates with peptide bonds at alkaline pH to form a blue coloured complex. 
BCA then interacts with the Cu+ produced to form a copper complex with a strong violet 
coloured absorbance at A562. This latter reaction is about 100-fold more sensitive than the biuret 
reaction and the assay is capable of detecting protein in the 0.5-20 pg/ml range. BSA standards 
were used to produce a standard curve and the assay was set up in 96 well, flat bottomed 
plastic plates with a total volume of 200 pi in each well of which 25 pi was sample or standard, 
75 pi dH20 and 100 pi Reagents A, B and C, mixed in the proportions 25:24:1, as per the Pierce 
protocol. The colour was developed by incubation at 60°C for 1 hour and the absorbance at A562 
determined using a plate reader (Multiskan EX, MTX Lab Systems, Virginia, USA) and Genesis 
software.
2.3 r3H1Rvanodine binding
Hot ryanodine mix: Radiolabelled Ryanodine (Perkin Elmer) Concentration 0.1 mCi/ml + cold 
ryanodine at equivalent concentrations in low salt buffer A (section 3.2.1) (Activity; 100 Ci
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/mmol) to provide 5 nM of each in the final assay concentration. Combining labelled with 
equivalent unlabelled ryanodine meant that the labelled ryanodine spread further in experiments 
while ensuring saturation of all potential ryanodine binding sites.
Cold ryanodine (Polvsciences Inc):.1.5 mM dissolved in dH20 . Ryanodine is a poisonous plant 
alkaloid with extremely high affinity to the ryanodine receptor.
Diltiazem: A non-dihydropyridine member of the group of drugs known as benzothiazepines, 
which are a class of calcium channel blockers of the same family as the K201 anti-arrhythmic 
drug. It is a potent vasodilator.
Dimethyl Sulfoxide (DMSQ): Miscible in a wide range of organic solvents including water.
FK506 monohvdrate (Sigma): 1 mM solution made up in DMSO. Stored at -20°C. Interacts with 
FKBP12/12.6.
Binding wash buffer: T ris 25 mM, KCI200 mM, dH20 , pH 8.0, stored at 4°C 
Scintisafe Liquid Scintillation Cocktail (Fisher): 50% efficiency for Tritium. A petroleum 
hydrocarbon based gelling cocktail for aqueous samples. Liberates tritium into solution to 
enable the radioactivity to be counted.
20 mm Glass fibre membranes GFF (Whatman): Soaked in binding buffer before use
2.3.1 Free Calcium Buffers
Stock buffer: PIPES 20 mM, CHAPS 0.05% w/v, KCI 2 M (high salt)/300 mM (low salt), dH20 , 
pH 7.4
Stock EGTA: 200 mM, dissolved in a small volume of 10 M NaCI and diluted into stock buffer 
(above), pH 7.4, serial dilutions in the stock buffer provide 20 mM final concentration. EGTA has 
a much higher affinity for calcium ions than magnesium ions and is useful for making buffer 
solutions that resemble the environment inside living cells, where the calcium ions are often at 
least a thousand fold less concentrated than magnesium.
Stock CaCk 100 mM of dihydrate in stock buffer (above)
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Table 2.12: Free Calcium Buffers
Free Ca*+ Cone (uM) 20 mM 
EGTA
Caz+ stock- high salt 
(ml)
Caz+ stock- low 
salt (ml)
Total
volume
1.00E-08 10 ml 2.65 of 100 mM 0.32 of 10 mM 100 ml
1.00E-07 10 ml 1.21 of 100 mM 1.28 of 10 mM 100 ml
5.00E-07 10 ml 1.76 of 10 mM 1.80 of 10 mM 100 ml
1.00E-06 10 ml 1.88 of 10 mM 1.88 of 10 mM 100 ml
5.00E-06 10 ml 1.98 of 10 mM 1.98 of 10 mM 100 ml
1.00E-05 10 ml 2.01 of 10 mM 2.01 of 10 mM 100 ml
1.00E-04 10 ml 2.20 of 10 mM 2.20 of 10 mM 100 ml
1.00E-03 10 ml 4.00 of 10 mM 4.00 of 10 mM 100 ml
‘values were calculated using the Maxchelator programme to calculate total calcium required 
with the following constants: assay temp 37°C, pH 7.4, Ionic strength 1 M for high salt and 0.15 
M for low salt, EGTA- Ca2+ dissociation constant: 10.98 from
http://www.stanford.edu/~cpatton/xlsconstants.htm on 04/03/2011.
2.3.2 3[H]Ryanodine binding protocol
Assays were set up as below to a total reaction volume of 300 pi and in duplicate for each 
condition type. Ryanodine coupled to radioactive tritium was used to measure the amount of 
ryanodine bound. Buffer A was added to make up the total volume in each case and the assays 
were then incubated in a 37°C water bath for 90 minutes.
Pre-soaked Whatman GFF membranes were then placed on columns of a vacuum manifold 
(Hoeffer). A vacuum was obtained using a Heto Master Jet pump. One full assay was pipetted 
into 5 ml wash buffer on top of the membrane. The membranes were then washed 2x with 5 ml 
ice cold binding wash buffer to stop the reaction and to wash away any un-bound radioactive 
ryanodine. Membranes were removed from the manifold and placed in a scintillation vial with 5 
ml Scintisafe liquid scintillation cocktail before counting radioactivity on the scintillation counter 
(counts per minute) (Packard Tricarb 2100TR Liquid Scintillation Analyser). This process was 
repeated for all assay samples.
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Table 2.13 Standard 3rHlRyanodine binding assay mix
Addition Volume (pi)
RyR preparation 50
Calcium buffer 150
Hot ryanodine mix 10
RyR modulator X
Buffer A to 300
X denotes the volume of RyR modulator added depending on stock concentration and desired 
final concentration. Control assays were set up per each experiment with 10 pi cold ryanodine 
added (3 mM stock) and with no RyR preparation added to detect non specific binding to the 
membranes used. A 10 pi sample of the hot ryanodine mix was also added directly to 5 ml 
scintillation fluid for each experiment to measure the total radioactivity counts per assay.
2.4 Health and Safety
All work done for this investigation was carried out using aseptic technique and all chemicals 
were handled in accordance with COSHH and local college safety regulations. All bacterial 
waste was disinfected with Actichlor (Adams Healthcare, Yorkshire, UK) at 1000 ppm available 
chlorine (1 tablet/1 litre of waste) prior to disposal.
2.5 Statistical analysis
All data are presented as mean values with the standard error of the mean. As most 
experiments were paired, the student’s paired t-test was used to determine statistical 
significance, with a value of p<0.05 considered significant. Where unpaired data were 
compared, an unpaired t-test has been used and this is indicated in the figure legend.
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CHAPTER 3: Preparation of functional RvR channels from native tissue
3.1 Introduction
The RyR complex was first isolated from rabbit skeletal muscle SR fraction in 1988 by Lai et al. 
(Lai, Erickson et al. 1988) CHAPS zwitterionic detergent was used to solubilise RyR protein 
from the SR membrane by creating proteolipids within which the RyR homotetramer is relatively 
stable (Lai et al 1988). Addition of Triton X-100 was reported to selectively remove calcium- 
ATPase, an abundant protein of SR membranes and potential contaminant of RyR 
preparations.
The solubilised protein was applied to sucrose density gradients to separate the RyR protein 
(2,200 kDa) from other solubilised membrane proteins, for example calcium-ATPase (100 kDa), 
or calsequestrin (66 kDa), on the basis of size. The RyR protein, moving more rapidly than its 
smaller companions, could be characterised and isolated from the lower fractions.
Sucrose gradient preparations give a relatively pure RyR samples but the high sucrose and 
NaCI concentrations used restrict their use in certain experimental procedures, for example 
protein-protein interaction studies. Exchanging the sucrose buffer, using dialysis, results in a 
considerable loss of RyR protein, possibly due to aggregation and precipitation. These issues 
were explored when SPR experiments for RyR1/2 and FKBP12/12.6 interaction studies were 
designed (Jones, Reynolds et al. 2005; Jones, D'Cruz et al. 2007; Blayney, Jones et al. 2010).
An alternative protocol, using FPLC and anion exchange, was employed to purify and exchange 
the buffer in one step, taking the CHAPs concentration down to 0.05%, instead of 0.5%, as 
present in sucrose gradients. In this protocol the final NaCI concentration was -300 mM, so the 
sample only required a 2x dilution before experimental application. Sucrose was eliminated from 
the purification method and a faster protocol resulted in extraction of RyR from a microsomal 
preparation in -4 .5  hours, greatly reducing the likelihood of loss of channel functionality for 
experiments.
Chapter 3
This chapter outlines the purification methods for extraction of functional RyR1 and RyR2 
protein from rabbit skeletal and pig heart tissue respectively. The preparations were stripped of 
endogenous FKBP12/12.6 and dephosphorylated or phosphorylated so that modulators of 
activity could be controlled and compared.
3.2 Methods and Materials
3.2.1 RyR extraction and purification from native tissue
RyR1 was extracted from rabbit skeletal muscle and RyR2 from pig hearts. Male New Zealand 
White rabbits (2-2.5 kg) were sacrificed with sodium pentobarbitone according to university 
guidelines and pig hearts were obtained from an abattoir. This investigation conforms to the 
Guide for the Care and Use of Laboratory Animals published by the US National Institutes of 
Health (NIH publication number 85-23, revised 1966).
NB/ Where protease inhibitors were used, they were made-up and added immediately prior to 
use.
Homogenisation buffer: PIPES (Disodium Salt) 10 mM, Sucrose 0.3 M, EDTA 0.5 mM 
(dissolved in 10 M NaOH), dH20 , pH 7.4, stored at 4°C (+protease inhibitors)
Resuspension buffer: KCI 0.6 M, PIPES 10 mM, dH20 , pH 7.1, stored at 4°C (+protease 
inhibitors)
Protease Inhibitor cocktail: Benzamidine hydrochloride 0.8 mM, lodoacetamide 1 mM, AEBSF 
0.2 mM, DTT 2 mM, dH20  (dilute 1:100 for use). Benzamidine is a reversible competitive 
inhibitor of trypsin, trypsin-like enzymes and serine proteases, lodoacetamide is able to bind 
covalently with cysteine, so disulfide bonds cannot form. AEBSF/FLUKA is a water soluble, 
irreversible serine protease inhibitor. DTT is an unusually strong reducing agent, owing to its 
high conformational propensity to form a six membered ring with an internal disulfide bond. 
Solubilisation buffer: PIPES 10 mM, EGTA 100 pM, CaCI2 150 pM, dH20 , pH 7.1, stored at 
4°C.
Triton buffer: 1 g Triton X-100 per 100 ml solubilisation buffer, stored at 4°C. Triton X-100 is a 
commonly used non-ionic detergent for solubilising membrane proteins during isolation of 
membrane-protein complexes. This stage selectively removes the calcium-ATPase from the SR 
membrane complex.
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CHAPS buffer: PIPES 10 mM, NaCI 1 M, CHAPS (Roche) 1.2% w/v, phosphatidylcholine (from 
soybean) 1% w/v, EGTA 100 pM, CaCI2 150 pM, dH20 , pH 7.1, stored at 4°C. CHAPS is a 
zwitterionic detergent for solubilisation of membrane proteins (which are often insoluble in 
aqueous solution due to their natively hydrophobic cellular environment).
No salt buffer (Buffer A): CHAPS 0.05%, PIPES 20 mM, EGTA 100 pM, CaCI2 150 pM, dH20 , 
pH 7.1, de-gassed and stored at 4°C (+protease inhibitors).
High salt buffer (Buffer B): Same as Buffer A with NaCI 1 M, dH20 , pH 7.1, de-gassed and 
stored at 4°C (+protease inhibitors).
Low salt buffer (Buffer A/B): 1 part Buffer B + 7 parts Buffer A to give 125 mM NaCI, degassed 
and stored at 4°C (+protease inhibitors).
FK506 monohvdrate (Siamal: 1 mM solution made up in DMSO. Stored at -20°C. FK506 is able 
to form a complex with FKBP12/12.6, preventing these proteins binding to their RyR binding 
sites.
Figures 3.1 and 3.2 outline the procedures used for extraction of RyR from native tissue.
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Muscle- chop and mince in food processor
100 g/ 400 ml homogenising buffer 
Waring blender- 1 min slow then 1 min fast
i
500ml centrifuge bottles- 20 min at 6500 rpm
i 1
Retain supernatant on ice Pellet -  rehomogenise (150ml buffer/pellet)
Centrifuge 20 mm 6500 rpm in 500 ml buckets
I . 1
Retain supernatant on ice Discard pellet
i
Combine supernatants and filter through muslin/ 
cheese cloth
i
70 ml tubes in 45 Ti rotor 45 min at 30,000 rpm
Discard supernatant Pellet -  Homogenise in Resuspension buffer 20 mi/
pellet. Incubate with gentle stirring at 4 °C for 1 hr
70 ml tubes 45 Ti rotor 45 min at 30,000 rpm
Discard supernatant Pellet -  Resuspend in 3 ml Homogenisation
buffer/pellet. Freeze rapidly in 1.5 ml eppendorf 
tubes. Store at -  80 °C.
Figure 3.1 Flow chart describing the protocol for preparation of SR 
membrane preparations from skeletal or cardiac muscle. Standard 
procedure typically involved preparation of ~500 g rabbit skeletal muscle or 
~500 g pig hearts to obtain n=1.
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SR microsomes (4 ml)
4 ml SR + 1.45 ml Triton buffer +9.11 ml solubilisation 
buffer + 0.15 ml DTT (2 mM). Stir for 10 min at 4 °C. 
Take sample for SDS-PAGE (RyR + T).
TLA ultracentrifuge 55,000 rpm for 15 min
Supernatant discarded (Maintain Pellets -  Homogenise in 14.56 ml CHAPS buffer 
sample for SDS-PAGE- TS) with 14 pi FK506 added. Stir at 4 °C for 1 hr.
Take sample for SDS-PAGE (TP)
I
TLA ultracentrifuge 55,000 rpm for 15 min
Decant and combine supernatants. Take Pellets -  combine and homogenise in 14.56 ml
sample for SDS-PAGE (CS). solubilisation buffer. Take sample for SDS-PAGE
I (CP)
Dilute supernatant 8x using Buffer A before 
application onto Source Q ion exchange column 
on FPLC
Figure 3.2 Flow diagram showing the steps involved in solubilisation of SR 
microsomes to extract functional RyR protein. Values shown are specific to a 
4 ml starting volume of SR microsomes (typically 25 mg/ml). FK506 (1 pM) was 
added to remove endogenous FKBP protein as shown previously (Blayney, 
Zissimopoulos et al. 2004). Samples were taken at each stage for analysis by 
SDS-PAGE and named as shown, where T corresponds to triton and C to 
CHAPS, S for supernatant and P for pellet at the respective stages.
3.2.2 RyR purification by ion exchange chromatography
Ion exchange chromatography separates ions and polar molecules, such as proteins, based on 
their charge. Charged molecules are retained on a column due to ionic interactions with 
functional groups displayed on the column. The ionic concentration of a solution passed over 
the column surface can be altered to elute the retained analyte. In cation exchange 
chromatography, a sodium salt gradient is used, where the increased availability of positively 
charged sodium ions will displace the positively charged functional group, binding to the 
negatively charged analyte and allowing it to be collected. When used for protein purification, 
UV absorbance at A28o is used to track the protein displacement and provide a measurement of 
peak elution times and quantities. Proteins with a low isoelectric point (pi), the pH at which their
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charge is zero, will elute at higher salt concentrations, as they bind more strongly to the column, 
requiring a greater concentration of sodium ions to displace them.
1 ml bed volume of Source Q anion exchange media was loaded into a column and washed 
with 10 ml degassed dH20  before priming with 10 ml 100% NaCI buffer (buffer B). This media 
was reused 3 times before changing. The column used provided a positive charge to enable 
binding of RyR which, at pH 7.4, has a negative charge.
Supernatant containing the solubilised RyR protein was diluted down 8x in volume with buffer A 
to bring the salt concentration down from 1 M to 125 mM, as RyR would not bind to the column 
in 1 M NaCI. The preparation was then passed through the anion exchange column using the 
FPLC (AKTA prime) before elution by application of a salt gradient. The standard protocol for 
elution of RyR1 involved applying a low salt ‘step’ (A/B buffer ~ 20% NaCI) to elute the less 
tightly bound proteins. A gradient was then applied to elute the remaining proteins from the 
column in as small a volume as possible without compromising on resolution.
RyR2 had a different program to RyR1 as the protein has previously been found to bind less 
tightly to the column, therefore a 50% NaCI step was used to remove the RyR2 in a small 
volume (1-3ml) in preference to a gradient to prevent the protein being too dilute for further use.
3.2.3 SDS-PAGE analysis of purified RyR protein
FPLC fractions and solubilisation samples were analysed on 5.5 % SDS-PAGE gels made up 
using Tris-HCI buffers. The rest of the protocol was completed as per section 2.2.1.
3.2.4 Phosphorylation and de-phosphorylation of RyR protein
Protein Kinase A (PKA) active subunit. Bovine heart: Dissolved in buffer A/B to give 1 active 
unit/ pi. Stored at -20°C in 5 pi aliquots. PKA is a serine/ threonine protein kinase.
Protein Phosphatase 1 (PP1): (New England Biolabs), thawed, spun down and stored at -80°C 
in 2 pi aliquots (5 units) Isolated from a source of Ecolab. Releases phosphate groups from 
protein serine/ threonine/ tyrosine residues. Manganese dependent.
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Manganese Chloride (MnCM: 1 mM stock (New England Biolabs), thawed, spun down and 
stored at -80°C in 44 |il aliquots
Ma/ATP: MgCI2 300 pM, ATP 300 pM, dissolved in buffer A/B. Stored at -20°C in 10 pi aliquots.
Table 3.1 Standard assay mix for phosphorylation and de-phosphorvlation using 200 ul 
purified RvR preparation
Phosphorylation Dephosphorylation
200 pi RyR 200 pi RyR
2 pi Mg/ATP 22 pi MnCI2
5 pi PKA (5 units) 1 pl PP1 (2.5 units)
16 pi buffer A/B
Total 223 pi
The RyR protein to be used in the experiment was divided, with half subjected to 
phosphorylation by adding Protein Kinase A (PKA), along with Mg/ATP (to provide the 
phosphate) and buffer A/B, and then incubating on the bench at room temperature for 1 hour. 
The other half of the protein mix was de-phosphorylated. De-phosphorylation involved 
incubation for 1 hour with Protein Phosphatase 1 (PP1) and Manganese Chloride (Table 3.1). 
To confirm efficiency of the phosphorylation and de-phosphorylation protocols, 20 pi samples 
were taken at 15 minute intervals during the 1 hour incubation period, boiled with 10 pi of 
3xSDS-loading buffer for 1 minute and run on 5.5% SDS-PAGE gels along with 20 pi RyR 
sample for control purposes (section 2.2.1). Western blotting was then carried out using BSA to 
block instead of Marvel milk as the phosphoserines in the milk interact with the anti- 
phosphoserine antibody used. The remainder of the protocol was followed as standard (see 
section 2.2.1.2) with anti-phosphoserine antibody 16B4 (Sigma) alongside an anti-RyR 1093 
antibody to determine whether the 1 hour incubation period was sufficient to enable full 
phosphorylation or de-phosphorylation of the ryanodine receptor. For secondary antibodies see 
section 2.2.1.2.
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3.3 Results
3.3.1 RyR1 solubilisation and purification by anion exchange
Figure 3.3 shows an increased proportion of RyR1 compared with other SR proteins in sample 
CS (Figure 3.2) which was loaded onto the FPLC. Contractile protein (-200 kDa) and Ca 
ATPase (-100 kDa) are still in high abundance but a large quantity of both are present in the 
triton supernatant (lane 4), which is discarded. This suggests triton is useful for dislodging some 
SR membrane proteins without removing RyR, as a first step in solubilisation. The triton pellet 
(Lane 3) was treated with CHAPs and high salt to solubilise the RyR, further cleaning the 
preparation. Following the FPLC anion exchange, RyR1 was cleaner still. This step enables the 
detergent concentration to be reduced and although there is still contamination of Ca-ATPase, 
this protein doesn’t bind ryanodine or the FKBP12 used in SPR experiments. Therefore this 
contaminant protein is not likely to participate in the interactions which are part of this study. 
The RyR was found to elute over several fractions as the A/B buffer ratio approached 30% 
(-300 mM NaCI) (black trace line on chromatogram, figure 3.4 A), peaking at fraction 19, as 
shown by SDS-PAGE analysis (Figure 3.4 B/C). Insertion of a step at -10%  ionic conductivity 
eluted Some of the lower ionic strength proteins (shown by blue line peak on chromatogram), 
but these are not visible on the SDS-PAGE gel due to the low resolution of smaller sized 
proteins on 5.5% gels. The quantity of RyR1 eluted was sufficient for [3H]ryanodine binding and 
due to the nature of the [3H]ryanodine binding experiments, further purification was not 
necessary. Fractions containing the highest level of RyR were pooled for experiments. From 
analysis of the SDS-PAGE gels and the chromatogram, it can be seen that CSQ elutes at a 
similar ionic strength to the RyR and peaks just before RyR on the trace. These two proteins 
have proved difficult to separate but generally the RyR peak fraction contains a lower proportion 
of this contaminating protein. RyR1 has a theoretical pi of 5.1, and is negatively charged at pH 
7.0. CSQ has a pi of -3.6, therefore would possess a similar charge to RyR at the conditions 
used for ion exchange (pH 7.4), this would explain the overlapping elution profiles, and the fact 
that calsequestrin elutes a little later than RyR, due to its slightly stronger charge.
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Contractile
protein
Calcium
Atpase
Figure 3.3 Solubilisation of RyR1 SR microsomes using Triton and CHAPS 
detergents. Samples were taken as shown in figure 3.2 and passed through 
buffer exchange columns (Biorad) to reduce the salt level. Samples were then 
run on a 5.5 % SDS-PAGE gel. Lane 1, Kaleidoscope protein size marker, sizes 
are shown on the left in kilodaltons (kDa). Lane 2, sample RyP+T. Lane 3, 
sample TP. Lane 4, sample TS. Lane 5, sample CP. Lane 6, sample CS. RyR 
protein is indicated on the gel.
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Figure 3.4 RyR1 purification by anion exchange chromatography
A) RyR1 elution chromatogram. Following solubilisation RyR preparation was passed over ion 
exchange resin in 125 mM NaCI on an AKTA Prime FPLC. A 20% salt step was used to elute the 
majority o f weakly bound proteins so that the RyR could be eluted in as small a volume as 
possible along a continuous salt gradient. Green line shows salt gradient program, black line is 
actual salt conductivity and blue line is UV absorbance.
B) and C) 1 ml samples of eluate were collected and analysed on 5.5% SDS-PAGE gels. Lane 1, 
Kaleidoscope protein size markers, sizes are shown on the left (kDa). Gel B, Lanes 2-9 
correspond to fractions 10-17. Gel C, Lanes 2-9 correspond to fractions 18-25. RyR protein is 
indicated on both gels, as well as Calcium ATPase and CSQ proteins. RyR is shown to peak in 
fraction 19.
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3.3.2 RyR2 solubilisation and purification by anion exchange
The same protocol for RyR1 solubilisation was applied to RyR2, however the number of SR 
samples processed was typically doubled from 4 ml to 8 ml to account for the lower RyR2 yield 
compared to RyR1, buffer volumes were also adjusted accordingly. Although concentrations of 
RyR2 in microsomal preparations may be 10x lower than RyR1, the number of SR samples was 
not increased 10 fold due to volume limitations of the anion exchange column. Overloading the 
column would result in a decreased resolution. The FPLC program used also varied in that a 
50% NaCI (500 mM) step was used to elute the RyR2 more sharply into a smaller volume 
(Figure 3.5 A), rather than allowing it to elute slowly over a continuous gradient (like RyR1) 
which has been shown to result in eluate that has too low a yield of RyR2 for experiments. Initial 
chromatography purification of RyR2 was done using a 1 ml column with a narrow bore, 
however experimentation with a wider bore column showed an increased yield of RyR2, due to 
increased resolution, therefore this was used in proceeding purifications. RyR2 yield was 
consistently found to be lower than that of RyR1, and always on the threshold for 
experimentation but the SDS-PAGE gel (Figure 3.5B) shows one of the better runs obtained. As 
500 mM NaCI was required to elute RyR2, rather than the 300 mM NaCI used to elute RyR1, a 
dilution step was necessary before this sample was used in further experiments to control for 
the relative salt concentrations. RyR was found to stick to membranes of commercial 
concentrator columns and therefore experiments with this isoform were somewhat limited in this 
investigation.
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Figure 3.5 RyR2 purification by anion exchange chromatography
A) RyR2 elution chromatogram. Following solubilisation RyR2 preparation was passed over ion 
exchange resin in 125 mM NaCI on an AKTA Prime FPLC. A 20% salt step was used to elute the 
majority of weakly bound proteins and then a 50% NaCI step was used to elute the RyR2 
specifically. The 50% salt step ensures the protein is all eluted into as small a volume as possible. 
Green line shows salt gradient program, black line is actual salt conductivity and blue line is UV 
absorbance.
B) 1 ml samples of eluate were collected and analysed on 5.5% SDS-PAGE gels. Lanes 1-8 
correspond to fractions 10-17, RyR peaks at fraction 13. Lane 9, RyR1 sample run as a control 
marker. RyR bands are highlighted. Lane 10, Kaleidoscope protein size markers, sizes are shown 
on the right in (kDa).
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3.3.3 RyR phosphorylation and de-phosphorylation
Analysis of RyR1 phosphorylation by western blotting using an anti-phosphoserine antibody 
showed that PKA activity on the RyR1 preparation continued for the full 90 minutes of the 
experiment and also that there was substantial endogenous phosphorylation of the RyR1 used 
in this study. This is quite unusual for RyR1 which has been previously shown to have no 
endogenous phosphorylation (Jones, D'Cruz et al. 2007). Therefore it was necessary to strip all 
RyR1 of phosphorylation using protein phosphatase 1 (PP1), as done by Blayney et al 
previously for RyR2 before experiments to provide an adequate control baseline for assays. 
Time course A in figure 3.6 shows that after 40 minutes the PP1 activity seemed to stabilise and 
though there was substantial decline in phosphoserine-detected phosphorylation, there was still 
some remaining. However, as all preparations were treated the same and there was evident 
stabilisation of PP1 activity by the end of treatment, this would have ensured a consistent 
baseline at the start of all experiments. The degree of phosphorylation was also considerably 
higher than the endogenous level after PKA treatment so there was a large difference between 
the de-phosphorylated and phosphorylated RyR1 for experiments. The RyR2 phosphorylation 
time course was very difficult to obtain due to the low yield problems mentioned in 4.3.2.
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Figure 3.6 RyR1 phosphorylation time course western blot
A) RyR1 dephosphorylation. Purified RyR1 preparation was incubated with Protein 
Phosphatase 1 as per table 3.1 for a total of 90 minutes, samples were taken at t=0, 20, 
40, 60 and 90 minutes and boiled with SDS loading buffer to stop enzyme activity. 
Samples were then run on a 5.5% SDS-PAGE gel, transferred to a nitrocellulose 
membrane and blotted with an anti-phosphoserine antibody. Lanes 1-5, 0-90 minutes. 
Lane 6, RyR1 control blotted with anti-RyR1 antibody (n=1).
B) RyR1 phosphorylation. Purified RyR1 preparation was incubated with Protein Kinase 
A for a total o f 90 minutes, samples were taken at t=0, 30, 60 and 90 minutes and boiled 
with SDS loading buffer to stop enzyme activity. Samples were then run on a 5.5% SDS- 
PAGE gel as for the dephosphorylation and subjected to the same antibodies. Lanes 1-4, 
0-90 minutes. Lane 5, RyR1 control (n=1).
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3.4 Discussion
This chapter evaluated the extraction and purification of functional RyR1 and RyR2 from native 
animal tissue and the preparation of this protein for subsequent experiments using 
phosphorylation and dephosphorylation.
RyR SR microsomes were successfully extracted from the native tissue following protocols 
previously employed by (Lai, Erickson et al. 1988). However, instead of a sucrose gradient 
purification stage, to prepare ‘heavy SR’, which has been shown to enrich the junctional SR 
where the RyR is predominant, a KCI step was added to solubilise contaminating contractile 
protein. It could have been advantageous to use sucrose density gradients as part of the 
microsomal purification step but this technique is suitable for preparations from small animals 
(e.g. rats or mice), however for preparations of microsomes from pig hearts or rabbit skeletal 
muscle with 500 g of starting tissue this would have proved an unwieldy step. SR microsomes 
were treated with a combination of detergents (Triton X-100 and CHAPS), and the lipid 
phosphatidylcholine to solubilise RyR for use in experiments. This protocol also allowed for the 
addition of FK506 to strip the RyR1/2 of endogenous FKBP12/12.6 and their removal during 
subsequent purification steps (Jones, Reynolds et al. 2005) FPLC purification of RyR using 
anion exchange gave a consistent and sufficient yield of RyR1.
RyR2 purification efficiency seemed to vary between different heart preparations which may 
mean that there was some fluctuation in the efficiency of the RyR2 extraction from the 
microsomal preparation. Solubilisation buffers were found to vary in their RyR purification 
efficacy if the supplier of CHAPS varied and the source of the phosphatidylcholine (egg yolk 
rather than soy bean) changed. But these changes were noted early in the investigation and 
amended accordingly. Modification of the standard RyR1 protocol by use of a wider bore FPLC 
column and sharp elution at 50% NaCI was shown to yield sufficient RyR2 in some instances, 
but was not reliably consistent. Three usable purified RyR2 preparations were obtained from 
one batch of pig hearts. The following batch processed did not provide sufficient purified RyR2 
from the microsomes to use in further experiments, the reasons for this can only be speculative. 
Pig hearts were handed to us immediately after slaughter at the abattoir and appeared to be of
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consistent size. However, the abattoir is a small one and we cannot be certain that each batch 
of pigs is of the same breed or age, this may have been an important variable. The RyR2 level 
within the microsomal preparations also appeared to be low, meaning that detecting even this 
protein by western blot was a challenge. Given that the solubilisation procedure is unlikely to 
result in 100% extraction of RyR, the starting material needs to be very RyR rich to account for 
any loss during solubilisation and subsequent purification stages, if the starting material is 
variable and sometimes poor, then this would explain the consistent problem. Although the 
RyR2 phosphorylation time course western blot could not be obtained due to the low yield of 
this protein, the enzymes have been shown to work for RyR1 and there is no reason why they 
should have reduced efficacy for the RyR2 preparation used. Figure 3.6 shows the RyR1 
phosphorylation for n=1, however this experiment was performed merely as confirmation of 
results obtained previously on a different batch of rabbit preparations (Blayney, Jones et al. 
2010), to test that the protocol was still valid in this instance. Ideally the blot should be repeated 
in the presence of a loading control to ensure protein amount is not variable across the time 
course western blot. It should be noted however that all lanes were loaded from the same RyR1 
and enzyme stock, therefore variability in protein quantity should be minimal.
The amount of endogenous RyR1 phosphorylation changed over the course of the study. In the 
early experiments no endogenous phosphorylation was detected. Skeletal muscle for 
microsomal preparation was sourced from rabbits which were used after sacrifice, and 
subsequent removal of vascular material, by another group. The experimenter changed, and 
higher background levels of phosphorylated RyR1 were noted. As a result, for all the work in 
this thesis, the protocol was changed and PP1 was then used to dephosphorylate preparations, 
and PKA to phosphorylate them, for matched experiments (see future chapters).
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CHAPTER 4: Physiological modulators of RvR1 activity
4.1 Introduction
RyR activity is subject to regulation by a large number of biochemical and protein modulators. It 
is also directly modified by protein kinase phosphorylation and redox potential. The relationship 
between FKBP12/12.6 and PKA phosphorylation of RyR channels has been previously 
assessed by this group as these two modulators have been linked to the pathology of CPVT 
and RyR1/RyR2 dysfunction (Blayney, Jones et al. 2010). This investigation aims to put these 
changes in the context of the domain interaction hypothesis. The intention was to look at 
domain peptide modulation of the same RyR preparations used in previous studies of our group 
(Jones, Reynolds et al. 2005; Blayney, Jones et al. 2010) and to study peptide interaction with 
other channel modulators including calcium, FKBP12, magnesium and ATP.
FKBP12, a cis-trans peptidyl-prolyl isomerase, was first identified by its copurification with the 
RyR1 (Collins 1991) and is now well documented as a potent and important regulator of RyR1 
function. Single channel bilayer studies have demonstrated its ability to stabilise and inhibit 
channel activity and thus reduce open probability (Brillantes, Ondrias et al. 1994). FKBP12 has 
greatest affinity for the RyR channel in its closed state, but retains a high affinity for the channel 
in the open state, as shown in recent work by our group (Jones, Reynolds et al. 2005). Four 
FKBP12 molecules can bind to an RyR homotetramer, with one binding per subunit 
(Jayaraman, Brillantes et al. 1992), however to date the region of FKBP12 binding to RyR1 has 
yet to be elucidated. Electron cryomicroscopy and three-dimensional reconstruction have shown 
these four FKBP12 molecules to bind close to the N-terminus of the RyR (Wagenknecht, 
Radermacher et al. 1997). The site of FKBP12 binding to RyR was originally thought to be in 
the central domain around a leucine-proline motif at site 2407-2520 (Cameron, Nucifora et al. 
1997), which corresponds to the proposed site of binding on the inositol (1,4,5) tris phosphate 
receptor. Mutations in this area were shown to decrease FKBP12 binding (Gaburjakova, 
Gaburjakova et al. 2001) and in the context of this study, this proposed binding region is within 
the DP4 peptide. Topology studies then suggested that the central domain cluster (2246-2534) 
mapped to the N terminus region, which alleviated the likelihood of the FKBP12 binding site for 
RyR1 being in this region of the central domain (Wagenknecht, Radermacher et al. 1997).
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Hence precise definition of the FKBP12 binding site has not yet been determined, and further 
structural analysis is required.
FK506 is able to inhibit interaction of FKBP12 with RyR by binding to the FKBP12 molecule at 
its binding site (Chelu, Danila et al. 2004). FK506 was found to increase channel open 
probability in single bilayer studies and sub-conductance states were reported in some 
instances, suggesting that inter subunit interactions of RyR occur which may be stabilised by 
the binding of FKBP12 (Brillantes, Ondrias et al. 1994). FKBP12 may also play a role in coupled 
gating of RyRs, given its ability to coordinate channel opening in bilayer studies. The location of 
the proposed FKBP12 binding site is distinct from the region of RyR-RyR interaction, suggesting 
it is able to exert an effect via allosteric modification of the neighbouring channels (Marx, 
Gaburjakova et al. 2001).
Loss of FKBP12 from RyR1, linked to aberrant calcium handling in skeletal myocytes, has been 
attributed to hyperphosphorylation of RyR1 by one group. Wehrens et al have shown defective 
function of RyR1 channels in HF skeletal muscle, analogous to those in RyR2 channels in 
failing myocardium. This manifested as PKA hyperphosphorylation and depletion of FKBP12, as 
well as a gain of function channel defect, and has been proposed as a key factor in the limited 
exercise capacity seen in patients with RyR2-linked cardiomyopathies (Wehrens, Lehnart et al. 
2005). The pertinence of RyR1 in cardiac ECC was originally suggested by the finding that 
FKBP12 null mice showed no apparent defect in the skeletal muscle, yet were shown to exhibit 
severe developmental cardiac defects. Therefore it seems there is an important physiological 
link between RyR1 and RyR2 modulation. The anti-arrhythmic drug K201 (JTV519) has been 
shown to increase skeletal muscle function, possibly by enhancing FKBP12 binding (Wehrens, 
Lehnart et al. 2005). Another drug, S107, which is a calcium channel stabiliser, has been 
proposed to preserve the binding of FKBP12 to RyR1 and was shown to increase the exercise 
capacity of WT mice, but not FKBP12 K/O mice, suggesting a mode of function involving 
interaction with FKBP12 (Bellinger, Reiken et al. 2008).
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Biacore technology has been used by (Jones, Reynolds et al. 2005) to measure the equilibrium 
binding kinetics of interaction between RyR1 and FKBP12. It was shown that the affinity of 
solubilised RyR1 for FKBP12 is lower for the open channel than for the closed, this was also 
true for RyR2 (Jones, Reynolds et al. 2005; Blayney, Jones et al. 2010). PKA phosphorylation 
was found to shift the affinity of the closed channel for FKBP12/12.6 to the lower affinity of the 
open channel, however, the affinity for the open channel remained high. It was concluded that 
this shift in affinity was part of the normal ‘fight or flight’ response mechanism, linked to p-AR 
stimulation of PKA phosphorylation. The data was suggested to demonstrate a change in RyR 
conformation caused by PKA phosphorylation, possibly a molecular movement towards a state 
which favours the open/closed transition. (Jones, Lai et al. 2006). A similar mechanism was 
suggested in single channel studies (Valdivia, Kaplan et al. 1995).
Calcium is known to be the main modulator of the RyR1 channel and the biphasic dose 
response, with maximal activation occurring at micromolar free calcium, in the absence of other 
regulatory ligands, has been well documented in the literature. Such a curve suggests that the 
calcium release channel possesses high-affinity activating and low-affinity inhibitory calcium 
binding sites (Meissner, Lai et al. 1990). In single channel studies, the channels open probability 
(P0) was close to zero with nanomolar free calcium on the cis (SR cytoplasmic) side of the 
bilayer. Addition of micromolar calcium to the cis chamber activated the channel and induced 
rapid channel openings and closings. The presence of millimolar calcium in the cis chamber 
resulted in channel inactivation (Meissner 2002). Ryanodine binding studies have also shown a 
bimodal regulation of the RyR by calcium (Meissner, Lai et al. 1990) (Meissner review 1994).
CICR has been found to be greatly potentiated by relatively high (mM) levels of ATP and 
optimal channel activation has been found in the presence of pM calcium and mM ATP. Bull et 
al. have demonstrated that cis-ATP addition of 3 mM decreased the threshold for calcium 
activation, increased maximal open probability and shifted channel inhibition to higher calcium 
in single channel bilayer studies (Bull, Finkelstein et al. 2007). However, it is likely that 
magnesium-ATP, rather than free ATP, is a major physiological regulator of the RyR channel 
because most of the ATP in cells is complexed with magnesium (Meissner 2002).
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Conversely, cytoplasmic magnesium has consistently been found to inhibit the RyR channel, 
suggesting RyR1 activation is strongly inhibited by magnesium under physiological conditions in 
resting muscle. Magnesium is a permeant cation of the RyR and likely inhibits the channel by a 
dual mechanism involving competing with calcium for the calcium activation site (H-site) and 
also binding to the low affinity calcium inhibitory site (l-site) (Meissner and Henderson 1987). It 
has been suggested that the physical activation of RyR1 by the LCC may reverse the 
magnesium block and thus permit activation by ATP and calcium (Lamb and Stephenson 1991). 
Further to this, a study was carried out with peptides impeding the region of interaction between 
the LCC and RyR1 (C-region), showing a decreased sensitivity of the RyR for magnesium 
inhibition and suggesting the LCC may be the key determinate of magnesium control if it 
reduces the magnesium affinity of the regulatory sites on RyR1 (Haarmann, Dulhunty et al. 
2005).
Caffeine has been reportedly unable to induce maximal calcium release from the SR at 
physiological magnesium levels suggesting activators of the RyR must first overcome 
magnesium inhibition before calcium release can occur. Thus magnesium may serve to stabilise 
CICR between periods of activation (Lamb, Cellini et al. 2001). Assessment of MH susceptible 
porcine muscle has shown a decreased sensitivity to magnesium inhibition and another group 
have shown this to be a common feature in human MH (Laver, Baynes et al. 1997; Duke, 
Hopkins et al. 2002).
One study has tested the effect of the anaesthetic halothane on magnesium inhibition, given 
that volatile anaesthetics, such as halothane, are the key trigger of MH. The results suggest that 
halothane induced calcium release from the SR in skeletal muscle is strongly reduced in the 
presence of physiological magnesium concentrations, however, when this level is reduced, 
halothane induced a marked efflux of calcium from the SR and resultant calcium waves. Given 
the reported reduction in magnesium inhibition evident in MH patients, this finding may be highly 
significant (Duke, Hopkins et al. 2003).
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Bull et al. have shown inhibition of [3H]ryanodine binding in the presence of 1 mM magnesium 
on RyR from the rat brain cortex (Bull, Finkelstein et al. 2007) and single channel studies have 
suggested that luminal calcium may influence RyR1 gating by an indirect mechanism involving 
reduction of the affinity of the cytosolic calcium activation site for magnesium. This would be 
explained by an allosteric, non-competitive effect, suggesting conformational change to mask/ 
un-mask the magnesium binding site (Laver, O'Neill et al. 2004).
The idea of a conformational change is also supported by studies assessing the effects of 
phosphorylation on magnesium inhibition. Phosphorylation has been shown to overcome the 
magnesium inhibition (Hain, Onoue et al. 1995; Uehara, Yasukochi et al. 2002), as has the 
central domain peptide (DP4) (Yamamoto, El-Hayek et al. 2000), suggesting central domain 
involvement as a potential regulator of a magnesium binding site. Given that PKA 
phosphorylation was also reported to modify the channels affinity for FKBP12 while remaining in 
a closed state, this suggests the same conformational change may mask the magnesium 
binding site prior to channel opening (Blayney, Jones et al. 2010). This idea is also supported 
by a fluorescence quench study (Yamamoto and Ikemoto 2002).
ATP has been shown to overcome magnesium inhibition on isolated RyR1 from rabbit skeletal 
muscle (Jona, Szegedi et al. 2001) and in one study carried out (Dias, Szegedi et al. 2006) 8 
ATP binding sites per one RyR homotetramer were proposed, with 2 different types of ATP site 
per each RyR monomer, this has also been suggested by ligand binding functional studies 
(Laver, Lenz et al. 2001). Biphasic activation of RyR in response to increasing concentrations of 
ATP has implied different classes of ATP binding sites (Jona, Szegedi et al. 2001) but the study 
by Dias et al. links this to magnesium inhibition. This work suggests that in the presence of 
activating calcium and inhibitory magnesium, all 8 ATP sites are available and occupied, but at 
inhibitory calcium concentrations, in addition to inhibitory magnesium concentrations, only 4 of 
these sites are occupied, in spite of high ATP concentration. Dias et al propose that occupation 
of all 8 ATP binding sites links to an open or ‘opening’ channel. This work ties in with a theory of 
conformational change of the RyR caused by the presence or absence of calcium or 
magnesium, which may be the cause of varied accessibility of ATP binding, resulting in maximal
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binding of either 4 or 8 ATP molecules. Binding ATP may then stabilise the open or closed 
conformation (Dias, Szegedi et al. 2006). Alternatively, the opening or closing events may be 
the result of conformational changes caused by ATP binding. The group hypothesizes that 
binding of 4 ATP sites per RyR tetramer is most likely linked to closure of the channel and 
hence increased channel stability.
In spite of the above evidence suggesting that both FKBP binding and ATP binding to RyR may 
result in a conformational change, modifying the propensity for an open or closed channel, few 
studies have combined FKBP12 with magnesium and ATP to determine their combined effect. 
This is of particular interest in the context of this project, which aims to identify the possible 
region of convergent regulation of the RyR as put forward by Blayney et al. (Blayney, Jones et 
al. 2010).
Before domain peptides could be included in experiments, it was necessary to determine the 
effect of these physiological modulators individually and in combination. In order to assess the 
functionality of the channels prepared for this investigation, they were first assessed for their 
dose response to free calcium concentrations. The calcium concentration found to maximally 
open the channel then served as the chosen concentration at which the effects of other RyR 
channel modulators were assessed. The fact that the control channel was already open meant 
that both inhibitors and activators could exhibit their effects.
The aim of this chapter is to assess the effects of physiological modulators shown previously to 
modify channel gating, on isolated RyR1 channels. Modulators were examined both individually, 
and in addition to one another. This chapter will first look at activators of the RyR1, that is 
calcium and ATP and then analyse the effects of the physiological inhibitors; FKBP12 and 
magnesium on ryanodine binding of RyR1. The FKBP12 protein for this study was produced 
and purified in house from a ready-made construct (ref to methods). This chapter will provide 
baseline data for the subsequent studies using [3H]ryanodine binding to examine the effects of 
inhibitory peptides (Chapter 6).
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4.2 Results
4.2.1 RyR1 dose response to free calcium
Ryanodine binding demonstrated that solubilised RyR1 channels exhibited the standard calcium 
biphasic dose response (Figure 4.1). For the calcium buffers used in this study, it would seem 
pCa4 opened the channel maximally. Therefore this calcium concentration was used to provide 
the 100% control in the experimental model. Assays were carried out on both PKA 
phosphorylated and PP1 dephosphorylated RyR and no significant difference was found in 
these conditions. Blayney et al. have documented previously that phosphorylation effects are 
rarely seen in [3H]ryanodine binding assays, but differences are sometimes unmasked using a 
more sensitive technique SPR (Biacore) kinetic analysis (Jones, Lai et al. 2006).
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Figure 4.1 RyR1 biphasic response to free calcium (pCa), 
demonstrated by pH] ryanodine binding
Each point represents the mean of 3 RyR 1 preparations. (pCa 4 is taken 
as 100%). Bars show standard error.
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4.2.2 RyR1 and dose response to ATP addition
ATP was shown to activate the channel over and above that at pCa4 (Figure 4.2A), suggesting 
full opening of the channel only occurs in the presence of both calcium and ATP. 2.5 mM ATP 
increased ryanodine binding maximally and it was then observed that increasing the ATP 
concentration further actually reduced [3H]ryanodine binding. The effect of ATP on the free 
calcium dose response curve showed a significant activation across all concentrations (Figure 
4.2B). There were no differences between phosphorylated and dephosphorylated preparations.
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Figure 4.2 Effect of ATP on RyR1 pH ] ryanodine binding. A) ATP dose response. Each 
point represents the mean of 6 RyR1 preparations. B) ATP effect on binding across the calcium 
biphasic response. Calcium response is shown in the presence and absence of 2.5 mM ATP. 
Each point represents the mean of 3  RyR1 preparations. (*) indicates a significant difference (p 
<0.05, students paired t-test) from the equivalent value on the calcium dose response without 
ATP addition. (Binding in pCa4 is taken as 100%). Bars show standard error.
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4.2.3 FKBP12 protein production and purification
To determine the effects of the protein modulator FKBP12, this was first prepared as a 
recombinant protein. FKBP12 had previously been cloned into pGEX-6P-1. FKBP12-GST 
protein was successfully grown in Rosetta and induced at 30°C for 3 hours. Following 
incubation of bacterial lysate colonies containing the FKBP12-GST protein with glutathione 
sepharose beads, samples were shown to contain sufficient quantities of FKBP12 by SDS- 
PAGE. 3C protease cleavage was effective, as shown by the lower band on the gel, however 
separation of the cleaved protein eluate and the beads showed there to be a large amount of 
residual uncleaved 3C and GST (Figure 4.3A). Gel filtration chromatography separates proteins 
based on their size and so this was used with a view to separate the protein contaminants from 
the cleaved FKBP12 protein. An S75 column was used but although FKBP12 was eluted in later 
fractions, there was considerable overlapping contamination. Figure 4.3B clearly shows 
contamination of FKBP12 protein which has been eluted along fractions 1-8. The chromatogram 
UV trace shows the protein eluting on the shoulder of the UV peak (Figure 4.3C), insufficiently 
resolved from 3C and GST. As the chromatography separation was incomplete, more 
glutathione sepharose beads were added back to the protein mixture to remove the GST- 
tagged 3C and cleaved GST by further affinity purification. Glutathione sepharose beads have a 
limited capacity so it was possible that with the large quantity of FKBP12-GST protein produced, 
the beads on the first affinity purification step were saturated. This was effective and figure 4.4 
shows the clean protein eluted from the beads. Protein identity was confirmed by western blot 
analysis using an anti-FKBP12 specific antibody and protein quantity was estimated by running 
dilutions of FKBP12 alongside known quantities of BSA control (Approximately 4 mg/ml).
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c
Conductivity
UV absorbance
Figure 4.3 FKBP12 cleavage with 3C protease and purification by gel filtration 
chromatography
A) Samples were collected before and after cleavage of FKBP12-GST with 3C protease and 
analysed by running on an 18% SDS-PAGE gel. Lane 1, Kaleidoscope protein size marker, 
sizes are indicated on the left (kDa). Lane 2, mixture of cleaved FKBP12 (12 kDa), GST (26 
kDa) and 3C-GST (48 kDa) following overnight incubation and prior to separation. Lanes 3 ana 
4, eluate containing cleaved FKBP12 after filtration of the GST beads and contaminating GST 
and 3C-GST. Lane 5, washed beads showing GST and 3C-GST and some residual cleaved 
FKBP12 due to inefficient washing. Arrow indicates FKBP12.
B) Gel filtration chromatography was used to further purify the cleaved FKBP12. Eluate was 
collected in 1 ml fractions and samples from each fraction were separated on a 15% SDS-PAGE 
gel for analysis. Lane 1, Kaleidoscope protein size marker, sizes are shown on the left (kDa). 
Lanes 2-10 correspond to fractions 1 to 9 on the FPLC trace (highlighted in red). FKBP12 elution 
peaks across fractions 3, 4 and 5. Arrow indicates FKBP12.
C) FPLC trace showing the elution profile for FKBP12 from an S75 gel filtration column. The 
blue line represents UV absorbance, smaller proteins are eluted last. The black line represents 
salt conductivity.
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Figure 4.4 FKBP12 further affinity purification, confirmation by 
western blot and quantification.
A) FKBP12 eluate was incubated for a second time with GST beads. 
Samples were taken and separated on a 15% SDS-PAGE gel for 
analysis. Lane 1, mixture o f cleaved FKBP12 (12 kDa), GST (26 kDa) and 
3C-GST (48 kDa) following overnight incubation and prior to separation. 
Lane 2, washed beads showing GST and 3C-GST and very little residual 
FKBP12 protein. Lane 3, FKBP12 eluate showing very little contaminating 
protein. Lane 4, Kaleidoscope protein size marker, sizes are shown on 
the right (kDa).
B) FKBP12 was transferred to a nitrocellulose membrane and blotted with 
an FKBP12 specific antibody to confirm presence of the correct protein. 
Lane 1, FKBP12 preparation diluted 10x. Lane 2, neat FKBP12. Lane 3, 
protein size markers, sizes are shown on the right (kDa).
C) Bovine serum albumin (BSA) standards were run alongside FKBP12 
recombinant protein to provide an estimate of quantification. Samples 
were run on a 15% SDS-PAGE gel. Lanes 1 and 10, Kaleidoscope 
protein size marker, sizes are given on the left (kDa). Lanes 2-6, serial 
dilutions o f BSA (66 kDa); 2, 20 pg, 3, 10 pg, 4, 5 pg, 5, 2.5 pg, 6, 1.25 
pg. Lane 7, Cleaved FKBP12 (12 kDa) 1:10 diluted. Lane 8, FKBP12 1:20 
diluted. Lane 9, FKBP12 1:50 diluted.
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4.2.3 Effect of physiological inhibitors on activators of RyR1
4.2.3.1 FKBP12
The recombinant FKBP12 generated in this chapter was shown to inhibit ryanodine binding by 
approximately 50% (Figure 4.5). The specificity of this result was shown by addition of FK506 
control protein which effectively inhibited the FKBP12 effect. Maximal inhibition of [3H]ryanodine 
binding was shown with 1 pM of FKBP12. PKA phosphorylation showed no difference 
compared to dephosphorylated preparations. When FKBP12 was added in the presence of 
varying concentrations of ATP there was a slight reduction in binding (-25%) compared with the 
ATP control but ATP activation at 2.5 mM was still evident (Figure 4.6B). The FKBP12 dose 
response in the presence of 2.5 mM ATP was shown to be shifted to the left so that a higher 
concentration of FKBP12 was required to see 50% inhibition (Figure 4.6A).
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Figure 4.5 Effect of FKBP12 on RyR1 fHJRyanodine binding. FKBP12 dose 
response. Each point represents the mean of 7 RyR1 preparations. (*) indicates a 
significant difference from the control value (p <0.05, students paired t-test) without 
FKBP12 addition. There was no significant difference between PP1 and PKA 
treatments. (Binding in pCa4 is taken as 100%). 10 pM FK506 was added as a control 
for specificity. (#) indicates a significant difference (p <0.05, students paired t-test) 
from the eauivalent value without FK506 addition. Bars show standard error.
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Figure 4.6 Effect of FKBP12 inhibition on ATP activaton of RyR1 fH ] ryanodine binding
A) FKBP12 dose response in the presence of 2.5 mM ATP. Each point represents the mean 
of 5 RyR1 preparations. (*) indicates a significant difference (p <0.05, students paired t-test) 
from the control value with no FKBP12 addition. (Binding in pCa4 calcium with 2.5 mM ATP is 
taken as 100%). There was no significant difference between PP1 and PKA treatments. B) 
ATP dose response is shown in the presence and absence of 10 pM FKBP12. Each point 
represents the mean of 6 RyR1 preparations. (*) indicates a significant difference (p <0.05, 
students paired t-test) from the corresponding values of the ATP dose response without 
FKBP12 addition. (Binding in pCa4 is taken as 100%). Bars show standard error.
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4.2.3.2 Magnesium
Magnesium inhibition of RyR has also been reported in previous studies and high ionic strength 
was reported to mask the magnesium effect (Padua, Nagy et al. 1994). In this study, ryanodine 
binding assays were originally designed with 1 M KCI in the assay buffer as this has been found 
to enhance binding, however, as shown in Figure 4.7A, Magnesium inhibition at this KCI 
concentration was not as dramatic as shown previously in the literature. When the KCI 
concentration was reduced to 150 mM, a strong magnesium effect was seen (Figure 4.7B) 150 
mM KCI was then used in all magnesium binding experiments and earlier experiments repeated 
where necessary to ensure a fair comparison. Magnesium and FKBP12 effects have not been 
combined in a single experiment previous to this investigation and it was found that the 
magnesium inhibition was further enhanced by the presence of FKBP12. Even when 
magnesium was present at 1 mM, FKBP12 was able to reduce binding further by approximately 
50%.
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Figure 4.7 Effect of KCI concentration on magnesium inhibition of RyR1 
f  H]ryanodine binding
A) Magnesium dose response in 1 M KCI. Each bar represents the mean of 5 
RyR1 preparations. B) Magnesium dose response in the presence of 150 mM KCI. 
Each bar represents the mean of 6 RyR1 preparations. (*) indicates a significant 
difference (p <0.05, students paired t-test) from the control value with no Mg2* 
addition. (Binding in pCa4 is taken as 100%). Bars show standard error.
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Figure 4.8 Effect of magnesium inhibition on RyR1 fHJRyanodine binding in the 
presence of PKA phosphorylation and FKBP12.
A) Magnesium dose response is shown in the presence and absence of PKA 
phosphorylation. Each point represents the mean of 6 RyR1 preparations. (*) indicates a 
significant difference (p <0.05, students paired t-test) from the control value with no 
magnesium addition. (#) indicates a significant difference (p <0.05, students t-test) from 
the magnesium effect in the absence of PKA. B) Magnesium dose response is shown in 
the presence and absence of 10 pM FKBP12. Each point represents the mean of 6 
RyR1 preparations. (*) indicates a significant difference (p <0.05, students paired t-test) 
from the control value without magnesium addition. (Binding in pCa4 is taken as 100%). 
Bars show standard error.
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4.3 Discussion
This chapter examined the effects of known physiological activators and inhibitors of RyR on 
ryanodine binding of native RyR1 channels purified from animal tissue. FKBP12 protein was 
produced and purified successfully for experiments and shown to exert inhibition on ryanodine 
binding. Channel opening was reduced by approximately 50%, in accordance with previous 
studies (Jones, Lai et al. 2006). Purified RyR1 was shown to exhibit the well documented 
biphasic response to calcium, with maximal binding occurring at pCa4 (100 pM), and channel 
inhibition at nM and mM free calcium. ATP (2.5 mM) was able to increase binding by ~4 fold 
consistently, confirming functionality of the protein. Maximal ATP activation at mM 
concentrations corresponds with studies by other groups (Meissner 2002; Bull, Finkelstein et al. 
2007).
Previous studies have reported activation of RyR by ATP that is independent of calcium 
(Meissner and Henderson 1987). In this current study the magnitude of binding at pCa7 is 
greatly increased from an almost closed level of binding, to approximately 75% of the maximal 
opening in the presence of calcium and ATP, suggesting that ATP enhances the sensitivity of 
RyR for calcium. Some binding was also observed at pCa8, in the presence of ATP, where nM 
levels of calcium alone were shown to completely inhibit binding.
ATP activation was shown to reduce the proportion of FKBP12 inhibition at 10 pM, but at lower 
ATP concentrations the FKBP12 effect was closer to 50%, the level seen in the absence of 
ATP. This suggests that the maximal opening of the RyR channel incurred by 2.5 mM ATP and 
calcium makes the channel less susceptible to stabilisation by FKBP12. This finding correlates 
with previous SPR studies carried out within this group, documenting a reduced affinity of RyR1 
for FKBP12 in the presence of ATP (Jones, Reynolds et al. 2005). It may therefore be the case 
that ATP induces a further conformational change to maximally open the RyR channel, which 
masks the FKBP12 binding site.
Magnesium inhibition however, was shown to be consistently enhanced by the presence of 
FKBP12, suggesting full channel stabilisation only occurs in the presence of both uM FKBP12
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and mM magnesium and that they have an additive effect. This finding would point to FKBP12 
and magnesium acting at independent sites, and a possible unmasking of the magnesium 
binding site(s) by FKBP12, enabling maximal inhibition. Maximal magnesium inhibition was 
shown at 1 mM, consistent with previous findings, however this was only observed in low salt 
binding conditions, as shown in figure 4.7. It has been reported previously that an increase in 
ionic strength enhances channel sensitivity to calcium, ATP and magnesium (Meissner 2002), 
however a paper by (Murayama, Kurebayashi et al. 1998) lead to an assessment of magnesium 
effect in high (1 M KCI) and low/endogenous (150 mM KCI) salt conditions (Padua, Nagy et al. 
1994; Murayama and Ogawa 1996). The lower ionic strength was found to greatly enhance the 
magnesium inhibition, thus this condition was used for all subsequent experiments, with earlier 
experiments repeated to enable a fair comparison.
Phosphorylation was able to partially overcome magnesium inhibition, as documented 
previously (Mayrleitner, Chandler et al. 1995). Magnesium inhibition is still evident, but 
consistently reduced in the phosphorylated preparations. This has been interpreted as a 
conformational change which may mask a magnesium binding site (Blayney, Jones et al. 2010). 
Had time permitted, it would have been interesting to test the effect of phosphorylation on the 
combined channel inhibition of magnesium and FKBP12. Although it has been shown previously 
that phosphorylation is able to reduce channel affinity for FKBP12, using SPR and Biacore for 
kinetic analysis, no differences between phosphorylated and dephosphorylated preparations 
could be observed in [3H]ryanodine binding experiments (Blayney, Jones et al. 2010). The 
phosphorylation status of the RyR preparations was not monitored over the time frame of the 
experiments in this investigation, however a previous assessment of phosphorylation on 
similarly prepared RyR was carried out after a 5 hour SPR experiment, and shown to remain 
unchanged (Blayney, Jones et al. 2010).
The effect of magnesium inhibition on ATP activation was not tested and would require the 
careful titration of ATP and magnesium, which form a complex, to control the level of ‘free’ 
magnesium concentration (Laver 2005). It has been reported that adenine nucleotides reduce 
the sensitivity of RyR to magnesium inhibition (Meissner and Henderson 1987) but others found
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no evidence of this in their study using AMPPCP, a nonhydrolyzable ATP analogue (Murayama, 
Kurebayashi et al. 2000).
Some of these studies have been performed by other groups using SR preparations and the 
isolated native RyR1 channels in this investigation have generally shown the same responses 
as previously documented. These results provide a positive indication that the isolated channels 
have retained key functional characteristics.
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Chapter 5; Production and 
purification of activatory domain 
peptides of RyR1
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CHAPTER 5: Production and purification of activatory domain peptides of RvR1
5.1 Introduction
The use of domain peptides originated from experiments to test the domain interaction 
hypothesis when it was first proposed (Yamamoto, El-Hayek et al. 2000). This hypothesis 
originated from a number of key observations. Topology studies had shown that there were 
discernable differences in electron density arising from changes in RyR channel architecture 
when comparing the open (calcium and ATP analogue) and closed (EGTA) conformations of 
the channel. These included the clamp (corner regions), a rotation of the transmembrane region 
and a decrease in size of the central channel pore region (Orlova, Serysheva et al. 1996). The 
MH mutations in RyR1, of which only a few were known at the time, were clustered in the N- 
terminus and central domain portions of the RyR1 protein sequence. Previous cross-linking 
studies (Wu, Aghdasi et al. 1997) had shown these central and N terminus regions to interact. 
Studies of SR vesicles or RyR1 channels containing MH mutations demonstrated 
hypersensitivity to activation. Furthermore, an Ab to an MH mutation site (G341) activated RyR 
and lowered the threshold for CICR and a peptide containing G341 was shown, using overlay 
assays, to bind to RyR1 regions 3010-3225 and 799-1172 suggesting subdomain interactions 
(Zorzato, Menegazzi et al. 1996).
A number of domain peptides to both the N-terminus and central domain regions have been 
tested previously, of these the most potent activatory peptide was DP4 (|_2442 to P2277), which 
increased 3[H]ryanodine binding to skeletal muscle microsomes ~3 fold. It was proposed that 
this is able to insinuate into the protein structure and compete with the endogenous central 
domain interaction, which stabilises the closed state of the channel. This causes activation by 
domain ‘unzipping’. The fact that the DP4M peptide (with the MH R2458C mutation) did not 
activate RyR was taken as evidence that this mutation altered the peptide structure so that it 
could not bind to the N-terminus. Thus, in MH patients, a fault in the stabilising N-terminus and 
central domain interaction might account for the hypersensitivity of RyR and contribute to the 
underlying pathology (Yamamoto, El-Hayek et al. 2000; Lamb, Posterino et al. 2001).
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Further studies with DP4 peptide containing other MH mutations R2452W, R2545C and 
R2458H showed that the R2452W mutation, in particular, increased activity by ~2 fold and all 
showed some activatory activity at 100 pM although this was least for R2458C (Bannister, 
Hamada et al. 2007). Thus, the R to C mutation was found to have the most severe reduction in 
the DP4 activatory effect. The authors considered that the majority of mutations falling into the 
most severe class involve arginine residues, suggesting interaction is governed by electrostatic 
forces and that mutations classed as modest generally involved hydrophobic residues. 
Antibodies produced against peptides including DP4 (central domain) and DP1 N-terminus 
(590D-C609) showed a dose-dependent activation of SR [3H]ryanodine binding and increased 
the sensitivity of SR calcium release to a highly specific activator of RyR, polylysine, further 
supporting the domain interaction hypothesis (Kobayashi, Yamamoto et al. 2004).
NMR analysis clearly indicated that DP4 has a defined 3D structure that is characterized by a 
helix 1-loop (turn)-helix 2. Since DP4 retained several important functional properties ascribable 
to its corresponding in vivo domain, it was suggested that the structure of the Leu-Pro region of 
RyR1, to which DP4 corresponds, has a similar or identical structure and critical residues 
appeared to be located in a particular area in the helix-loop region (Bannister, Hamada et al. 
2007). Experiments involving domain peptides carried out by the Ikemoto group are based on 
the underlying assumption that peptides are capable of mimicking native conformations in the in 
vitro solution.
Thus one of the central beliefs of the domain interaction hypothesis is activation of RyR by a 
homologous activatory domain peptide, by binding to an endogenous partner domain and 
thereby disrupting a closed and stable RyR conformation. The inability of an MH-, or CPVT- 
containing mutant peptide to mimic the WT gives credence to the destabilising effect of a 
critically placed point mutation and provides a compelling mechanism for a ‘leaky’ RyR 
underlying the disease phenotype (Yamamoto, El-Hayek et al. 2000; Yamamoto and Ikemoto 
2002). This was the rationale for using DP4 (and DPc10- see chapter 7) to identify the potential 
region of conformational change linked to reduced FKBP12/12.6 affinity for RyR1/2 elicited by
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phosphorylation. The central domain is considered to be a likely candidate for this proposed 
region of co-ordinated regulation (Blayney, Jones et al. 2010).
Functional experiments in this investigation; 3[H] ryanodine binding using synthetic peptides 
purchased from Severn Biotech (Worcestershire, UK), yielded significant activation of RyR1 
(see chapter 6). However, the mutant peptide (DP4M) was as active as the WT. 5 mg of 
DP4WT peptide was received as a gift from the Ikemoto group (IK-DP4WT), which gave very 
similar results to the DP4WT purchased. Unfortunately we were unable to obtain any of the 
mutant peptide from the same source. The expense of a further purchase of peptides for 
comparison from a different commercial supplier prompted exploration into a novel avenue for 
producing the peptides as a bacterial recombinant protein. Producing and purifying the peptides 
‘in-house’ may actually be beneficial, although time consuming, because the peptides ordered 
from elsewhere are lyophilised and subjected to harsh chemicals during synthesis which could 
alter the properties of the protein.
N-terminus
heix 1
Figure 5.1 Structural model of DP4 achieved using 
NMR. MH mutation residues are labelled white with side 
chains and cluster close to the C-terminal end of helix 1 
and at the N-terminal of the loop connecting helix 1 and 
helix 2  (Bannister, Hamada et al. 2007).
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This chapter outlines the protocols involved in production and purification of DP4WT and DP4M 
recombinant peptides.
5.3 Results
5.3.1 PCR cloning of DP4 into pGEX-6P1.
DP4 was created by cloning from rRyR1 template using DP4 forward and reverse primers 
designed with BamH1 and EcoR1 restriction sites (Figure 5.2 A and B). The PCR amplicon was 
shown to run at the correct size on a 3% agarose gel (section 2.1.1.1) and was then gel 
extracted (section 2.1.2.3). Gel extraction was found to be more effective for removal of PCR 
reagents for the DP4 amplicon of 133 bp, because the cut-off for PCR clean-up resin is 100 bp, 
close to the size of this piece, and it was found to result in loss of yield (Figure 5.3A). Both the 
DP4 insert (Figure 5.3B) and pGEX-6P-1 vector (Figure 5.3C) were cut with BamH1 and EcoR1 
restriction enzymes in order to prepare them for ligation. Gels B and C confirm a reduction in 
size of the DP4 amplicon and linearization of pGEX-6P-1 respectively. The digested DP4 was 
gel extracted again to remove residual enzymes and buffers, and a small sample run on a gel to 
gain an estimation of quantity for ligation. The cut insert was ligated into the compatible cut 
vector’s multiple cloning site using a 5:1 ratio of insert to vector (as described in section 
2.1.2.6). Following transformation colonies were screened by diagnostic colony PCR using the 
pGEX forward primer and the DP4 reverse primer. The pGEX primer increases the expected 
amplicon size by 100 bp and of the 10 colonies screened, two were shown to generate PCR 
product (Figure 5.3D). These colonies were then ‘miniprepped’ (section 2.1.2.9) and the 
resultant plasmid preparations sequenced using the BIG DYE sequencing kit (section 2.1.2.10). 
The electropherogram and alignment using the BLAST ‘align two sequences’ software (Figure 
5.4) confirmed the correct insert was in frame within the pGEX-6P-1 vector. The 3C protease 
site is indicated in-frame with the BamH1 restriction site. The codon for R2458 is shown and the 
stop codon and EcoR1 site are correct.
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A
clamp BamH1 rRyR1 cDNA
< V  V ” *\
DP4 F (5’ - 3’) TATATGGATCCCTGATCCAAGCCGGCAAGG
clamp EcoR1 Stop
( V \ l — V
r RyR1 cDNA
DP4 R (5’ -  3 ’) CTATCGAATTCTCflGGGGATCTGCAGCGGG
B
Peptide Gene of Interest Genebank Size of
name Accession Amplicon (bp)
Number
DP4W T rRyR1 X15750 133
C
DP4M F (5’ -  3’) TCCGCGCCATCCTTTGCTCCCTCGTGCCCC
DP4M R (5’ -  3 ’)
Figure 5.2 DP4 and DP4M forward and reverse primer design
A) DP4WT forward and reverse primer sequences. The stop codon on the reverse primer is 
highlighted in red. Restriction endonuclease sites were incorporated as shown. GC content is 
approximately 50%.
B) Table demonstrating average primer annealing temperatures- designed to be similar for 
forward and reverse primers to increase PCR efficiency. Gene sequence was obtained from 
published GenBank sequence, the accession number for which is provided.
C) DP4M forward and reverse primer sequence used in site-directed mutagenesis. The pink 
highlighted area shows the region incorporating the base change mutation.
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Figure 5.3 Cloning o f DP4 into pGEX-6P-1
A) DP4 sequence was amplified from RyR1 template using PCR with primers 
DP4F and DP4M and the product was run on a 3% (w/v) TAE agarose gel 
(section 2.1.1.1) Lane 1, 1 Kb DNA marker, sizes are shown on the left (bp). 
Lane 2, DP4 PCR synthesized DNA product running at 133 Bp.
B) DP4 PCR amplicon was gel extracted and subjected to a double digest with 
BamH1 and EcoR1 restriction endonucleases. The products were separated on 
a 3% TAE agarose gel. Lane 1, hyperladder V DNA marker, sizes are shown on 
the left in base pairs (bp). Lane 2, undigested gel extracted DP4 PCR product. 
Lane 3, digested gel extracted DP4 product.
C) pGEX-6P-1 vector was prepared for ligation by EcoR1 and BamH1 double 
digest and treatment with protein phosphatase. Product was run on a 1% (w/v) 
TAE agarose gel. Lane 1, 10 Kb DNA size marker, the 5000 bp marker is 
indicated on the left. Lane 2, pGEX-6P-1 digested vector.
D) Of the colonies that grew on LB agar with Ampicillin following transformation, 
10 were selected and subjected to a colony PCR screen (section 2.1.2.8) using 
the pGEX forward primer and the DP4 reverse primer. PCR products were 
separated on 3% w/v TAE agarose by gel electrophoresis. Lane 1,1 Kb DNA 
marker with sizes shown on the left in base pairs (bp). Lanes 1-8 and 11 show 
colony PCRs with no insert. Lanes 9 and 10 show positive colony PCR 
amplicons.
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A 3C protease site BamH1
10 20 10 40 50 !,n_______________ l a _______________ d L   21: : : . : - : : | ; I
100 110 120 110 140 150 160 170 180
o j i c a s o c c o  o c a  a  a  o o t q  a o  a c c c  t o  c o  a a t c c q c  o c c a t c c t - ^ cJt c c c t c o  t o c c c c  t g  a a c g a c c t c o t o  a  g c  a t  c a t  c a o c c t c c c q c t t
R codon
100 100   210 220 230 240 250 260 270 280
| - |  : ~ ^ 7 g O C T C 0 A C T C O i q C Q 8 C C t l C A 7 C O 7 O  AC T O A C T G A C O  AT  C T O C C T C O C O C C T T T C G Q T O A T O A C f l Q T Q A A A A C C T
S to p E co R I
B
DP4 - pGEX - 6P-1 CTGATCCAAGCCGGCAAGGGTGAGGCCCTGCGAATCCGCGCCATCCTTCGCTCCCTCGTG
I I I I I  I I I I I I I I I I I I I I I I I I I I I I I I  I I I I I I I I I I I I I I I I I  I I  I I I I I I I I I I I I
X15750 (7 455 -75 14) CTGATCCAA GCCGGC AAGGGT GAGGCC CTGCGA ATCCGC GCCATC CTTCGC TCCCTC GTG 
DP4-pGEX-6P-1 CCCCTGGAC GACCTC GTGGGCATCATCAGCCTC CCGCTG CAGATC CCC
I I I I I I  I I I I I  I I I I I !  11 I I I I I  11 I 11 1 1 ! 1 1 1 1  M  ! I <
X15750 (7 515-75 62) CCCCTGGACGACCTCGTGGGCATCATCAGCCTCCCGCTGCAGATCCCC
Figure 5.4 Sequencing o f DP4-pGEX-6P-1
A) Electropherogram sequencing result. BamH1 and EcoR1 restriction sites are highlighted which 
flank the DP4 sequence . C-protease cleavage site is shown to be present and in frame. The R- 
codon is the site where the DP4M mutation would occur and is shown to be in the wildtype format. 
There is a stop codon immediately before the EcoR1 restriction site.
B) Sequence identity is confirmed by a BLAST sequence alignment with RyR1 sequence from the 
GenBank database (Accession number X15750) showing 100% match.
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5.3.2 Insertion of the R2458C point mutation
A maxiprep of the DP4 wildtype in pGEX-6P-1 was prepared (section 2.1.2.9) and used as the 
template for site-directed mutagenesis to insert the point mutation R2458C (section 2.1.3). 
Specific primers containing the desired mutation were used as part of the QuikChange 
mutagenesis kit (Figure 5.2 C). The protocol involves a PCR cycle to generate mutant sequence 
from the wildtype template, followed by an enzyme (Dpn1) digest process to eliminate 
methylated parental wildtype DNA (which was synthesised by and extracted from Top10 E.coli, 
section 2.1.2.7), whereas the PCR produced DNA was not methylated. This step therefore 
selected for the PCR synthesised DNA which should contain the point mutation. The treated 
DNA was then transformed into XLGold E.coli and plated onto LB agar plates supplemented 
with ampicillin and chloramphenicol and incubated overnight (section 2.1.2.7). Five colonies 
grew and minipreps were prepared for each of them. The DNA was sequenced to confirm the 
presence of the mutation. Figure 5.5A shows insertion of the correct single base mutation in the 
electropherogram, as well as a fully intact and in frame 3C protease site, and BamH1 and 
EcoR1 sites. BLAST alignment confirmed the remainder of the DP4 sequence remained intact. 
To eliminate any possible misreads in the vector sequence as a result of the QuikChange PCR 
reaction, which could compromise subsequent protein expression, DP4M was recloned into 
pGEX-6P-1. One of the positive mini preps was used as a template for a PCR reaction to 
generate DP4M. This was run on a 1% gel and extracted. The product was then cut using a 
BamH1 and Eco R1 double digest (Figure 5.5B) and ligated into similarly cut fresh pGEX-6P-1 
as described above for ligation of the DP4WT.
Chapter 5
Figure 5.5 DP4-pGEX-6P-1 Quick change mutagenesis to insert the 
R2458C mutation.
A) Sample of the sequencing electropherogram result showing the codon 
change from R (DP4WT) CGC to C (DP4M) TGC
B) Colonies grown on selective agar following quick change mutagenesis 
(section 2.1.3) were screened by colony PCR and a maxi prep was 
generated from a positive DP4M containing colony. The DP4M insert was 
then excised from maxi prep vector using BamH1 and EcoR1 enzymes 
and was subsequently ligated into freshly cut pGEX-6P-1. Digesteo 
DP4M product was run on a 3% (w/v) TAE agarose gel by gel 
electrophoresis. Lane 1, DNA size marker, sizes are shown on the left in 
base pairs (bp). Lane 2, digested DP4M.
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3C protease site Bam H1
10 20 30 40 50  a ___________g____________  10 _________
C T G C C  C OCCGGGG C T T C 1 C  C C G T T T G G T G G r G G C G  ACC*  T C C T C C A A A T C O  0  Hlf C TO 0  M O T  TC T G : G G G 0 . 3  ~ G |c J I
90 100 110 120 130   140 150 ISO 170 180
: T G  A T C CA A G C C G G C A A G G  G T G  1 G G C C C  T G C G H T C C G C G C C M C C  T t | t  G c | t  C C C T C G T G C C C C T G G A C G 5 C C T C G T G G G C » t C A T C A G C C T C C C G
C codon
190 ICO 210 220 230 240 250 250 270 <
1 7 G  C G '  C C C C | :  G A / . : : '  c j: C G G G T CG AC : C G '■ G C G  G C C G C  C G G A C T G A C T G  '■ C G r ;  : G C C T C G C G C G T  : T C G G T G A T G A C G G T G  AC
S to pE co R I
DP4m- pGEX - 6 P -1 CTGATCCAA GCCGGC AAGGGT GAGGCC CTGCGA ATCCGC GCCATC CTTTGC TCCCTC GTG
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 ! 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  I I  1 1 1 1 I I  1 I I  1 1 1 I I  1
X15750 (7455-7514)
1 I I  1 1 1 1 1 1 1 I I  1 I I  1 I I  1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 
CTGATCCAA GCCGGC AAGGGT GAGGCC CTGCGAATCCGC GCCATC CTTCGCTCCCTC GTG
DP4m-pGEX-6P-1 CCCCTGGAC GACCTC GTGGGC ATCATC AGCCTC CCGCTG CAGATC CCC
1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1
X15750 (7515-7562)
1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
CCCCTGGAC GACCTC GTGGGC ATCATC AGCCTC CCGCTG CAGATC CCC
Figure 5.6 Sequencing of DP4M-pGEX-6P-1
A) Electropherogram sequencing result. BamH1 and EcoR1 restriction sites are highlighted which 
flank the DP4M sequence. The C-protease cleavage site is shown to be present and in frame. The 
C-codon is the site where the DP4M mutation was inserted and is shown to be TGC rather than 
CGC. There is a stop codon immediately before the EcoR1 restriction site.
B) Sequence identity is confirmed by a BLAST sequence alignment with RyR1 sequence from the 
Gen Bank database showing 100% match with the exception of the mutated base.
5.3.3 Optimisation of Recombinant Protein Expression
The DP4WT and DP4M vector clones were transformed into E.coli Rosetta strain (section 2.2.2) 
for protein expression. 1 litre cultures were seeded with 20 ml of overnight starter culture and 
grown at 37°C. Their OD was tracked at A600 every 30 minutes and once the OD reached 0.6 
the temperature of the incubator was reduced to either 30°C or 25°C, depending on the chosen 
induction temperature, over 30 minutes (Figure 5.8). At this point a 50 ml sample was harvested
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(tmduction= 0 hour) and the pellet frozen. IPTG (final concentration 0.1 mM) (section 2.2.2) was 
added and further 50 ml samples were pelleted and frozen (at -20°C) every hour for 4 hours.
The pellets were thawed and protein expression was determined by capture of the GST-tagged 
protein on glutathione sepharose beads (section 2.2.3). After washing, the protein was released 
from the beads by the addition of 3x SDS sample buffer and 5 pi loaded onto SDS PAGE gels 
for analysis by Coomassie staining and Western Blot (section 2.2.1), (Figure 5.8). The expected 
size of the GST-DP4WT/M protein was 30.7 kDa. The protein markers used for these 
experiments do not give a good estimate of the protein size and they tend to run higher than 
their expected MW. This has been noticed for a number of proteins (see figures 7.7 and 7.8) 
and GST/DP4M runs consistently half way between the 23 kDa (green) and the 30 kDa markers 
on all the gels. Both 30°C and 25°C gave good expression and this was maximal by 3 hours 
with very little expression of protein pre-induction (t=0). The presence of the GST tag was 
confirmed by the Western Blots using anti-GST Ab.
B
GST- DP4
1.5.
ooCO
<
IPTG added
Temp reduced0.5
0 1 2 3 4 5 6
GST-DP4M
1.5
ooCO
< ^  IPTG added
0.5
Temp reduced
0 1 2 3 4 5 6
Time (hr) 30°C25°C Time (hr)
Figure 5 .7 Induction of GST-DP4WT/DP4Mprotein
The time course of bacterial growth was plotted by taking OD600 absorbance readings on a UV 
spectrophotometer every 30 minutes from the start of incubation at 37°C until the end of protein 
expression after induction with IPTG as indicated for A) GST-DP4WT and B) GST-DP4M.
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Figure 5.8 Induction o f GST-DP4WT/DP4M protein
Protein expression was monitored from the time of IPTG addition (t=0) until t=5 hours by 
taking 50 m l samples o f culture at hourly intervals. Samples from each hour were separatea 
on a 15% SDS-PAGE gel and samples were also transferred to nitrocellulose membranes 
for blotting with anti-GST antibody to confirm expression of the correct protein. This protocol 
was repeated at both 30°C and 25?C to see if temperature difference resulted in increased 
yield.
A) DP4 expression optimisation. Lanes 0-4 in all images correspond to t=0,1,2,3 and 4 
hours of induction respectively. Lane 5, Kaleidoscope protein size marker, sizes are shown 
on the right (kDa). Upper images are SDS-PAGE gels, lower images are western blots.
B) DP4M expression optimisation. Lanes 0-4 in all images correspond to t=0,1,2,3 and 4 
hours o f induction respectively. Lane 5, Kaleidoscope protein size marker, sizes are shown 
on the right (kDa). Upper images are SDS-PAGE gels, lower images are western blots.
117
Chapter 5
5.3.4 Purification of GST-DP4WT and GST-DP4M
1 litre cultures were harvested and the pellets stored frozen at -20°C. The pellets were thawed 
and treated with lysozyme and DNAase (Benzonase) for 4 hours at 4°C (section 2.2.3). The 
lysates were then subject to three 30 second cycles of sonication before centrifugation at 
10,000 g for 20 minutes to remove cell debris and unbroken bacteria. The supernatants were 
mixed with washed glutathione beads and rolled gently at 4°C overnight. The beads were 
washed with 10x their volume of 20 mM Tris/HCI buffer pH 8.0, 2 mM EDTA, 2 mM DTT plus 1 
M NaCI followed by a similar wash with 50 mM NaCI. GST-DP4WT or GST-DP4M were eluted 
from the glutathione beads by rolling with 10 ml of 10 mM reduced glutathione in 50 mM 
Tris/HCL buffer pH 8.0 for 2 hours at 4°C. The beads were transferred to a 20 ml column and 
the eluate drained and kept. The beads were washed with a further 10 ml of glutathione buffer 
and both eluates combined. Eluates were applied to a 20 ml Vivaspin 10,000 MWCO 
concentrator and the total eluate was reduced in volume to ~1 ml. To remove the glutathione, a 
diafiltration cup was placed in the concentrator and filled with 15 ml of 20 mM PIPES buffer pH
7.1 containing 150 mM NaCI. This diafiltration step was repeated. The protein concentration of 
the GST-DP4WT/M was determined from the A28o and calculated using the amino acid 
sequence, (Figure 5.9). Coomassie stained SDS PAGE of the GST-DP4WT and GST-DP4M 
preparations captured on beads are shown in (Figure 5.11) The concentration of the protein 
was continued to achieve -1 5  mg/ml so that a x5 dilution into the assay of GST-DP4WT/M 
effects on [3H]ryanodine binding would give a final concentration of 100 pM (see chapter 6)
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Figure 5.9 UV quantification estimate of concentrated protein.
The protein peak is at A28o- The flat extinction between 300 and 400 nm shows minimal light 
scattering indicating that the protein is free from aggregation. A) GST-DP4WT and B) GST- 
DP4M.
5.3.5 Purification of peptides R-DP4WT and R-DP4M
Recombinant (R-) peptides were prepared by removal of the GST tag from affinity purified GST- 
DP4WT or GST-DP4M via the 3C cleavage site. A pellet from a 1 litre culture of GST-3C 
protease was subjected to the same lysis, affinity capture, and wash protocol as the GST- 
DP4WT/M bead capture (section 2.2.3.1). 3C beads and GST-DP4WT or GST-DP4M were 
mixed in a ratio of 1:6 and rolled overnight at 4°C in 10 ml of 20 mM Tris/HCI pH 8.0, 2 mM 
EDTA and 2 mM DTT buffer. The beads were transferred to a column and drained free of 
eluate. They were washed with a further 10 ml of cleavage buffer. The cleavage is illustrated in 
Figure 5.11. The theoretical pi of R-DP4WT was -8 .6  and hence the protein was positively 
charged at pH 7.0. Capture after cleavage was therefore attempted using a 20 ml Vivapure IEX 
S (which is negatively charged) centrifugal spin column (20 ml -maxi M) with a capacity of 15- 
20 mg protein. The final volume of eluate containing the cleaved peptide was 27.5 ml in pH 8.0 
buffer. For successful capture on the spin column the pH was reduced to 7.0 by adding an 
equal volume of 20 mM MES buffer pH 6.0 - total volume 55 ml. This was passed through the 
Vivapure column 15 ml at a time using the Allegra centrifuge -  500 g (1475 rpm). The column 
was washed twice with 20 mM PIPES buffer pH 7.0. The peptide was eluted in 2 ml steps of 
increasing NaCI concentration in PIPES buffer, (0, 50, 150, 300, 400 and 500 mM) keeping the
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eluate for BCA protein assay, which quantifies protein based on peptide bonds (Figure 5.12). R- 
DP4M purification using this technique has not yet been tested as the discovery that this protein 
has a negative charge at pH 7.0 means an alternative, positively charged Vivapure column is 
needed for this stage.
To prepare a larger batch of R-DP4WT, this was captured onto GST beads and washed and 
cleaved as described above. The pH was adjusted to 7.0 and the cleaved peptide captured 
using the Vivapure protocol. The peptide was eluted from the resin by 2 ml of 300 mM NaCI in 
20 mM PIPES pH 7.0. This was allowed to drain through slowly for 30 minutes before a final 
spin at 500 g to complete the process. The peptide was concentrated using a 3000 MWCO 
Vivaspin concentrator to give a final concentration, which was measured by BCA assay as 
0.257 mg/ml (450 pi). The final product was run on an SDS PAGE gel to see if bands of 
contaminating protein could be detected. None were evident (Figure 5.13).
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Amino acid composition:
Ala (A) 3 7.3%
Arg (R) 3 7.3%
Asn (N) 0 0.0%
Asp (D) 2 4.9%
Cys (C) 0 0.0%
Gin (Q) 2 4.9%
Glu (E) 1 2.4%
Gly (G) 5 12.2%
His (H) 0 0.0%
H e (I) 6 14.6%
Leu (L) 9 22.0%
Lys (K) 1 2.4%
Met (M) 0 0.0%
Phe (F) 0 0.0%
Pro (P) 4 9.8%
Ser (S) 3 7.3%
Thr (T) 0 0.0%
Trp (W) 0 0.0%
Tyr (Y) 0 0.0%
Val (V) 2 4.9%
Pyl (0) 0 0.0%
Sec (U) 0 0.0%
Peptide name Molecular weight (Da) Theoretical pi
R-DP4WT 4274.1 8.74
R-DP4M 4221.1 6.11
Figure 5.10 R-DP4WT and R-DP4M proteomic analysis using Expasy Protparam 
software.
A) The amino acid composition for R-DP4WT is shown to be lacking any phenylalanine or 
tryptophan residues, and therefore has no extinction coefficient for analysis.
B) Highlights the dramatic change in the isoelectric point of the peptide on insertion of the R 
-  C mutation, meaning that the charge of the wildtype at pH 7.0 will be positive, and the 
mutant negative.
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DP4M
Figure 5.11 Cleavage of GST-DP4WT and GST-DP4M
15% SDS PAGE gels were stained with Coomassie. A) GST-DP4WT cleavage. Lane 1, 3C 
protease captured onto glutathione beads (released by x3 SDS sample buffer). Lane 2, GST- 
DP4WT captured onto glutathione beads, Lane 3, beads post cleavage with 3C captured and 
the lower band which could either be remaining uncleaved GST-DP4WT or GST and Lane 4 
MW markers. B. GST-DP4M cleavage. Lane 1, DP4M captured onto GST beads, Lane 2, 3C 
protease captured onto glutathione beads and Lane 3, beads post cleavage. Sizes are shown 
on the right (kDa).
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Figure 5.12 R-DP4WT purification using ion exchange
A) Pierce BCA protein assay was used to measure the absorbance of BSA protein 
standards. This graph shows the correlation between absorbance at 562 nm and the 
protein quantity in pg/ml.
B) Cleaved DP4 protein was passed through a Vivapure ion exchange centrifugal spin 
column at pH 7.0. Elution occurred by passing 2  ml aliquots of increasing NaCI 
concentration buffer through the column and measuring the absorbance of protein in each 
eluate fraction. R-DP4W T elution peaked at ~ 300 mM NaCI.
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Figure 5.13 R-DP4W T purification analysis
Following 3C cleavage, protein was concentrated (section 
2.2.5) and the resultant product was run on an 18% SDS 
PAGE gel to check for contaminating protein. Lane 1, 
1xSDS sample buffer. Lane 2, eluate from the 3C 
cleavage. Lane 3, concentrated DP4 peptide preparation. 
Lane 4, kaleidoscope protein size marker, sizes are shown 
on the right (kDa).
5.4 Discussion
DP4 was cloned into the pGEX-6P-1 vector system and the R2458C mutation was successfully 
inserted using a Quikchange kit. Expression of protein as a GST tagged (GST-DP4WT/M) 
construct was optimised and expression levels were high. Cleavage of the R-DP4WT/M 
peptides from the tag was accomplished using 3C protease, though this resulted in a significant 
loss of peptide judged by the theoretical yield predicted at this stage. A limited number of 
experiments were performed using the peptides, both attached to the GST tag and cleaved from 
it (see chapter 6). There were, however, difficulties in the purification process and in finding a 
means of concentrating liberated peptide due to its small size. Assessing the purity and tracking 
the peptide was also problematic due to its unique amino acid composition.
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5.4.1 Purification of recombinant peptide
The peptides were not amenable to our normal purification protocols post-cleavage as their 
small size, of ~4 kDa, made them difficult to concentrate using centrifugal concentration before 
further purification by ion exchange and gel filtration chromatography. Attempts with 3000 
MWCO concentrators resulted in no appreciable increase in protein concentration. The 
theoretical pi of the peptides was calculated as 8.9, which would give it a positive charge at pH 
7.0. It was therefore decided to capture the liberated peptide using a Vivapure column IEX S 
(which is negatively charged). The captured protein could then be thoroughly washed before 
elution to increase purity. Contamination by other proteins would be reduced by this step as the 
majority are negatively charged at pH 7.0. This also might represent a potential concentration 
step if the high salt necessary in the elution buffer can be tolerated in future assays, as a 2 ml 
elution volume could be used to release the peptide from the ion exchange resin, representing a
27.5 fold concentration from a starting volume of 55 ml. Dialysis with 3000 MWCO, the lowest 
available size, could not be used to exchange the buffer to a lower NaCI.
The R-DP4WT and R-DP4M were remarkable peptides in that they contained no amino acids 
that could be used to measure or track the protein through purification protocols. A26o, for 
example relies upon the UV absorption of the aromatic rings in tryptophan, tyrosine and 
phenylalanine residues, which were absent in the peptide protein sequences (Figure 5.10). 
Similarly Coomassie based protein assay is not suitable for small peptides (~3 kDa) and this 
would also limit detection of peptide on Coomassie-stained SDS gels. BCA protein assay, which 
measures peptide bonds, was therefore chosen for protein determination.
Yields of cleaved R-DP4WT and R-DP4M were lower than expected from the quantities of GST- 
DP4WT/M affinity captured by glutathione beads. The yields of GST-DP4WT and GST-DP4M 
were 3.6 mg/L and 2.5 mg/L respectively. The expected yield of peptide from its GST-peptide 
upon cleavage would be -0 .5  mg/L. However, the total yield was 0.030 mg/L (of culture) and 
0.015 mg/L for R-DP4WT and R-DP4M respectively and thus only 3-6% of the theoretical yield 
was obtained. It was not easy to ascertain where the loss was occurring. One possibility was 
poor cleavage, although the batch of 3C protease used for these experiments was one which
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was used routinely for a larger recombinant protein (data not shown). It is possible that the 
protease might be active but the cleavage site was sterically obscured by the peptide. In 
addition, these peptides were only 4 kDa and it was not clear whether the cleaved GST could 
be distinguished from uncleaved GST-DP4WT by SDS PAGE in Lane 3 of Figure 5.11, even on 
a 15% gel. Recombinant GST, run as a control, was not a defining option as it has the multiple 
cloning site also expressed which adds an additional 18 amino acids between the cleavage site 
and the first stop codon, making it only 10 amino acids shorter than GST-DP4WT. Thus, the 
efficiency of cleavage could not be determined from SDS PAGE analysis. It was deduced that 
the BCA assay was likely to be measuring R-DP4WT and R-DP4M peptides in the concentrated 
product from elution, due to the low level of contaminants (Figure 5.13), but this assay could not 
be used to track protein yield in the earlier steps where the eluates were much more dilute. As 
the protein could not be visualised using SDS PAGE, the purity is unknown. The most important 
test would be the peptide activity (see chapter 6). Loss of the peptide due to insolubility also has 
to be considered, although no obvious aggregates or precipitates were seen in the cleavage 
solution.
For a x10 dilution into an assay for [3H]ryanodine binding at a final active concentration of 100 
pM, a peptide solution of 1 mM would be required which equates to -4 .3  mg/ml. For a 2 ml 
elution from the Vivapure IEX 8.6 mg would need to be captured. For 8.6 mg to be liberated 
from the GST fusion the starting mass of GST-DP4WT would need to be 61 mg of protein. The 
efficiency of the cleavage and capture process to produce the peptides therefore requires more 
consideration and refinement.
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Chapter 6; Peptide and 
pharmacological regulation of RyR1
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CHAPTER 6; Peptide and pharmacological regulation of RvRI
6.1 Introduction
Previous studies have shown there are appreciable differences in the 3D structure of RyR 
between non-activated and activated states (Orlova, Serysheva et al. 1996; Serysheva, Schatz 
et al. 1999). In order to understand the mechanism of channel regulation in both normal and 
diseased states it is important to identify and characterize the domains involved in this 
conformational control.
Most MH-linked mutations have been found to reside in the N-terminus and central domains of 
RyR1, whereas those linked to CCD populate the C-terminus, especially the transmembrane 
domain. MH mutations on these domains cause aberrant channel function, including hyper 
activation and hyper sensitization of the channel to various physiological and pharmacological 
agonists, resulting in a leaky calcium channel (Dirksen and Avila 2002). These findings suggest 
that these MH domains are involved in the conformational control of RyR calcium channels . 
Domain peptides are useful as functional probes as they are able to maintain their native 
conformational structure in vitro in solution. Clustering of MH mutations to the DP4 region of 
RyR1 suggests that this region may play a critical role in inter-domain interaction. Domain 
interactions are proposed to maintain the channel in its closed state but undergo a 
conformational change as part of the molecular rearrangement of the RyR as it gates from the 
closed to open conductive state (Yamamoto, El-Hayek et al. 2000; Bannister, Hamada et al. 
2007).
The tetragonal symmetry of the RyR provides four identical regulatory sites for every RyR 
modification or interaction (Orlova, Serysheva et al. 1996). It is not yet known whether they 
require saturation with all sites occupied or whether there is cooperativity once one subunit is 
modified. The domain interaction could be intra subunit or between adjacent subunits of the 
homotetramer. A recent study labelling the N terminus and Central domains with fluorescent 
peptides and measuring FRET has suggested an inter subunit interaction is likely (Liu, Wang et 
al. 2010). Some studies have shown that for MH, irrespective of the individual point mutation, 
the phenotypes were similar. This indicates that mutations in either of these domains make an
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equivalent contribution to the abnormal mode of channel regulation regardless of position. 
Therefore channel disorder may be controlled by a global mechanism involving a domain or 
domains of the RyR, rather than specific residues (Treves, Anderson et al. 2005).
Initial experiments using the DP4 peptide (Yamamoto, El-Hayek et al. 2000) have shown a 
calcium biphasic dose response unchanged in the presence of 100 |iM DP4, but with a 4 fold 
increase in the magnitude of binding activity observed in activating calcium concentrations. DP4 
was also able to significantly enhance ryanodine binding at 0.01 pM calcium, because this level 
of calcium is associated with an almost closed channel state this suggests there are calcium 
dependent and calcium independent activation mechanisms at work in the mode of DP4 
activation. [3H]ryanodine binding experiments were also carried out in the presence of varying 
magnesium concentrations, the EC50 with and without DP4 was approximately the same, 
implying that the magnesium is still able to exert a significant inhibitory effect in the presence of 
the activatory peptide. An alternative peptide, corresponding to the LCC has also been shown to 
activate the RyR1 and is proposed by the group to mimic voltage-dependent induction of 
skeletal muscle type ECC (allosteric activation). DP4 was shown to have an effect additive to 
this peptide. Polylysine (an RyR-specific ligand) was also tested with DP4, where it was shown 
to shift the biphasic activation curve to the left. These effects correspond to changes in the 
activity pattern in MH conditions i.e. Hyperactivation of the release channel activity and the 
increased affinity to the release triggering reagents. The R to C mutation of DP4 was shown to 
abolish the activatory effect of the wildtype peptide, as mentioned earlier, indicating the high 
specificity of amino acid sequence required for this RyR1 domain. The peptide DP1, 
corresponding to the N-terminal, activated the RyR1 in a similar fashion to the DP4 central 
domain peptide, however a combination of both resulted in half maximal activation, which was 
interpreted as a sign that the peptides are competing for a common site of regulation. These 
observations lead to the N-terminus and central domain interaction hypothesis (Yamamoto, El- 
Hayek et al. 2000).
DP4 was combined with CHAPs in studies by Murayama et al. as CHAPs was known to 
override the reduction in CICR gain seen in RyR1 compared to RyR3 in mammalian skeletal
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muscle. DP4 was able to activate RyR1 but not RyR3 and the drug Dantrolene, a potent 
inhibitor of RyR1 used to treat MH, reversed the effects of both DP4 and CHAPs in an identical 
manner suggesting that activation of RyR1 by DP4 and CHAPs may be through a common 
mechanism (Murayama, Oba et al. 2005). FKBP12 has been proposed to bind to a region of the 
central domain inherent to the DP4 sequence (Gaburjakova, Gaburjakova et al. 2001). By 
incubating SR vesicles with both the peptide and FK506 (to remove all endogenous FKBP12 
protein), it was determined whether DP4 resulted in competitive dissociation of FKBP12. DP4 
and DP4M had no notable effect. [3H]ryanodine binding in the presence and absence of DP4 
alongside FK506 also showed the same extent of activation. These results indicate an FKBP12 
independent mechanism of activation by both DP4 and CHAPs (Murayama, Oba et al. 2005).
In single channel studies, ATP has been shown to increase the open probability of the channel 
at least 4 to 8 fold (Laver, Lenz et al. 2001). In most studies using DP4, although activation is 
seen, this peptide does not increase activity to the same degree as ATP (Murayama, Oba et al. 
2005). One [3H]ryanodine binding study using the non-hydrolysable ATP analogue (AMPPCP), 
showed an increase in binding of 7 to 8 fold at all AMPPCP concentrations in the presence of 
100 pM DP4. There was no significant difference in the activation pattern observed, the EC50 
was approximately the same in both instances, suggesting that DP4 has no additional effect in 
the presence of ATP (Murayama, Oba et al. 2005). Previous studies carried out in the presence 
of the DP4 wildtype and mutant peptides have shown it was able to increase spark frequency in 
permeabilised frog skeletal muscle fibres (Shtifman, Ward et al. 2002). Frog muscle fibres were 
also assessed for spark generation in the presence of magnesium and DP4 was found to be 
activatory even in the presence of mM levels of magnesium, although its effect was decreased 
compared to the control. Frog SR single channel studies have incorporated RyR into lipid 
bilayers for single channel analysis in the presence of 1 mM magnesium, and 100 pM DP4 
showed a severe reduction in channel activity in the presence of magnesium, which was mildly 
overridden by the DP4 addition and a slight increase in opening rate was seen, but was not as 
dramatic as the effects seen measuring sparks in the muscle fibre preparations. DP4 was 
shown to have a lower apparent affinity for RyR in the presence of magnesium, suggesting 
magnesium is able to modulate the ability of DP4 to ‘unlock’ the channel. This group
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hypothesize that it is the low affinity l-binding site for magnesium involved in regulation of DP4 
effectiveness (Murayama, Oba et al. 2005).
A combination of experimental data from RyR1 studies incorporating the DP4 peptide and its 
mutant have contributed to the understanding of RyR modulation in normal and disease (MH 
and CCD) states. Although the effects of magnesium and ATP have been characterised 
previously not much is known of the effects of other physiological modulators in addition to one 
another and, more importantly in an RyR model where phosphorylation and endogenous FKBP 
levels are controlled and standardised. The latter concept has been addressed in this study to 
enable a tighter grasp on the modulatory effect of DP4, and to simultaneously assess the region 
of convergent regulation previously proposed for PKA and FKBP12 modulatory effect (Blayney, 
Jones et al. 2010).
This chapter will examine the effects of DP4WT and DP4M on isolated RyR1, in the presence of 
FKBP12, magnesium, ATP, both to characterise these effects on our solubilised RyR1 
preparations and to add new insight into whether the effects of RyR modulators are linked to the 
N-terminus and central domain interaction. Preliminary studies using [3H]ryanodine binding will 
provide valuable information on the activation/deactivation of the channel. Due to the 
aforementioned effect of the anti-MH drug on DP4WT activation (chapter 5) and previous work 
done by Blayney et al. showing inhibition of both RyR1 and RyR2 by K201 (Blayney, Jones et 
al. 2010), there was an initial plan to assess the effects of the anti-arrhythmic drug K201 on 
DP4WT activation to assess whether this also had an inhibitory effect. However, due to the lack 
of availability of the benzothiazepine K201, diltiazem, a less specific derivative, was tested 
instead. The respective structures of these two compounds are shown in figure 6.1. Diltiazem is 
a broad range calcium channel blocker but has been shown to suppress arrhythmias in 
isoprenaline perfused mouse hearts in one study, suggesting a role in treatment of p-adrenergic 
related arrhythmias (Balasubramaniam, Chawla et al. 2004). Given that approximately 50% 
channel inhibition has been observed in [3H]ryanodine binding studies in the presence of K201 
(Blayney, Jones et al. 2010), it was of interest to test whether a less specific drug would 
demonstrate the same inhibition.
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Figure 6.1 Structures of A) Diltiazem and B) K201
6.2 Results
6.2.1 Effect of synthetic DP4WT and DP4M peptides on RyR1 [3H]ryanodine binding
DP4WT synthetic peptide from Severn Biotech was shown to have the greatest effect on 
[3H]ryanodine binding at 100 pM, increasing binding from the control value of 100% to 182.46% 
± 11.66 (Figure 6.1 A). DP4M synthetic peptide showed a similar potency to the wildtype, 
increasing from 100% to 202.1% ± 15.01 (n=4). DP4WT activation was compared to ATP 
activation of RyR1, as demonstrated earlier in chapter 4, and it is clear that although the 
DP4WT peptide is capable of increasing binding, and therefore opening the RyR channel above 
that caused by calcium alone, ATP is still more activatory, increasing binding to close to 400% 
(370.77% ± 32.06) (Figure 6.2). However, the expense of the peptides prevented the extension 
of the dose response curve to higher concentrations.
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Figure 6.2 Effect o f synthetic DP4W T peptide on RyR1 fHJryanodine binding
A) DP4 dose response is shown for both the wildtype and mutant DP4 peptides. Each 
point represents the mean of paired data for 1 RyR1 preparation, except for 100 pM ol 
peptide which was the average of 4 RyR1 preparations. (*) indicates a significant 
difference (p <0.05, students paired t-test) from the control value without peptide 
addition. (Binding in pCa4 is taken as 100%). Bars show standard error.
B) Comparison of the effect of 100 pM synthetic DP4WT with ATP activation of RyR1 
fHJryanodine binding. Each point represents the mean of 4 RyR1 preparations. (*) 
indicates a significant difference (p <0.05, students unpaired t-test) from the control 
value without ATP or DP4 addition. (Binding in pCa4 is taken as 100%). Bars show 
standard error.
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6.2.2 Effect of inhibitors of RyR1 activity on DP4WT activation of the channel
6.2.2.1 Magnesium
0.5 mM magnesium reduced the activatory effect of the DP4WT and DP4M peptides used at 
100 pM (Figure 6.3). Although the DP4WT activation was not completely reversed by 
magnesium, it was significantly reduced (p <0.05, students t-test) when compared to activation 
in the absence of magnesium. The results for magnesium inhibition of RyR1 by 0.5 mM and 1 
mM magnesium are shown for comparison.
250 i
Figure 6.3 Effect o f synthetic DP4W T activation on RyR1 pHJryanodine 
binding in the presence o f Mg2*
Magnesium (0.5 mM) and DP4WT/M (100 pM) effect are shown compared with 
DP4WT and DP4M (100 pM) peptides added in the presence of magnesium Each 
point represents the mean of 4 RyR1 preparations. (*) indicates a significant 
difference (p <0.05, students paired t-test) from the control value without 
magnesium or peptide addition. (#) indicates a significant difference (p <0.05, 
students paired t-test) from the DP4WT control. (Binding in pCa4 is taken as 
100%). Bars show standard error.
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6.2.2.2 FKBP12
Figure 6.4 shows the effect of 10 pM FKBP12 addition to RyR1 was to reduce the activity of the 
control by 50%. The addition of 10 pM FKBP12 to DP4WT activated RyR1 also reduced activity 
to a similar extent, returning the binding to control levels. DP4M activation was also reversed 
but to a lesser extent.
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Figure 6.4 Effect o f synthetic DP4W T activation on RyR1 f  HJryanodine 
binding in the presence o f FKBP12.
FKBP12 (10 pM) and DP4 (100 pM) effect are shown compared with DP4WT and 
DP4M (100 pM) peptides added in the presence of FKBP12. Each point 
represents the mean of 3 RyR1 preparations, except for DP4M+FKBP12 which is 
n=1. (*) indicates a significant difference (p <0.05, students paired t-test) from the 
control value without FKBP12 or peptide addition. (#) indicates a significant 
difference (p <0.05, students paired t-test) from the DP4WT control. (Binding in 
pCa4 is taken as 100%). Bars show standard error.
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6.2.3 Effect of the original Ikemoto DP4WT peptide
The dose response to the Ikemoto wildtype (IK-DP4WT) peptide (Figure 6.5) was shown to be 
similar to that for the Severn Biotech wildtype peptide (Figure 6.2A). Used at 100 pM peptide 
the relative increase in binding compared to the control was approximately 2-fold in both cases. 
Due to the limited quantity of IK-DP4 available for experiments, an n of 2 was only obtained for 
the dose response and 100 pM was the chosen concentration for all further experiments. 
Magnesium and FKBP12 reduced DP4 activation compared with the control DP4 data, 
magnesium reduced binding to almost control level (without additions), whereas FKBP12 
reduced activity by approximately 50% (Figure 6.6). A higher (n) is required to determine 
whether these differences observed are statistically significant.
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Figure 6.5 Effect of IK-DP4WT peptide on RyR1 fHJryanodine 
binding.
IK-DP4W T dose response is shown. Each point represents the mean 
of 2  RyR1 preparations. (Binding in pCa4 is taken as 100%). Bars 
show standard error.
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Figure 6.6 Effect o f IK -DP4W T peptide activation on RyR1 fHJryanodine 
binding in the presence o f magnesium and FKBP12.
A) Magnesium (0.5 mM) effect is shown compared to IK-DP4WT (100 pM) 
and IK-DP4WT added in the presence of magnesium.
B) FKBP12 (10 pM) effect is shown compared to IK-DP4WT (100 pM) and IK- 
DP4WT added in the presence of FKBP12. Each point represents the mean 
of 2 RyR1 preparations. (Binding in pCa4 is taken as 100%). Bars show 
standard error.
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6.2.4 Effect of recombinant peptides in comparison to the original Ikemoto peptide
The cleavage of R-DP4WT and R-DP4M from the GST tag and particularly subsequent 
purification proved difficult (see chapter 5). Thus we tested the GST tagged peptides to see if 
they had an activating effect. GST-DP4W T and GST-DP4M were found to have little activatory 
effect on ryanodine binding compared with other peptides used in this study. Figure 6.7 shows 
the IK-DP4 response at 100 pM compared with the GST-DP4WT and GST-DP4M and the latter 
effects were not shown to vary greatly from the control with no peptide addition. A greater (n) 
would be required to determine the significance of this result.
250 n
o> 200
S 2 150 - 
c c
1 8
100 n
>  .
DP4 W/T-GST
50 - DP4M-GSTn
IK-DP4
100100
Peptide (pM)
Figure 6.7 Effect of recombinant GST-DP4WT/M on RyR1 fHJryanodine 
binding.
GST-DP4WT and GST-DP4M dose responses compared with IK-DP4W T at 100 pM. 
Each point represents the mean of 2  RyR1 preparations. (Binding in pCa4 is taken as 
100%). Bars show standard error.
Figure 6.8 shows the effect of the cleaved DP4 recombinant peptide, without the GST tags and 
although the maximal concentration available for these peptides was only 10 pM, a comparison 
with the wildtype IK-DP4 at the same concentration suggests that the recombinant peptide is 
equally as activatory.
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Figure 6.8 Effect o f the recombinant DP4W T peptide on RyR1 
fHJryanodine binding com pared with IK-DP4W T peptide.
Binding in the presence o f 10 pM R-DP4WT (DP4 cleaved) is shown 
compared with 10 pM of IK-DP4WT. Each point represents the mean of 2 
RyR1 preparations. (Binding in pCa4 is taken as 100%). Bars show 
standard error.
6.2.5 Peptide interaction with FKBP12 protein
DP4WT and DP4M contain the putative FKBP12 binding motif (Gaburjakova, Gaburjakova et al. 
2001; Murayama, Oba et al. 2005), thus the effect of addition of high concentrations of peptide 
could be to counteract RyR-FKBP12 binding. The GST-DP4WT construct was used in a GST- 
pull down assay (Figure 6.9). No FKBP12 was detected as being pulled out of solution by GST- 
DP4WT, as shown by the lack of an FKBP12 band on both the coomassie and the western blot 
probed with anti-FKBP12 Ab. This indicates that the DP4WT moiety did not interact with 
FKBP12.
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Figure 6.9 G ST-D P4W Tpull down assay for FKBP12
A) GST-DP4W T was incubated with FKBP12 for one hour in both the 
presence and absence o f FK506 to determine whether there was any 
interaction between these proteins. Following incubation, samples were boiled 
with SDS loading buffer and separated on 15% SDS-PAGE gels A) Lane 1, 
GST-DP4W T control ( -3 0  kDa) without FKBP12 or FK506. Lane 2, GST- 
DP4W T after incubation with FKBP12. Lane 3, GST-DP4WT after incubation 
with FKBP12 in the presence o f FK506. Lane 4, FKBP12 (10 pM) control. 
Lane 5, kaleidoscope protein size marker, sizes are shown on the right (kDa).
B) Samples were also transferred to a PVDF membrane for blotting with anti- 
FKBP12 specific antibody. Lanes 1-4 contain the same as in A), all were 
probed with anti-FKBP12 antibody.
6.2.6 Pharmacological modulation of RyR1
Previous studies have shown that the anti-arrhythmic drug K201 is able to reduce [3H]ryanodine 
binding by approximately 50%. The initial aim was to incorporate this drug into experiments as 
part of this investigation however a supply sent to us as a gift and found to be effective 
previously was exhausted, and we didn’t have the rights to use more of this drug. K201 was 
designed as a diltiazem analogue, so experiments were carried out to determine its effect on
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[3H]ryanodine binding (Figure 6.10) and if it could be used in a similar way to K201. Diltiazem 
had no effect at pM concentrations even when increasing the baseline open level of the RyR, by 
adding 2.5 mM ATP (described earlier in chapter 4). No effect was seen until a concentration of 
100 mM, when there was a dramatic decrease in binding. This was a very high concentration for 
a pharmacological effect so it was concluded that diltiazem could not be used as a surrogate for 
K201.
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Figure 6.10 Effect of Diltiazem on RyR1 f3HJryanodine binding.
Diltiazem dose response in the presence and absence of 2.5 mM ATP. Each point 
represents the mean of paired data for 1 RyR1 preparation. (Binding in pCa4 is taken as 
100%). Bars show standard error.
6.3 Discussion
The domain peptide DP4 has proved to be a useful tool in the characterisation of the N- 
terminus/central domain interaction. It was the intention to use DP4 to determine whether the 
regulation of RyR by phosphorylation and FKBP12 is part of the same interaction. It was first 
necessary to characterise the effect of DP4WT and DP4M on channel activation using 
solubilised RyR preparations and [3H]ryanodine binding The initial experiments using peptides 
chemically synthesised by Severn Biotech showed that the DP4WT and DP4M peptides were 
equipotent rather than DP4M being an inactive control as described in the literature (Yamamoto,
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El-Hayek et al. 2000). This result has necessitated comparison of various sources of the 
peptides and the functional effects on RyR activity are discussed below.
DP4WT activation was shown to increase up to 100 pM, higher concentrations were not tested 
but this concentration has been used in previous experiments (Yamamoto, El-Hayek et al. 
2000). This group found [3H]ryanodine binding to increase to 400% of the control value (100%), 
and an increase to approximately 200% was only ever observed in our investigation, where the 
two sources of DP4WT peptide were shown to have similar activational curves and one of these 
peptides was the original IK-DP4WT peptide. For both peptides DP4WT activation was shown 
to be less than that observed in the presence of 2.5 mM ATP. The assay conditions used for 
[3H]ryanodine binding on SR preparations (Yamamoto, El-Hayek et al. 2000) were very similar 
to those used in this study so it is interesting that a smaller effect was seen in our experiments. 
One factor could be the use of solubilised RyR preparations which are different from SR in a 
number of respects. FKBP12 is stripped off and the preparations were dephosphorylated. This 
could have contributed to resetting the open closed conformation giving a different ‘baseline’ 
from which DP4 has to interact with RyR and this may redefine the ease of opening. RyR within 
the SR membrane may have a more ‘natural’ physiological environment but this makes the 
parameters governing its regulation more difficult to dissect.
Of particular importance was the finding that DP4M had the same activatory effect on 
[3H]ryanodine binding as DP4WT. All of the papers in which DP4WT and DP4M have been 
used have resulted from collaborations with the Ikemoto Group who have supplied the peptides 
(Kobayashi, Bannister et al. 2005; Bannister, Hamada et al. 2007; Hamada, Bannister et al. 
2007). These were synthesised using Fmoc [N-(9-florenyll)methoxycarbonyl] as the amino 
protecting group. The peptides were released from the solid support resin and deprotected 
using 95% trifluoroacetic acid and purified by reverse phase HPLC. The commercial peptides 
which were synthesised by Severn Biotech were also supplied as a salt of trifluoroacetic acid 
and these too had been purified by reverse phase HPLC. To solubilise the Severn Biotech 
peptide we used DMSO. The peptides were then diluted with water to give a 50% DMSO 
solution of 1 mM final peptide concentration. The dilution into the [HJryanodine binding assay
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was x10 giving a final DMSO concentration of 5% with a maximum active peptide concentration 
of 100 pM. Serial dilutions of DP4WT/M for the assays were always made with 50% DMSO and 
this maintained a constant 5% DMSO concentration in all assay tubes including the controls. 
The Ikemoto W T peptide was treated in the same way so that it was strictly comparable to our 
purchased peptide.
DP4WT activation was shown to increase up to 100 pM, higher concentrations were not tested 
but this concentration has been used in previous experiments (Yamamoto, El-Hayek et al. 
2000). This group found [3H]ryanodine binding to increase to 400% of the control value (100%), 
and an increase to approximately 200% was only ever observed in our investigation, where the 
two sources of DP4WT peptide were shown to have similar activational curves and one of these 
peptides was the original IK-DP4WT peptide, Although it must be noted that low availability of 
IK-DP4 has only enabled an n of 2 to be obtained in all experiments, therefore these data 
cannot be considered statistically significant. For both peptides DP4WT activation was shown to 
be less than that observed in the presence of 2.5 mM ATP. The assay conditions used for 
[3H]ryanodine binding on SR preparations (Yamamoto, El-Hayek et al. 2000) were very similar 
to those used in this study so it is interesting that a smaller effect was seen in our experiments. 
One factor could be the use of solubilised RyR preparations which are different from SR in a 
number of respects. FKBP12 is stripped off and the preparations were dephosphorylated. This 
could have contributed to resetting the open closed conformation giving a different ‘baseline’ 
from which DP4 has to interact with RyR and this may redefine the ease of opening. RyR within 
the SR membrane may have a more ‘natural’ physiological environment but this makes the 
parameters governing its regulation more difficult to dissect.
The effects of the physiological inhibitors FKBP12 and magnesium were tested to see if they 
could inhibit RyR activity in the presence of DP4. For DP4 both the Severn Biotech peptide and 
the IK-DP4WT were -5 0 %  inhibited by 10 pM FKBP12. This is the same as the maximal effect 
of 50% inhibition of [3H]ryanodine binding without peptide addition. Unfortunately there was 
insufficient peptide from any source to obtain a dose response curve for FKBP12 at 100 pM
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DP4 and determine whether the K, for FKBP12 was different from that of the control without 
peptide.
However, there has been suggestion that DP4 houses an FKBP12 putative binding site 
(Gaburjakova, Gaburjakova et al. 2001), which may provide an explanation for the inhibitory 
effect, if the FKBP12 is bound to GST-DP4W T with high affinity and thereby neutralised its 
binding to the site within the RyR1 molecule. Therefore a GST pull down experiment was 
carried out where the GST-DP4W T peptide was incubated with FKBP12, both in the presence 
and absence of FK506 as a control for specificity and with glutathione beads, so that the GST- 
DP4WT was affinity purified following incubation. The products were run on a gel following wash 
steps and western blotted with anti-FKBP12 antibody to check for bound FKBP12 ‘pulled-down’ 
with the affinity purified GST-DP4W T (Figure 6.9). This shows that there was no evident binding 
of GST-DP4WT with the FKBP12 protein used in these experiments and that the effects seen in 
[3H]ryanodine binding are attributable to an allosteric effect of FKBP12 binding to RyR1 at a 
different site and probably influencing the conformational change in the DP4 binding domain.
Magnesium significantly reduced the DP4 activation as reported previously (Murayama, Oba et 
al. 2005). This inhibition appeared to be less potent for the Severn Biotech peptide but 
equipotent for IK-DP4WT (where despite a low n the error bars were small) in comparison to the 
effect of magnesium in the absence of peptide. A higher n for these experiments and a dose 
response would be required to see if this was a real difference or the result of insufficient data. It 
has been shown that magnesium has the same EC50 in the presence and absence of DP4 
(Bannister, Hamada et al. 2007).
The majority of previous studies using IK-DP4M have shown very little activation and this is one 
of the key findings that has led to the domain interaction hypothesis, as the single amino acid 
change in the mutant peptide mimics an MH mutation which has previously been suggested to 
be sufficient to disrupt domain interaction and thus RyR stability. It is of note however, that one 
study (Bannister, Hamada et al. 2007), comparing various DP4M peptides containing other MH 
or alternative mutations, showed a range of activation by all mutant peptides tested, but the
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DP4M R-C mutation had the least effect. At 100 pM, activation by the R-C mutant peptide 
(DP4M) was comparably less than the wildtype, but still showed activation of the RyR, 
increasing with concentration.
This leaves us with the question as to why, in these experiments, the synthetic DP4M peptide 
was as active as DP4WT. NMR data shows the backbone of the WT peptide to consist of two 
helices connected by a loop (Bannister, Hamada et al. 2007). The MH mutations published to 
date, in this region, all fall in the loop or in the first helix adjacent to the loop. The position of 
R2458 is shown in the centre of the loop, which is consistent with interaction with another 
protein since interaction sites are frequently in such loop regions (Figure 5.1) (Bannister, 
Hamada et al. 2007). The protein concentration necessary for NMR was 4 mg/ml. The mutant 
could not have its structure assessed as it was not soluble at this concentration in the desired 
buffer. One of the disadvantages of the use of these peptides is the apparent very low affinity of 
the DP4WT for their partner interaction site (30 -100 pM Kd) and this necessitates using these 
peptides at very high concentrations (Bannister, Hamada et al. 2007). To achieve the 500 pM 
concentration of peptide in some of the dose response curves the final assay concentration 
would need to be 2 mg/ml. Thus even for a 1:1 assembly of an assay mix the starting 
concentration would need to be 4 mg/ml and even higher if a greater dilution was required to 
make additions to the assays. Differences in solubility, which limited the concentrations that 
could be compared for activity, were also noted for DP4 peptides containing R2452W, R2454C 
and R2458H mutations. These peptides could only be compared up to a maximum final 
concentration of 200 pM (Bannister, Hamada et al. 2007). This begs the question as to whether 
the inactivity of the DP4M as a synthetic peptide might be a function of its solubility under some 
assay conditions, particularly at high concentrations. In this study, it was possible to solubilise 
the Severn Biotech peptides, both mutant and WT, in 50% DMSO to 1 mM and the IK-DP4WT 
peptide was treated similarly. The IK-DP4WT was supposed to be soluble in water but in our 
hands this was not the case.
GST-DP4WT was not found to be an effective substitute for the standard peptides as no 
increase in [3H]ryanodine binding was observed. It is possible that the GST tag (26 kDa) 
prevented interaction. However, larger molecules such as an antibody to DP4 and DP1
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peptides have been used to activate RyR, in a similar way to the peptides (Kobayashi, 
Yamamoto et al. 2004), so access to the interdomain space is not the reason for this 
observation. Alternatively, perhaps the peptides are sterically prevented from interacting with 
their binding domain. It was encouraging to observe that once the GST tag was removed, the 
wildtype peptide appeared to be activatory at the equivalent concentration (10 pM) to the 
original IK-DP4, although this was too low a concentration for a definitive result, so it would be 
interesting to see whether this peptide would be as active at 100 pM. Purification difficulties 
following 3C cleavage of the GST tag, as discussed in chapter 5, have prevented the 
development of a more concentrated peptide preparation as yet.
Previous experiments have used K201 as a useful tool in conformational studies. As an 
alternative to K201, Diltiazem was tested and found to have no significant effect on 
[3H]ryanodine binding, and even in the presence of ATP, which is known to open the channel 
maximally (Meissner 2002), no effect was observed until concentrations of the drug were 
reached that were unlikely to be pharmacologically useful. This finding suggests that Diltiazem 
does not serve as a suitable alternative therapy to the anti-arrhythmic drug K201. Perhaps the 
less specific nature of Diltiazem means that in an SR preparation the apparent effect on RyR 
might not be due to a direct effect on the RyR molecule. A previous study linking the use of 
Diltiazem with suppression of p-adrenergic arrhythmia found the drug to be effective at 
micromolar concentrations on perfused mouse hearts, suggesting a more intact cardiovascular 
model is required for efficacy of this drug (Balasubramaniam, Chawla et al. 2004). However the 
isolated channels used in our investigation would require a drug that directly modulates RyR to 
show any effect on [3H Jryanodine binding.
Using [3H]ryanodine binding, the effect of the DP4WT activatory peptide on both magnesium 
and FKBP12 inhibition of isolated, native RyR1 stripped of endogenous FKBP12 has been 
demonstrated. It is worth noting that binding in the presence of DP4WT could be reduced by 
either FKBP12 or magnesium, as seen in the absence of DP4WT, showing that inhibition by 
these modulators can counter the activatory effect of the DP4WT peptide. The effect of 
FKBP12 on DP4WT activation was a novel finding and an effect that was attributed to an
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allosteric interaction and not competition resulting from FKBP12 binding to the peptide. The 
data supports the concept that the effects of DP4WT on the central domain interaction and 
those of magnesium and FKBP12 regulation of RyR activity may be linked. Peptides were of 
insufficient concentrations to enable paired experiments to be carried out on phosphorylated 
and de-phosphorylated preparations. For the future it will be of interest to test whether this has 
any impact on the ability of DP4WT to activate the channel. Given previous findings it may be 
the case that no difference would be observed with [3H]ryanodine binding (Jones, Lai et al.
2006). A more subtle change in affinity for FKBP12 may be measured using the Biacore (Jones, 
Reynolds et al. 2005). The finding that FKBP12 was unable to bind to the DP4WT peptide is 
valuable as it enables the Biacore experiments to be carried out in the knowledge that the 
inclusion of peptide would not result in it binding to the sensor chip and directly competing with 
RyR binding. This would test the effect of the peptides to alter the kinetics of FKBP12 binding to 
RyR1 in response to phosphorylation and link the central domain interaction to the 
conformational change caused by phosphorylation (Blayney, Jones et al. 2010).
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CHAPTER 7: Modulation of RvR2
7.1 Introduction
In parallel with the studies on RyR1, it was proposed to examine the effects of the physiological 
modulators of RyR2 function; calcium, ATP and magnesium and to compare these with the 
action of the activatory peptide DPc10.
The RyR2 dose response curve to free calcium concentration has been shown to be biphasic 
suggesting that like RyR1, RyR2 has high affinity activation sites and lower affinity inactivation 
sites. (Xu, Mann et al. 1996),(Liu, Pasek et al. 1998). These have been labelled A for activation 
and I for inhibition (Laver 2007). Single channel bilayer studies have demonstrated that calcium 
alone cannot completely open an RyR2 channel (Sitsapesan, Montgomery et al. 1995),(Laver
2007). ATP at ~2 mM in addition to calcium is necessary to fully activate a channel and the 
presence of ATP decreases the Ka for calcium from 6 to 1 pM (Laver 2007).
The physiological concentration of free magnesium in the heart is estimated to be ~100mM 
(Hohl, Garleb et al. 1992), (Koretsune, Corretti et al. 1991), with much of the total magnesium 
being complexed with ATP. Studies assessing magnesium and ATP effects on RyR2 have 
yielded similar results to those for RyR1, although Meissner et al have suggested that RyR2 
from cardiac muscle is not activated by ATP to the same extent as RyR1 in the absence of 
calcium (Meissner, Rousseau et al. 1988).
DPc10 peptide (G2460-P2495), a peptide homologous to the RyR2 central domain, is an RyR2 
equivalent of DP4, and has been shown to increase the sensitivity of RyR2 to activating calcium 
and increase [3H]ryanodine binding, much like DP4 (Yamamoto and Ikemoto 2002). DPdO  
studies are pertinent to arrhythmias linked with the disease CPVT as the mutant of this peptide 
(DPdOM) includes the R2474S CPVT mutation, and this was found to be inactive compared to 
the WT D PdO  (Laver, Honen et al. 2008). Single channel studies with RyR2 incorporated from 
SR preparations have tested the effect of the RyR2 peptide DPdO and showed that with 
calcium alone D P dO  caused activation but DPdOM  did not. ATP caused an increase in 
channel activation, but no further increase was observed with DPdO  addition. This implied that 
ATP had fully opened the channel (Laver, Honen et al. 2008). DPdO has also been shown to
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lower the threshold for spontaneous calcium release in a study using permeabilised rat 
cardiomyocytes as it increased the number of spontaneous calcium sparks (Yang, Ikemoto et 
al. 2006).
FKBP12.6 can regulate RyR2 in a similar manner to FKBP12 regulation of RyR1. It binds to the 
channel and stabilises its activity (see main introduction). The relationship between FKBP12.6, 
RyR2 and phosphorylation has become an important focus in the mechanism underlying 
arrhythmia and SCD in HF. The hyperphosphorylation hypothesis suggests that increased 
sympathetic activity results in persistent phosphorylation of RyR2 and this causes the loss of 
FKBP12.6 which destabilises channel activity (Marx, Reiken et al. 2000). This results in diastolic 
leak of calcium resulting in DADs, as described previously (chapter 1). Experiments, mainly 
using a paced dog model of heart failure, have investigated the underlying mechanisms in 
respect of the involvement of a faulty domain interaction. In SR preparations from control dogs, 
DPdO (but not DPdO M ) caused a calcium leak, which could be inhibited by K201 (JTV519). 
However, D PdO  was shown to have no appreciable effect on dissociation of FKBP12.6 from 
RyR2 or on the phosphorylation level in the absence of cAMP, suggesting a link to (3-AR 
stimulation. When SR was preincubated with cAMP, FKBP12.6 dissociation occurred in a 
concentration-dependent manner concurrent with an increase in PKA phosphorylation (Oda, 
Yano et al. 2005). When similar experiments were performed on SR derived from the paced 
dogs neither D PdO  nor cAMP caused an increase in calcium leak. Using DPdO to carry a 
fluorescently labelled probe into the target domain it was shown that in HF the domains were 
already ‘unzipped’ explaining the lack of effect of the peptide and cAMP. The anti-arrhythmic 
drug, K201 was able to restabilise the domains. Similar experiments using the fluorescence 
quench method showed that oxidation also unzipped the domain targeted by DPdO. The 
DPdO domain peptide (but not D PdO M ) was shown to increase the number of spontaneous 
calcium sparks in permeabilised myocytes and K201 was able to suppress this effect (Tateishi, 
Yano et al. 2009).
Extending this type of study to look at the CPVT mutation clusters and again using fluorescent 
quench analysis to determine whether FKBP12.6 mediated stabilization of RyR2 is produced by
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abnormal domain interaction with the D P dO  peptide, Hamada et al found K201 (JTV519) 
almost completely inhibited D P dO  induced calcium leak (Hamada, Gangopadhyay et al. 2009). 
The amount of FKBP12.6 bound was unchanged in the presence of K201, suggesting inhibition 
of calcium leak by K201 is not mediated by rebinding of FKBP12.6 to the SR vesicle (see main 
introduction). However, the group have postulated that destabilisation incurred by DPdO may 
result in RyR2 phosphorylation having a greater effect on FKBP12.6 dissociation- suggesting a 
possible link between the two mechanisms. The affinity of FKBP12.6 for RyR2 has been shown 
to be reduced when the channel is in the open state, as it is for RyR1 in Biacore affinity studies 
done by (Blayney, Jones et al. 2010). In the closed channel state, binding affinity to FKBP12.6 
was shown to be reduced to the level of the open channel in the presence of PKA 
phosphorylation, although the binding affinity remained high throughout, suggesting modification 
of RyR conformation incurred by PKA phosphorylation, which is not observable in [3H]ryanodine 
binding studies.
A more recent study by (Liu, Wang et al. 2010) has involved the use of FRET with CFP and 
YFP fluorescent probes in RyR2 transfected HEK cells to determine whether the RyR domain 
interaction occurs between neighbouring subunits (inter-subunit) or remains confined to 
individual subunits (intrasubunit). Results show that there is in fact evidence of inter-subunit 
interaction between the N-terminus and central domain. The group postulate that this region of 
inter-subunit interaction is of critical importance for normal channel function of Ryr2 and that 
mutations in either domain may weaken the normal subunit-subunit interactions, thus altering 
stability of the channel.
However, no studies have assessed the effect of magnesium inhibition on DPdO activation, or 
ATP and D PdO  effects on ryanodine binding, further adding to the validity of pursuing this 
study on the RyR2 isoform.
This chapter aims to assess the effect of known physiological modulators of RyR2. The 
FKBP12.6 protein for this study was produced and purified in house using molecular cloning 
techniques. Initially there was an aim to generate D PdO  peptides with a view to repeat
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experiments carried out using the RyR1 isoform with RyR2. This chapter describes the cloning 
and expression of the D P dO  wildtype peptide, however experiments with this peptide were not 
realised and the mutant was not developed due to time constraints. This chapter will serve as 
control data for subsequent studies as proof of effect on RyR2 channel opening due to the 
specificity of [3H]ryanodine binding for the RyR.
7.2 Results
7.2.1 Physiological modulators of RyR2
Purified RyR2 native channels (chapter 3) were shown to exhibit the classic biphasic dose 
response to calcium using [3H]ryanodine binding, thus demonstrating correct functionality of the 
protein and its suitability for further experiments (Figure 7.1). Phosphorylation and 
dephosphorylation had little effect on [3H]ryanodine binding. pCa4 buffer was shown to have 
maximal effect on channel opening, therefore this buffer was used for proceeding experiments. 
ATP was shown to exert maximal effect at 2.5 mM and the total activation observed was 250% 
in the presence of calcium and ATP (Figure 7.2). Due to the low yield of RyR2 protein obtained 
after purification, this experiment was only repeated twice, however the values obtained at 0.5 
and 1 mM ATP have been shown to be significantly different from the control. A higher (n) 
number is required to determine whether the overall activation of RyR2 with ATP is consistently 
lower than for RyR1. The full calcium response was repeated in the presence of 2.5 mM ATP 
and although these results are not shown to be significantly different from the corresponding 
values on the calcium curve without ATP, it is clear the ATP is having a notable activatory effect 
at all calcium concentrations able to open the channel significantly (Figure 7.2 B).
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Figure 7.1 RyR2 biphasic response to varying free calcium (pCa).
Each point represents the mean of 2  RyR2 preparations. (pCa4 is taken as 
100%). Bars show standard error.
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Figure 7.2 Effect of ATP on RyR2 fHJryanodine binding.
A) ATP dose response in the presence and absence of phosphorylation. (*) indicates a 
significant difference (p <0.05, students paired t-test) from the control without ATP 
addition.
B) ATP effect on binding across the calcium biphasic response. Calcium response is 
shown in the presence and absence of 2 .5  mM ATP. Each point represents the mean of 2  
RyR2 preparations. (*) indicates a significant difference (p <0.05, students paired t-test) 
from the equivalent value of the calcium dose response without ATP addition. (Binding in 
pCa4 is taken as 100%). Bars show standard error.
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7.2.2 Cloning, production and purification of FKBP12.6
FKBP12.6 primers were designed (Figure 7.3) and successfully amplified the FKBP12.6 
sequence from cDNA template as shown in figure 7.4 A. The PCR amplicon was digested using 
BamH1 and EcoR1 restriction endonucleases (section 2.1.2.5) and the PCR clean-up kit 
(section 2.1.2.3) resulted in sufficient cleaved product for ligation (Figure 7.4 B and section 
2.1.2.6)). Of 5 minipreps generated from selected colonies (section 2.1.2.9), one was shown to 
have the correct size insert following restriction digestion with BamH1 and EcoR1 enzymes 
(Figure 7.5). Subsequent sequencing of this miniprep (Figure 7.6) showed that the insert was 
correct. The electropherogram confirmed all sequencing was in frame with the 3C restriction site 
and the BamH1 and EcoR1 sites were present with the stop codon before the EcoR1 site 
(section 2.1.2.10). The sequence was aligned with the GenBank sequence for FKBP12.6 using 
BLAST NCBI software, showing 100% match.
The protocol for protein production was assumed to be the same as for FKBP12, due to the 
high homology of these proteins, therefore protein was induced at 30°C for 3 hours, which was 
sufficient to generate a high yield of protein. Affinity purification of FKBP12.6 gave excellent 
results (Figure 7.7 and section 2.2.3), with a very high efficiency of 3C cleavage, shown by 
SDS-PAGE analysis. Cleaved FKBP12.6 protein quantity was estimated by running a sample 
alongside known BSA controls (~1 mg/ml) (Figure 7.8A). Protein identity was confirmed by 
Western blot using an anti-FKBP12.6 specific antibody (Figure 7.8B and section 2.2.1).
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clamp BamH1 hFKBP12.6
r ■y  ^ r ---------------------------------------->>
FKBP12.6 F (S ’S ’ ) TACTTGGATCCATGGGCGTGGAGATCGAGA
clamp EcoR1
( Y---------------^
hFKBP12.6
FKBP12.6 R (S ’S ’ ) GCGCGGAATTClCACTCTAAGTTGAGCAGC
B
Protein Gene of Interest Genebank Size of
name Accession Amplicon (bp)
Number
FKBP12.6 hFKBP12.6 BC002614 340
Figure 7.3 FKBP12.6 forward and reverse prim er design
A) Forward and reverse primer sequences. Start codon is highlighted on the forward 
primer in green and the stop codon on the reverse primer in red. Restriction 
endonuclease sites were incorporated as shown. GC content is approximately 50%.
B) Table demonstrating average primer annealing temperatures- designed to be 
similar for forward and reverse primers to increase PCR efficiency. Gene sequence 
was obtained from published GenBank sequence, the accession number for which is 
provided.
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Figure 7.4 Cloning o f FKBP12.6 by PCR and preparation for ligation into pGEX-6P-1 
vector
A) PCR was used to generate a 340 bp fragment of FKBP12.6 using the standard PCR cycle. 
PCR products were separated on a 3% (w/v) TAE agarose gel by gel electrophoresis. Primers 
used were FKBP12.6F and FKBP12.6R (Figure 7.3) Lane 1, 1 kb DNA marker, sizes are shown 
on the left in base pairs (bp). Lane 2, FKBP12.6 PCR synthesized DNA product.
B) PCR synthesized FKBP12.6 was restriction digested with BamH1 and EcoR1 and PCR 
cleaned to remove residual enzymes and dNTPs. Product was separated on a 3% w/v TAE 
agarose gel by gel electrophoresis. Lane 1, FKBP12.6, estimated at ~60 ng/pl. Lane 2, 1 Kb 
DNA marker with sizes to the right o f gel in base pairs (bp).
C) Circular vector was subjected to a sequential digest and treatment with alkaline phosphatase 
to prevent self annealing. Following alcohol precipitation of the digested vector a 10 pi sample 
was separated on 1% w/v TAE agarose by gel electrophoresis. Lane 1, digested pGEX-6P-1 
vector, quantity estimated at ~240 ng/pl by UV spectrophotometry. Lane 2, Hyperladder I DNA 
marker with sizes shown on the right in base pairs (bp).
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Figure 7.5 Screening for positive FKBP12.6-pGEX-6P-1 
transformed TOP10 colonies
Of the colonies that grew on LB agar with Ampicillin, 5 were selected 
and subjected to a plasmid ‘mini-prep’. Products were digested with 
BamH1 and EcoFU restriction endonucleases and separated on 3% 
w/v TAE agarose by gel electrophoresis. Lane 1, 1 Kb DNA marker 
with sizes shown on the left in base pairs (bp). Lanes 2, 3, 5, 6 show 
minipreps yielding no FKBP12.6-pGEX-6P-1. Lane 4, positive 
miniprep showing correct sized band following restriction digest.
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A BamH1 Start
B FKBP12.6-pGEX-6P-l TCACTCTAA GTTGAG CAGCTC CACGTC AAAGAT GAGGGT GGCATT GGGAGG GATGAC ACC
1 1 1 i 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 I I  1 1 1
BC002614 (463-404)
1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 I I  1 1 1 I I  1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 
TCACTCTAA GTTGAG CAGCTC CACGTC AAAGAT GAGGGT GGCATT GGGAGG GATGAC ACC
FKBP12.6-pGEX-6P-l GGGGTGGCC CGTGGC TCCATA TGCCAC ATCAGG GGTGCA GGTCAG CTTCGC CCTCTGCCC
M I N I M I  I M M M M M I  M I N I  M I N I  M I N I  M I N I  M M M  M M N M
GGGGTGGCC CGTGGC TCCATA TGCCAC ATCAGG GGTGCA GGTCAG CTTCGC CCTCTG CCCBC002614 (403-344)
FKBP12.6-pGEX-6P-l CAAGCTCAT CTGGGC TGCACC CTCTTC AAAACC TTTGAT GACTTC CTGTTT GCCAAT TCT
M M I I I I I  M M M  M M M  M M M  l l l l l l  M M M  M M M  M M M  M M M  I I I
CAAGCTCAT CTGGGC TGCACC CTCTTC AAAACC TTTGAT GACTTC CTGTTT GCCAAT TCTBC002614(343-284)
FKBP12.6-pGEX-6P-l GAACTTGAA AGGTTT GTTTCT GTCTCT GGATGA ATCAAA CTTCTT CCCATT TTGGAG CAT
M M I I I I I  M M M  M M M  M M M  M M M  M M M  M M M  M M M  M M M  I I I
GAACTTGAA AGGTTT GTTTCT GTCTCT GGATGA ATCAAA CTTCTT CCCATT TTGGAG CATBC002614(283-224)
FKBP12.6-pGEX-6P-l TCCTGTGTA GTGCAC CACACA CGTTTG GCCCTT CTTGGG GAATGT CCTTCC GTCTCC GGG
M l l l l l l l  l l l l l l l l l l l l  l l l l l l  l l l l l l  l l l l l l  l l l l l l  l l l l l l  l l l l l l  I I I
TCCTGTGTA GTGCAC CACACA CGTTTG GCCCTT CTTGGG GAATGT CCTTCC GTCTCC GGGBC002614(223-164)
FKBP12.6-pGEX-6P-l GGAGATGGTCTCGATCTCCAC GCCCAT
1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 1 1 1 I I  1 1 1 1 1 1
BC002614(163-137)
I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 1 1 
GGAGATGGT CTCGAT CTCCAC GCCCAT
Figure 7.6 Sequencing o f FKBP12.6-pGEX-6P-1. A) Electropherogram sequencing result. 
BamH1 and EcoR1 restriction sites are highlighted which flank the FKBP12.6 sequence . C- 
protease restriction site is shown to be intact. B) Sequence identity is confirmed by a BLAST 
sequence alignment with FKBP12.6 sequence from the GenBank database (Accession number 
BC002614) showing 100% match.
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FKBP12.6
Figure 7.7 FKBP12.6 expression, GST affinity purification and cleavage of the 
GST tag
FKBP12.6 mini-prep was used to transform competent Rosetta cells. A single positive 
transformant was grown in 1 litre of selective LB broth, protein induced and harvested. 
The resultant pellet was then lysed and the supernatant combined with glutathione 
sepharose. The protocol for 3C cleavage of the GST tag was then followed. Samples 
were analysed on an 18% SDS-PAGE gel to determine protein production and 
purification efficiency. Lane 1, Kaleidoscope protein size markers with approximate 
sizes shown on the left (kDa). Lane 2, cleaved FKBP12.6 (12.6 kDa), GST (26 kDa) 
and 3C-GST (48 kDa) following overnight incubation and prior to separation. Lanes 3 
and 4, eluate containing cleaved FKBP12.6 after filtration of the GST beads. Lane 5, 
washed beads showing GST and 3C-GST but very little FKBP12.6. Lane 6, Undeaveo 
FKBP12.6-GST (38.6 kDa). Lane 7, GST. It is apparent that all proteins, including the 
GST control, are running slightly different to their respective marker. As mentioned in 
chapter 5, the NEB markers used seem to consistently run higher than they should.
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175  ------
8 0 -----
5 8 -----
4 6 -----
3 0 -----
2 3 -----
1 7 ------
7 -----
Figure 7.8 Quantification o f purified cleaved FKBP12.6 and FKBP12.6-GST and western 
blotting
A) Bovine serum albumin (BSA) standards were run alongside FKBP12.6 recombinant proteins 
to provide an estimate o f protein concentration. Samples were run on a 15 % SDS-PAGE gel. 
Lane 1, Kaleidoscope protein size marker, sizes are given on the left (kDa). Lanes 2-7, serial 
dilutions of BSA (66 kDa); 2, 20 pg, 3, 10 pg , 4, 5 pg, 5, 2.5 pg, 6, 1.25 pg, 7, 0.63 pg. Lane 8, 
Cleaved FKBP12.6 (12.6 kDa). Lane 9, FKBP12.6-GST (38.6 kDa). The NEB marker used is 
shown to run high compared with the BSA standards.
B) Neat FKBP12.6 was serially diluted and run on a 15% SDS-PAGE gel. Protein was 
transferred to a PVDF membrane and incubated with anti-FKBP12.6 antibody for 2 hours at room 
temperature to confirm that the recombinant protein was correct. Lane 1, FKBP12.6 at 
approximately 0.25 mg/ ml. Lane 2, FKBP12.6 at approximately 0.5 mg /ml.
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7.2.3 FKBP12.6 effect on RyR2 [3H]ryanodine binding
Low RyR2 yields meant that few experiments were carried out using the recombinant FKBP12.6 
protein, however, a dose response of FKBP12.6 effect on RyR2 [3H]ryanodine binding (section 
2.3.2) was obtained and shown to inhibit binding by approximately 50% at a concentration of 10 
pM. This result was shown to be significantly different (students t-test) from the control without 
FKBP12.6 addition. This effect was also shown to be specific by the addition of FK506 as a 
control, which successfully inhibited the FKBP12.6 effect.
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Figure 7.9 Effect of FKBP12.6 on RyR2 fHJryanodine binding.
FKBP12.6 dose response. Each point represents the mean of 4 RyR2 
preparations. 10 pM  FK506 was added as a control. (*) indicates a significant 
difference (p <0.05, students paired t-test) from the control without FKBP12.6 
addition (Binding in pCa4 is taken as 100%). Bars show standard error.
7.2.4 Cloning of DPc10 into pGEX-6P-1 and optimisation of protein expression.
Primers were designed (Figure 7.10) to amplify the DPc10 sequence from hRyR2 cDNA 
template at ~2 ng/pl using the standard extended PCR cycle (section 2.1.2.2). Figure 7.11 A 
shows the PCR DPc10 amplicon following gel extraction (used instead of PCR clean-up as for
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DP4, section 2.1.2.3) and following a restriction digest with BamH1 and EcoR1 enzymes 
(section 2.1.2.5) to prepare the insert for ligation into pGEX-6P-1 vector (section 2.1.2.6). The 
vector was prepared as previously and a ligation reaction set-up and incubated overnight at 4°C 
with an insert to vector ratio of 10:1. Following transformation of TOP10 E.coli chemically 
competent cells (section 2.1.2.7), 9 colonies grown on selective agar were selected for 
screening by colony PCR (section 2.1.2.8) using the pGEX forward primer and the DPc10 
reverse primer which adds (100 bp) to the size of the expected PCR amplicon. The gel shows 4 
positive PCR products running at approximately the correct size (Figure 7.11B), although each 
appears to be different from the next, therefore the brightest band (lane 2) was grown and mini- 
prepped to extract the plasmid DNA, and this was sent for sequencing (section 2.1.2.10).
The electropherogram (Figure 7.12) shows a correctly in frame DPc10 sequence with BamH1 
and EcoR1 and 3C sites intact. Alignment using BLAST ‘align two sequences’ software 
confirmed 100% match with RyR2 sequence on GenBank. Although mutagenesis primers were 
designed to insert the R2474S CPVT mutation into this peptide, time restraints and an inability 
to obtain sufficient RyR2 for experiments meant that the D P d  0 Quikchange mutagenesis was 
not carried out. Nevertheless, protein expression for the wildtype DPdO  was tested and 
optimised.
Maxi-prep DNA (section 2.1.2.9) containing the D PdO  insert was used to transform chemically 
competent Rosetta bacteria. These were grown overnight on selective Amp-Chlor LB agar, then 
grown in 20 ml of selectable LB broth as a starter culture, before seeding 1 L LB cultures and 
growing at 37°C. The Optical density (OD) of the culture was tracked at A600 every 30 minutes 
until an OD of 0.6 was obtained. At this point the culture was transferred to a 30°C incubator for 
approximately 30 minutes to cool down, before addition of IPTG (final concentration 0.1 mM). 
50 ml samples were removed from the culture every hour for 4 hours, from the time of IPTG 
addition (t=0), bacteria were pelleted and frozen at -20°C for further analysis (section 2.2.2). 
Following thawing of the pellets, bacteria were sonicated in 3 x 30 second bursts on ice to avoid 
over heating of cells. Lysed bacteria were centrifuged to remove unlysed bacteria and debris 
and the supernatant containing protein incubated with PBS washed Glutathione sepharose
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beads to capture the GST tagged peptide for 2 hours at 4°C. Beads were then pelleted using an 
Allegra desk-top centrifuge and washed 3x with 20ml high salt buffer to wash away any excess, 
non-specifically bound protein. A final wash was done with PBS and a sample of the beads was 
added to SDS loading buffer and boiled at 100°C for 1 minute to release protein from the beads, 
before running on a high percentage SDS-PAGE gel (section 2.2.1) for analysis alongside a 
SIGMA wide-range kaleidoscope marker by coomassie staining. This process was repeated 
with an induction temperature of 25°C instead of 30°C to determine whether there was any 
difference in protein expression levels, this was not the case, (Figure 7.11). The coomassie 
stained gels show substantial protein induction at both temperatures, and the protein appears to 
be running at the correct size, a GST control has been run alongside although, as suggested for 
the DP4, the sizes of the GST-DPc10 and the recombinant GST alone will be unresolvable on a 
coomassie gel. There appears to be a double band forming on both gels, it was assumed that 
the upper band corresponds to the GST-DPc10 as the lower band seems to be transcribed 
before the induction period.
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A
DPc10 F (5’-3’ )
Peptide Gene of Interest Genebank Size of
name Accession Amplicon (bp)
Number
DPclOWT hRyR2 X98330 133
Figure 7.10 D P d O  forward and reverse prim er design
A) Forward and reverse primer sequences. Start codon is highlighted on the forward 
primer in green and the stop codon on the reverse primer in red. Restriction 
endonuclease sites were incorporated as shown. GC content is approximately 50%.
B) Table demonstrating average primer annealing temperatures- designed to be similar 
for forward and reverse primers to increase PCR efficiency. Gene sequence was 
obtained from published GenBank sequence, the accession number for which is 
provided.
clam p BamH1 hRyR2
f  V  V -------------------------------------------- >
G ACATG G ATCCG G G TTTTG CCAG ATCACA
clam p EcoR1 hRyR2
( v  \ r  >
TGTGTGGAATTCTCATGGCAGAAAGCCAACCTCA
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Figure 7.11 D P d O  cloning into pGEX-6P-1
A) DPdO forward and reverse primers were used to amplify the desired peptide sequence in a 
standard PCR reaction. PCR product was then subjected to a restriction double digest with Bam H1 
and EcoR1 enzymes and ethanol precipitated. Samples were separated on 3% (w/v) agarose using 
gel electrophoresis. Lane 1, 1 Kb molecular weight size marker, sizes are shown on the left in base 
pairs (bp). Lane 2, DPdO  PCR product before restriction digestion. Lane 3, DPdO post restriction 
digestion and ethanol precipitation. Quantity estimated at ~1 ng/pl.
B) 10 colonies grown on selective LB were selected for screening by colony PCR using pGEX-6P-1 
forward primer and the reverse D PdO  primer. PCR samples were separated on 3% w/v agarose by 
gel electrophoresis. Lane 1, 1 Kb molecular weight DNA size marker, sizes are shown on the left in 
base pairs (bp). Lanes 2, 5, 7 and 10 show positive DPdO-pGEX containing colonies. The pGEX 
forward primer adds on 100 bp to the amplicon size, meaning that a band is seen between the 200 
and 300 bp markers.
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A
BamH1
EcoR1
B DPclO-pGEX-6P-l GGGTTTTGC CCAGAT CACAAG GCAGCC ATGGTT TTATTC CTTGAC AGGGTC TATGGG ATT
I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
X98330 (7496-7555)
I I II II I I I I II II II II I II II II II I II II II I II II I II II I I II I II II II II I II
GGGTTTTGC CCAGAT CACAAG GCAGCC ATGGTT TTATTC CTTGAC AGGGTC TATGGG ATT
DPclO-pGEX-6P-l GAGGTTCAA GACTTC CTCCTC CATCTT CTTGAG GTTGGC TTTCTG CCA
I I 1 1 I I I I I I I I I I I I I I I 1 I I I I 1 I I I 1 I I I 1 I I I I I I I I 1 I I I I 1 I
X98330 (7556-7603)
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GAGGTTCAA GACTTC CTCCTC CATCTT CTTGAG GTTGGC TTTCTG CCA
Figure 7.12 Sequencing of DPc10-pGEX-6P-1.
A) Electropherogram sequencing result. BamH1 and EcoR1 restriction sites are highlighted which 
flank the DPdO sequence. C-protease restriction site is shown to be intact.
B) Sequence identity is confirmed by a BLAST sequence alignment with RyR2 sequence from the 
GenBank database (Accession number X98330) showing 100% match.
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Figure 7.13 DPc10-GST expression optimisation
A) Induction at 3(fC . Samples were taken at hourly intervals and combined with glutathione 
sepharose. Samples were then separated on 15% SDS-PAGE gels. Lane 1, Kaleidoscope 
protein size marker, sizes are shown on the left (kDa). Lane 2, t=0, Lane 3, t=1 hour. Lane 4, t=2 
hours. Lane 5, t=3 hours. Expected GST-DPc10 size is ~31 kDa.
B) Induction at 2&C. Samples were taken at hourly intervals and combined with glutathione 
sepharose. Samples were then separated on 15% SDS-PAGE gels. Lane 1, Kaleidoscope 
protein size marker, sizes are shown on the left (kDa). Lane 2, t=0, Lane 3, t=1 hour. Lane 4, t=2 
hours. Lane 5, t=3 hours. Lane 6, t= 4 hours. Lane 7, GST (26 kDa).
7.3 Discussion
The effects of calcium, ATP and FKBP12.6; physiological modulators of RyR2, on native RyR2 
[3H]ryanodine binding were examined. The FKBP12.6 protein used was successfully cloned, 
produced and purified for experiments as a recombinant protein. DPdO activatory peptide was 
also generated by molecular biology. DPdO will serve as a valuable tool in future RyR2 
experiments aiming to elucidate the mechanism of modulation involved in aberrant RyR2 
function as described for DP4 (chapter 6).
RyR2 channels were found to be functionally active and to respond to calcium in the well 
documented fashion that is a biphasic dose response. Maximal [3H]ryanodine binding was seen 
in pCa4, with channel inhibition at 1 mM free calcium. ATP activation of [3H]ryanodine binding
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was found to be maximal at 1- 2.5 mM ATP but was lower than that for RyR1 (~2-fold rather 
than ~4-fold), suggesting that RyR2 is relatively opened more by calcium than RyR1. 
Phosphorylation was not shown to have any effect on [3H]ryanodine binding, this is consistent 
with previous findings by Jones et al. who suggest that phosphorylation induced channel 
conformational change measurable by kinetic binding experiments to FKBP12/12.6 using 
Biacore, but not seen with [3H]ryanodine binding (Jones, Lai et al. 2006).
ATP was able to increase binding at pCa7 to a greater proportion of the maximal binding than 
calcium alone, consistent with the idea of a calcium independent mode of ATP activation. This 
activation was not evident at pCa8 however, suggesting ATP required a small level of calcium 
activation to exert any effect.
Recombinant FKBP12.6 was shown to inhibit the native RyR2 channel (SR preparation) by 
approximately 50%, reflecting the effect of FKBP12 on RyR1 isolated channels and previous 
findings by other groups. This also further stresses the importance of RyR1 analysis as a 
mediator to RyR2 functionality.
The DPdO  mutant peptide still needs to be cloned using site-directed mutagenesis as for 
DP4M (see chapter 5) and the purification procedure needs to be optimised for both the 
wildtype and mutant peptides. Given the low yield of cleaved DP4 peptide obtained after 
treatment with 3C protease, it may be better to modify the purification protocols using the 
DPdO peptide, which can be tracked using A28o as this peptide contains four phenylalanine and 
one tyrosine residue and therefore the use of FPLC and a UV absorbance monitor can be used. 
It may also be possible to see a band on SDS PAGE coomassie-stained gels. As the peptides 
are the same size, they ought to elute at a similar point on a gel filtration column after 3C 
cleavage, so it may be a case of ‘working blind’ for the DP4 following optimisation with DPdO. 
The FPLC fractions found to consistently contain cleaved DPdO  could be quantified using the 
BCA kit and DP4 presence confirmed using MALDI. The ability to produce significant quantities 
of DPdO  should therefore, greatly assist DP4 purification optimisation and enable further 
studies with these peptides and their mutants in the very near future.
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CHAPTER 8: Discussion
The domain interaction hypothesis (Yamamoto, El-Hayek et al. 2000) was originally tested 
using homologous domain peptides. These were proposed to insinuate between the interacting 
domains and disrupt the natural association, resulting in channel activation. This effect has 
been observed in a number of experimental models, including single channel studies using 
artificial lipid bilayers (Shtifman, Ward et al. 2002; Murayama, Oba et al. 2005), SR (Shtifman, 
Ward et al. 2002; Kobayashi, Yamamoto et al. 2004; Murayama, Oba et al. 2005; Oda, Yano et 
al. 2005; Bannister, Hamada et al. 2007) and whole cell analysis (Lamb, Posterino et al. 2001; 
Yang, Ikemoto et al. 2006; Tateishi, Yano et al. 2009). In particular, a domain interaction 
between the N-terminus and the central domain coincident with disease causing mutation 
clusters for MH/CCD in skeletal muscle and CPVT/ARVD in cardiac muscle has been described 
using DP4 and D P dO  peptides respectively.
Our previous work has lead to a hypothesis of convergent regulation where a number of key 
regulators of RyR function are proposed to act in concert on a defined region of conformational 
change (Blayney, Jones et al. 2010). Circumstantial evidence suggests that the central domain 
may participate in the regulatory events described in our studies (Yamamoto, El-Hayek et al. 
2000; Kobayashi, Yamamoto et al. 2004; Liu, Wang et al. 2010). To determine whether this is 
so, this investigation has explored the use of DP4 in our experimental system. This investigation 
has provided data which further our understanding of the modulation of RyR function in the 
aberrant calcium handling characteristic of RyR1 (MH and CCD) and RyR2 (CPVT and HF) 
related disorders.
8.1 The domain interaction hypothesis
The original experiments supporting this hypothesis involved the use of domain peptides and 
their Abs to activate RyR (Kobayashi, Yamamoto et al. 2004). A recent study using FRET 
probes has advanced this work further (Liu, Wang et al. 2010). FRET can take place between 
two fluorescent proteins if they are within -1 0  nm of each other. By insertion, through cloning, 
of the sequence for two probes into the same DNA strand within the N-terminus (YFP- yellow 
fluorescent protein) and central domains (CFP- cyan fluorescent protein) of recombinant RyR2
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and expressing the protein in HEK cells, the proximity of the two domains could be examined 
under experimental conditions. Using ATP, DPdO, caffeine and DP4 to activate RyR the two 
domains were ‘unzipped’ and FRET diminished, whereas dantrolene, which stabilises the 
domain interaction (Kobayashi, Bannister et al. 2005) could reverse their effects. By cloning the 
two probes individually and transfecting both into HEK cells, heterologous assembly of RyR 
tetramers occurred. If it was an intra-domain interaction then no FRET should be visible 
because the two FRET reporters would not be within the same subunit and thus too far apart. If 
the natural conformation was the N-terminus of one subunit interacting with the central domain 
of the next then some of the heterologous tetramers could assemble with a FRET partner in an 
adjacent subunit and a FRET signal should be visible. The latter was shown to be the case and 
so an inter-subunit interaction was proposed (Liu, Wang et al. 2010).
This is an exciting prospect in terms of RyR regulation. MH and CPVT are usually heterozygous 
with one normal and one gene containing the mutation (Lehnart, Mongillo et al. 2008; Grievink 
and Stowell 2010). If both are expressed at the same time then heterologous assembly of RyR 
tetramers is a possibility which may explain the RyR instability. If just one mutation failing to 
interact correctly with a partner domain could cause a perturbation in channel gating then 
perhaps occupation of one modulator site per sub unit, or one subunit being phosphorylated, 
could be sufficient to fully modulate a channel. This might explain how the RyR molecule is able 
to cope with so many modulators and sub optimal occupancy of all four subunits (Blayney and 
Lai 2009). In this regard, -10-20%  occupancy by FKBP12.6 has recently been suggested to be 
the physiological norm for RyR2 in mouse and rat hearts (Guo, Cornea et al. 2010). Although 
the authors suggest this shows that FKBP12.6, despite its high affinity, is not an important 
regulator of RyR2 function, this could also be interpreted as an indication of the ability of 
subsaturation FKBP12.6 binding to be sufficient to modulate RyR, especially in light of inter­
subunit interactions (Liu, Wang et al. 2010), which may mean one FKBP12.6 molecule bound to 
one RyR subunit is sufficient to exert effect on not only all 4 subunits of RyR, but also 
neighbouring RyR channels. An array of RyR molecules which form the functional unit may be 
made up of two different homotetramers, some W T and the others mutant, where the mutant 
channels are capable of disrupting the function of neighbouring wildtype channels through inter­
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subunit interaction. The role of RyR/RyR molecular interactions, termed coupled gating, may 
then contribute to the underlying phenotype (Marx, Gaburjakova et al. 2001).
8.2 Mode of action of DP4/ DPc10
The aim of this study was to test known physiological modulators of the RyR1/ RyR2 channel, in 
the presence of the activatory domain peptides DP4/DPc10 or disease specific mutant forms, 
with a view to ascertain a potential region of convergent regulation (Figure 1.12).
The key experiment to confirm this idea of convergent regulation would be to test the effect of 
DP4/DPc10 on the kinetics of FKBP12/12.6 association with RyR1/ RyR2 using SPR as in 
previous experiments (Blayney, Jones et al. 2010) and under different conditions of channel 
activation. Before these experiments can be carried out it is necessary to determine the effect of 
DP4/DPc10 on the open probability of the channel under compatible experimental conditions, 
for example, the effects of the mutant peptides in the presence of calcium, FKBP12/12.6, 
magnesium and phosphorylation. Additional experiments using the physiological modulator ATP 
are included as this, like the DP4 peptide, is able to activate the RyR channel over and above 
the level achieved by calcium alone (Laver, Lenz et al. 2001). In order to establish these 
baseline parameters, [3H]ryanodine binding experiments were used to measure the open 
probability, a valuable technique since ryanodine binds to the open state of the channel 
(Meissner 1992).
This is the first study that has used synthesized DP4 peptides from an independent source, and 
compared them to those from the Ikemoto group, who first proposed the domain interaction 
hypothesis (Yamamoto, El-Hayek et al. 2000). The DP4WT peptide synthesized by Severn 
Biotech and that gifted from Ikemoto both gave the same responses in this study. Both 
increased open probability by 200% and their effects were inhibited by magnesium, which is 
supported by the current literature (Yamamoto, El-Hayek et al. 2000; Murayama, Oba et al. 
2005). In the presence of DP4WT, inhibition by 10 pM FKBP12 was -50% , which is the 
maximum effect seen at that concentration in the absence of the peptide. This was observed for 
both DP4WT peptides used and this is a novel finding. The effect of phosphorylation on these
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parameters has yet to be explored. It can be concluded that the peptides are acting, overall, in 
the manner anticipated by previous experiments. Experiments using the IK-DP4 have a low (n) 
(Figures 6.5- 6.7) due to limited availability, therefore this data needs to be viewed with caution, 
but it is encouraging to see similar activation levels to those seen with the Severn Biotech WT 
peptide where the (n) was higher.
The mutated peptide used in this study activated to the same extent as the wildtype. However, 
the inhibition of this effect by magnesium and FKBP12 was not as pronounced. This finding has 
resulted in a detailed examination of the use of these peptides as experimental tools, and the 
interpretation of the experimental results. The activation seen by DP4WT does not dispute the 
domain interaction hypothesis. However the validity of the mutant peptide as a mimic of the 
disease state, and as a necessary control for experiments, is called into question (Yamamoto, 
El-Hayek et al. 2000). This finding immediately suggests that the single mutation in the 
corresponding DP4 region of RyR1, is not singly able to prevent RyR stabilisation as a cause of 
aberrant calcium signalling. This has some implications for interpretation of many of Ikemoto's 
studies involving the DP4W T and DP4M peptides. The conundrum of the mutant peptide 
activation has necessitated consideration of a number of factors; source of the peptides, 
potential effects of the mutation on peptide structure and physical properties, and also the 
relative physical properties of the DP4WT and DP4M peptides. A number of central domain 
mutations have been tested in the DP4 peptide in the Ikemoto studies, these have been 
compared and it is clear that the mutations did not necessarily eliminate the activatory 
properties of the peptide, but most were less active than the wildtype. However, their relative 
solubilities have not been compared, though this has been raised as an issue in some papers 
(Bannister, Hamada et al. 2007) and considered in the discussion of chapter 5.
NMR spectroscopy has provided a backbone structure for the DP4WT peptide but DP4M could 
not be concentrated sufficiently to obtain similar data (Bannister, Hamada et al. 2007), however, 
Abs to these peptides do bind to native RyR suggesting that a similar structure is preserved 
(Kobayashi, Yamamoto et al. 2004). The affinity of DP4 for the RyR1 (KD50 -  100 pM 
(Yamamoto, El-Hayek et al. 2000) is considerably lower than, for example FKBP12 affinity for
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RyR1 (Kd -0.01 pM -  1nM) (Jones, Reynolds et al. 2005) as shown by the concentrations 
required for any observable effect. This low affinity interaction between peptides and their 
interacting native domain may reflect the necessity of the native domains to move apart and 
reform rapidly as the channel gates. Perhaps, with this in mind, phosphorylation of the RyR 
channel would result in lower concentrations of DP4 required to give a comparable effect on 
channel opening due to the lower threshold that needs to be overcome to push the channel 
open. The link between the action of DP4 with respect to phosphorylation has not yet been 
assessed by any other groups but would be especially interesting given the changes in affinity 
to FKBP noted by Jones et al in their Biacore studies (Jones, Reynolds et al. 2005).
8.3 Purified RyR preparations
This study, using purified RyR preparations, shows a consistently lower activation magnitude by 
DP4WT peptide compared to previous studies (Murayama, Oba et al. 2005; Bannister, Hamada 
et al. 2007) using whole SR microsomal preparations (2-fold increase rather than 4-fold). The 
reason for this difference is not clear. Isolation of the channels from the SR membrane will 
considerably alter the immediate environment surrounding any one channel. The microdomain 
environment of the RyR within the SR microsomal membrane maintains the 
compartmentalisation of cytoplasm and lumen (Meissner 2002). It is possible that the native 
RyR arrays within the SR environment will contribute to the stability of the channels and provide 
a more durable backdrop for studies of conformational change. Thus when using the peptides 
in this environment there may be a greater magnitude of the change. This may be lost for 
isolated channels. However, to speculate on this point would be to over interpret the difference.
Using SR in experiments means that alteration of one parameter can change others. For 
example, phosphorylation would upregulate phospholamban and increase SERCA activity and 
calcium flux. In addition, SR preparations generally include FKBP12/12.6, which binds very 
tightly to the RyR (Jayaraman, Brillantes et al. 1992). Endogenous phosphorylation is rarely 
accounted for and nor is the FKBP12/12.6 content of SR preparations. It is not easy to examine 
differences in terms of the model and the experimental protocols and draw firm conclusions.
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The DP4WT peptides (from the two different sources) behaved similarly, both were solubilised 
in DMSO and the 5% which was carried into the assays was accounted for in the controls. The 
only difference in the response to the DP4WT is the magnitude and not the dose response 
characteristics nor characteristics of inhibition, so although the difference was noted, it would 
appear that the peptide was acting to interfere with the domain interaction in our solubilised 
preparations in a similar manner to its action in SR preparations.
Bannister et al have shown a significantly reduced level of activation with the R2458C mutant 
DP4 peptide compared with the wildtype, but this is actually still increasing ryanodine binding by 
approximately 2 fold (Bannister, Hamada et al. 2007). Given that the magnitude of DP4 
activation, seen in our study, at 100 pM was only ever 2 fold compared with the control, it is 
perhaps not surprising that there was no difference in the DP4WT and mutant activation level. If 
solubilised RyR preparations had shown greater activation by the DP4WT peptide, there would 
have been a noticeable difference in effect. It may be the case therefore, that the use of DP4M 
as a control and model of MH in RyR1 is only really revealed using whole SR RyR preparation, 
as this somehow enables full DP4W T activation.
The intended goal, involving kinetic interactions studies using SPR (Jones, Reynolds et al.
2005), requires a preparation of RyR in solution. The value of this experimental technique is that 
the biochemical and protein modulators regulating the RyR molecule are limited by isolation, 
and key modulators of the channel, FKBP12/12.6 and phosphorylation can be carefully 
controlled. The solubilisation protocol, for example, is used to strip FKBP12/12.6 from the native 
protein. We have previously characterised these preparations (Jones, Reynolds et al. 2005; 
Blayney, Jones et al. 2010). The RyR preparations used in this study are similar in that they 
showed a typical biphasic dose response to free calcium concentration. There were differences 
in the phosphorylation profile as discussed in chapter 3 but changing the 
phosphorylation/dephosphorylation protocols enabled phosphorylated and dephosphorylated 
preparations to be obtained comparable to previous experiments. ATP had not been used in 
previous [3H]ryanodine binding experiments on isolated RyR and we found that the magnitude 
of activation by ATP (about -400% ) in our preparations was comparable with those in the
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literature for SR vesicles (Laver, Lenz et al. 2001). In general the results for DP4WT are as 
expected in terms of the published concentrations required to activate RyR preparations and the 
inhibition predicted by the addition of 0.5 mM magnesium (Yamamoto, El-Hayek et al. 2000). In 
addition we found that DP4W T channel activation was inhibited by the channel modulator 
FKBP12.6.
Thus we are left to consider whether there is something odd about our batch of DP4M peptide 
and this requires further experimental investigation by comparison with another source of 
mutant peptide. The mutant peptide activation was indistinguishable from the wildtype and it 
was inhibited by magnesium and FKBP12 in the same manner but not to the same extent. As 
the WT and mutant peptides were synthesized by the same supplier it is unlikely that the 
process of synthesis would affect the mutant alone. Unfortunately we were unable to obtain any 
mutant peptide from the Ikemoto group to enable comparison of its effect in our experimental 
model.
To enable further investigation of the mutant peptide from an alternative source, recombinant 
peptides were produced ‘in house’, and although the GST-tagged DP4WT and DP4M peptides 
had no notable effect on [3H]ryanodine binding, the cleaved wildtype peptide (without the GST 
tag) had an activatory effect equivalent to both the Ikemoto wildtype and the synthetic peptide 
tested at 10 pM. The low (n) obtained for experiments with the recombinant peptide (Figure 6.8) 
means no strong conclusions can be drawn from this data, however the preliminary results are 
promising given the similar level of activation to other peptides tested in this study. To further 
assess this peptide, the purification strategy needs to be refined so greater yields are available 
for experiments. The DP4M peptide also has a different pi to the DP4WT, and therefore would 
require a different purification protocol. Solubility of both peptides has yet to be determined but 
the high concentrations needed for experiments at 100 pM (~4 mM stock concentration) may 
result in solubilisation difficulties (Bannister, Hamada et al. 2007).
The ability to produce this domain peptide in house would greatly increase the opportunities for 
RyR channel analysis as this would provide a consistent and constant source. In house
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purification means the proteins will be fresh and treated as mildly as possible to increase the 
validity of results generated. It is also important to obtain large yields for future analysis of 
FKBP12 binding using SPR experiments.
8.4 RvR1 as a surrogate for RvR2
Our experiments employ a strategy of showing conformational changes and their modulators in 
RyR1 and using key experiments to show that the mechanism is similar for RyR2. The validity of 
using RyR1 as a surrogate for RyR2 is supported by the many similarities between the two 
isoforms. The overall amino acid sequence of the two isoforms share 66% homology. Both 
isoforms exist as homotetramers and are associated with much smaller accessory proteins such 
as FKBP12/12.6 and calmodulin present as four molecules per receptor, i.e. one per sub unit 
(Meissner 2002). Topology models have shown the same overall structure with the cytoplasmic 
and transmembrane domains and indeed, the mutational clusters found to be associated with 
the conditions MH and CCD in RyR1 are directly translated into the same clusters for the RyR2- 
linked pathologies, CPVT and HF (Orlova, Serysheva et al. 1996; Serysheva, Schatz et al. 
1999; Lobo and Van Petegem 2009). Most MH carriers exhibit a normal range of skeletal 
muscle function although patients with the more severe CDD phenotype have some muscle 
weakness and structural changes in skeletal myocyte contractile protein architecture 
(Denborough 1998). This range of symptoms is mimicked in CPVT and ARVD with the latter 
showing fatty streaks in the right ventricle. Both conditions require a trigger to unmask the life- 
threatening symptoms. For skeletal muscle it is halothane anaesthetics that destabilise RyR1 to 
trigger MH (Girard, Treves et al. 2002). In cardiac muscle fatal arrhythmias are triggered by 
physical and emotional stress and the heart performs normally at rest (Brini 2004). The trigger in 
cardiac myocytes (and also experimentally for RyR1) is linked to phosphorylation (Marx, Reiken 
etal. 2001).
Mutations manifest in both isoforms as increased sensitivity to calcium and activatory ligands 
such as polylysine. The DP4 activatory peptide for RyR1, corresponding to a portion of the 
central domain ‘hot spot’ for mutations, has also been shown to activate RyR2, suggesting the 
same regulatory domain interaction (Yamamoto, El-Hayek et al. 2000; Yamamoto and Ikemoto
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2002; Liu, Wang et al. 2010). Both channels are also known to be modulated by 
phosphorylation by both PKA and CaMKII and are responsive to calcium and magnesium ions, 
although the extent of the sensitivity to these ions has been proposed to differ between the two 
isoforms in single channel studies (Meissner 2002). Full activation of both RyR1 and RyR2 is 
also only seen in the presence of ATP. Both channels show sensitivity to the same 
pharmacological modulators, the plant alkaloid ryanodine binds specifically to the open channel 
of both isoforms and the antiarrhythmic drug K201 has also been suggested to stabilise both 
channels (Meissner 2002; Lehnart, Wehrens et al. 2003; Wehrens, Lehnart et al. 2005; Blayney 
and Lai 2009). In addition, treatment of rodent HF models with the drugs K201 and S107, 
previously linked to enhanced FKBP12.6 binding to RyR2, has been shown to result in 
improved skeletal muscle function suggesting a similar mechanism of modulation by these 
drugs of the binding of FKBP12/12.6 to RyR1/2 (Bellinger, Reiken et al. 2008).
LCCs are voltage sensitive channels present in t-tubules at the junctional face membrane of the 
SR and communicate with both RyR1 and RyR2, as part of the signal transduction of ECC. 
However, as mentioned in the introduction, there is a key difference in the way the signal is 
transmitted to the RyR from the LCC for the two isoforms. RyR1 relies on direct allosteric 
modulation by the LCC, where RyR2 receives a trigger calcium signal across the dyadic cleft 
without any direct physical interaction and activation is amplified by CICR. RyR2 may have 
evolved earlier than RyR1 (Tunwell, Wickenden et al. 1996) so it may be that the allosteric LCC 
interaction with RyR1 is a later development, particularly as RyR1 can be activated 
experimentally by cytoplasmic calcium in the same way as RyR2 (Meissner 2002). One other 
notable difference is the possible reduced affinity of calcium binding to CaM bound to RyR2, 
compared with CaM bound to RyR1. This was proposed by one group given that the RyR2 
inhibition by calcium-CaM was ten-fold lower than that of the RyR1 isoform (CaM acts to both 
inhibit and activate the RyR channel, with calcium binding turning on the inhibitory mode as 
cytoplasmic calcium rises) (Rodney, Williams et al. 2000; Puceat 2010).
In terms of RyR structure and conformational regulation the channels, once activated by their 
respective means, may behave in very similar ways. Using RyR1, which being more abundant,
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can be extracted in greater quantities, to establish experimental protocols and explore definitive 
experimental approaches has been a necessary and valid strategy for our experimental 
approach to studies aligning function with conformational change. Key experiments have been 
chosen to establish that the basic concepts apply to both isoforms (Jones, Reynolds et al. 2005; 
Blayney, Jones et al. 2010). The difficulty in obtaining large yields of purified RyR2 may limit the 
extent to which those experiments carried out on RyR1 can be repeated on the cardiac isoform 
in future work. However a different batch of hearts may provide greater RyR2 yields, especially 
if the source was more controlled. Using the purification protocols tested in this study, enough 
protein was available to carry out some key experiments once the preliminary data with RyR1 
had been obtained. An increased RyR2 yield would be necessary to carry out more thorough 
analysis of recombinant DPdO  peptide on the native RyR2. To this aim, further purification 
optimisation is required for the RyR2, perhaps alternative animal sources may generate greater 
yields or changes in the purification protocol may need to be developed and tested so the ratio 
of RyR that is extracted from the native tissue is increased compared with that lost in the 
solubilisation stages.
8.5 Do the findings using DP4 peptide support our hypothesis of convergent regulation?
The model of convergent regulation has been proposed as a unifying idea accounting for the 
combined regulation of RyR by phosphorylation, FKBP12/12.6, magnesium, K201 and domain 
interaction. It was the intention to test this model using DP4 and D PdO  peptides to determine 
whether the conformational change observed previously corresponded to the central domain. 
Circumstantial evidence suggests the central RyR domain may be a key site of convergent 
regulation. DP4 has been shown to reduce magnesium inhibition (Yamamoto, El-Hayek et al. 
2000) . This has been demonstrated previously by other groups and also within this 
investigation. The proposed PKA phosphorylation sites (S2030 and S2808) flank the central 
domain region(Wehrens, Lehnart et al. 2006; Xiao, Tian et al. 2007), and the K201 binding site 
coordinate is close to the central domain and proposed to bind to it (Yamamoto, Yano et al. 
2008).
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The finding that domain activation by DP4 can be inhibited by FKBP12 modulation is particularly 
interesting. The Kj needs to be established with a dose response to FKBP12 to determine 
whether the affinity for FKBP12 is altered by the activatory peptide. Interestingly, the FKBP12 
dose response observed with [3H]ryanodine binding in the presence of ATP has shown a shift to 
the right, suggesting FKBP12 is less effective in the presence of ATP. Although 50% inhibition 
was the maximal effect observed by FKBP12 with ATP, as seen in the presence of calcium 
alone, the EC50 was shifted from 0.1 pM to 1 pM, a 10 fold difference. ATP did not feature in the 
original model, however, it is well known that calcium alone cannot instigate full channel 
opening (Xu, Mann et al. 1996; Laver, Lenz et al. 2001). Thus it may be that ATP causes a 
further conformational change from the level of maximal calcium activation. Perhaps DP4 is 
acting in a similar fashion to ATP in forcing a final conformation movement required for full 
activation of the channel.
Previous SPR experiments have shown a reduced affinity of RyR for FKBP12 in the presence of 
ATP, which is consistent with this idea (Jones, Reynolds et al. 2005). Further experiments, 
using the Biacore technique, as suggested earlier, could be used to measure the affinity of RyR 
binding to FKBP12, in real time in the presence of the channel modulators DP4 or ATP to see if 
this conformational change is consistent with a further decrease in FKBP12 affinity.
Another novel finding of this study has shown the effects of magnesium and FKBP12 on 
channel inhibition to be additive. This could be accounted for by FKBP12 binding to the RyR 
and inducing a conformational change which closes the channel and in the process revealing 
the magnesium inhibition site(s) giving magnesium access to its site of regulation, and hence 
exerting an additional inhibitory effect. This would be consistent with the model and with the 
findings of others proposing the masking and unmasking of magnesium inhibition sites (Laver, 
Baynes et al. 1997; Blayney, Jones et al. 2010). It may also be consistent with ATP binding 
sites being masked as the channel closes, during the same transition (Dias, Szegedi et al.
2006).
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PKA phosphorylation had no notable effect on [3H]ryanodine binding, apart from on magnesium 
inhibition. This supports the idea that phosphorylation may poise the channel between the open 
and closed states (Jones, Lai et al. 2006) to enable faster movement to a fully open state under 
conditions of |3-adrenergic stimulation. These findings all serve to complement and add to the 
convergent regulation hypothesis, as documented prior to this investigation.
To continue with these experiments it is now necessary to determine the effects of 
phosphorylation, and with more peptide, proceed to the kinetic measurements. The tools are 
also now in place to enable parallel experiments with the RyR2 isoform.
8.6 Further work
• Optimise cleavage from the GST tag and improve purification protocols for the cleaved 
DP4WT and DP4M so that an alternative source of mutant peptide can be tested in our 
experimental model.
•  Ascertain whether the reduced effect of DP4 activation seen in our model is an artefact
of the isolated RyR by carrying out parallel experiments with SR preparations from the
same source as the isolated channels. These preparations must be stripped of
endogenous FKBP12 and dephosphorylated in the same manner as the isolated RyR.
• Generate the D P dO  mutant peptide and optimise purification of the wildtype and 
mutant peptides, possibly in parallel to DP4 as D PdO  can be tracked more easily.
• Test the peptide effect in relation to phosphorylation, essentially using SPR to assess
the affinity for FKBP12 in the presence of DP4 and phosphorylation.
• Test alternative central domain mutations for comparative effects.
• Perform [3H]ryanodine binding and SPR experiments to assess DPdO activation on
isolated RyR2.
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8.7 Conclusion
In summary, the data provided in this thesis have shown the following;
The DP4 peptide is able to increase RyR1 channel opening above that induced by calcium 
alone, suggesting interruption of the central and N-terminus interaction does increase the 
isolated RyR1 channel open probability, but to an amount less than observed by ATP. In 
addition ATP has been shown to reduce RyR1 sensitivity to FKBP12 inhibition, these findings 
point to another potential conformational change induced by ATP over and above those 
proposed in our original model which may be measured as a reduced affinity for FKBP12.
The DP4 activatory effect on RyR1 may be reduced in isolated RyR channels, compared with 
RyR channels in intact SR membrane preparations, suggesting additional modulation by a 
factor outside the experimental model used. If this is true then the use of the DP4 mutant 
peptide as a mimic of the disease state is only valid in an SR experimental model. Alternatively, 
a single base mutation inserted into the DP4 peptide may not be sufficient to prevent channel 
activation, and hence is not an accurate interpretation of the disease state.
FKBP12 and magnesium inhibition of RyR1 is reduced by the DP4 peptide, also, FKBP12 and 
magnesium inhibition of RyR1 are additive, supporting the idea that a conformational change 
induced by FKBP12 may unmask a magnesium binding site.
In addition, the tools are now in place to enable further assessment of these findings using SPR 
to assess changes in RyR1 binding affinity for FKBP12 with DP4 and the other modulators 
tested in this investigation. Subsequent studies can also be pursued using the RyR2 isoform, 
the DPdO peptide and its CPVT mutant to ascertain whether the same model of convergent 
regulation applies to RyR2 modulation. This is of great significance for future studies regarding 
RyR1/2 dysfunction in arrhythmias linked to MH and CPVT respectively.
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APPENDIX
Expasv Proteomics Results
http://www.expasv.ch/tools/protparam.html - Protein parameter computation tool.
RyR1. Rabbit skeletal muscle
Accession number: P11716 
Number of amino acids: 5037 
Molecular weight: 565252.7 
Theoretical pi: 5.16
A m in o  a c i d  
c o m p o s i t i o n :
Ala (A) 394 7.80%
Arg (R) 298 5 . 90%
Asn (N) 170 3 .40%
Asp (D) 254 5.00%
Cys (C) 100 2 . 00%
Gin (Q) 200 4 . 00%
Glu (E) 483 9 . 60%
Gly (G) 367 7.30%
His (H) 132 2 . 60%
H e (I) 197 3 . 90%
Leu (L) 561 11.10%
Lys (K) 227 4 . 50%
Met (M) 146 2 . 90%
Phe (F) 207 4 .10%
Pro (P) 270 5.40%
Ser (S) 282 5.60%
Thr (T) 223 4 .40%
Trp (W) 65 1 .30%
Tyr (Y) 142 2 . 80%
Val (V) 319 6.30%
Pyl (0) 0 0 . 00%
Sec (U) 0 0 . 00%
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RyR2. Human cardiac muscle
Accession number: Q92736 
Number of amino acids: 4965 
Molecular weight: 564741.9 
Theoretical pi: 5.87
A m in o  a c i d  
c o m p o s i t i o n :
Ala (A) 304 6.1%
Arg (R) 261 5.3%
Asn (N) 191 3.8%
Asp (D) 279 5.6%
Cys (C) 92 1.9%
Gin (Q) 198 4.0%
Glu (E) 400 8 .1%
Gly (G) 302 6.1%
His (H) 144 2 . 9%
H e (I) 234 4 . 7%
Leu (L) 550 11.1%
Lys (K) 318 6.4%
Met (M) 160 3.2%
Phe (F) 225 4.5%
Pro (P) 197 4 . 0%
Ser (S) 360 7.3%
Thr (T) 221 4.5%
Trp (W) 63 1.3%
Tyr (Y) ,166 3.3%
Val (V) 300 6.0%
Pyl (0) 0 0.0%
Sec (U) 0 0 . 0%
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FKBP12. Rabbit 
Accession number: P26943
Sequence:
GPLGSMGVQV ETISPGDGRT FPKRGQTCW HYTGMLEDGK KFDSSRDRNK PFKFMLGKQE 
VIRGWEEGVA QMSVGQRAKL TISPDYAYGA TGHPGIIPPH ATLVFDVELL KLE
Number of amino acids: 113 
Molecular weight: 12362.1 
Theoretical pi: 8.08
A m in o  a c i d  
c o m p o s i t i o n :
Ala (A) 5 4.4%
Arg (R) 6 5.3%
Asn (N) 1 0 . 9%
Asp (D) 6 5.3%
Cys (C) 1 0.9%
Gin (Q) 5 4.4%
Glu (E) 7 6.2%
Gly (G) 15 13 .3%
His (H) 3 2 . 7%
H e (I) 5 4.4%
Leu (L) 8 7 .1%
Lys (K) 8 7 .1%
Met (M) 4 3 . 5%
Phe (F) 5 4.4%
Pro (P). 8 7 .1%
Ser (S) 6 5.3%
Thr (T) 7 6.2%
Trp (W) 1 0.9%
Tyr (Y) 3 2.7%
Val (V) 9 8 . 0%
Pyl (0) 0 0 . 0%
Sec (U) 0 0 . 00%
FKBP12.6. Human
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Accession number: P68106 
Sequence:
GPLGSMGVEI ETISPGDGRT FPKKGQTCW HYTGMLQNGK KFDSSRDRNK PFKFRIGKQE 
VIKGFEEGAA QMSLGQRAKL TCTPDVAYGA TGHPGVIPPN ATLIFDVELL NLE
Number of amino acids: 113 
Molecular weight: 12193.9 
Theoretical pi: 8.64
A m in o  a c i d  
c o m p o s i t i o n :
Ala (A) 6 5.3%
Arg (R) 5 4.4%
Asn (N) 4 3.5%
Asp (D) 5 4.4%
Cys (C) 2 1.8%
Gin (Q) 5 4.4%
Glu (E) 7 6.2%
Gly (G) 15 13 .3%
His (H) 2 1. 8%
H e (I) 6 5.3%
Leu (L) 8 7 .1%
Lys (K) 9 8 . 0%
Met (M) 3 2 . 7%
Phe (F) 6 5.3%
Pro (P) 8 7 . 1%
Ser (S) 5 4.4%
Thr (T) 8 7 .1%
Trp (W) 0 0 . 0%
Tyr (Y) 2 1. 8%
Val (V) 7 6.2%
Pyl (0) 0 0.0%
Sec (U) 0 0 . 0%
Domain peptide 4 (DP4WT). Rabbit skeletal muscle
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Sequence:
G P L G S L IQ A G  KGEALRIRAI LRSLVPLDDL VGIISLPLQI P
Number of amino acids: 41 
Molecular weight: 4274.1 
Theoretical pi: 8.74
A m in o  a c i d  
c o m p o s i t i o n :
Ala (A) 3 7 3%
Arg (R) 3 7 3%
Asn (N) 0 0 0%
Asp (D) 2 4 9%
Cys (C) 0 0 0%
Gin (Q) 2 4 9%
Glu (E) 1 2 4%
Gly (G) 5 12 2%
His (H) 0 0 0%
H e (I) 6 14 6%
Leu (L) 9 22 0%
Lys (K) 1 2 4%
Met (M) 0 0 0%
Phe (F) 0 0 0%
Pro (P) 4 9 8%
Ser (S) 3 7 3%
Thr (T) 0 0 0%
Trp (W) 0 0 0%
Tyr (Y) 0 0 0%
Val (V) 2 4 .9%
Pyl (0) 0 0 .0%
Sec (U) 0 0 0%
Domain peptide 4 mutant (DP4M). Rabbit skeletal muscle
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Sequence:
GPLGSLIQAG KGEALRIRAI LCSLVPLDDL VGIISLPLQI P 
Number of amino acids: 41 
Molecular weight: 4221.1 
Theoretical pi: 6.11
A m in o  a c i d  
c o m p o s i t i o n :
Ala (A) 3 7.3%
Arg (R) 2 4.9%
Asn (N) 0 0.0%
Asp (D) 2 4.9%
Cys (C) 1 2.4%
Gin (Q) 2 4 . 9%
Glu (E) 1 2.4%
Gly (G) 5 12 .2%
His (H) 0 0.0%
H e (I) 6 14.6%
Leu (L) 9 22 . 0%
Lys (K) 1 2.4%
Met (M) 0 0.0%
Phe (F) 0 0.0%
Pro (P) 4 9.8%
Ser (S) 3 7.3%
Thr (T) 0 0.0%
Trp (W) 0 0 . 0%
Tyr (Y) 0 0.0%
Val (V) 2 4 . 9%
Pyl (0) 0 0.0%
Sec (U) 0 0 . 0%
GST-tagged domain peptide 4 (GST-PD4WT). Rabbit skeletal muscle
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Sequence:
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID
GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV
DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD W L Y MDPMCL DAFPKLVCFK
KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD L E V L F Q G P L G  SL IQ A G K G E A
L R IR A IL R S L  V P L D D L V G II  S L P L Q IP
* Underlined is DP4 sequence
Number of amino acids: 267
Molecular weight: 30686.8
Theoretical pi: 5.92
A m in o  a c i d  
c o m p o s i t i o n :
Ala (A) 13 4.9%
Arg (R) 12 4.5%
Asn (N) 4 1. 5%
Asp (D) 20 7.5%
Cys (C) 4 1.5%
Gin (Q) 8 3.0%
Glu (E) 18 6 . 7%
Gly (G) 19 7 .1%
His (H) 6 2.2%
H e (I> 19 7 .1%
Leu (L) 38 14 .2%
Lys (K) 22 8.2%
Met (M) 9 3.4%
Phe (F) 10 3.7%
Pro (P) 17 6.4%
Ser (S) 12 4.5%
Thr (T) 6 2.2%
Trp (W) 4 1.5%
Tyr (Y) 14 5.2%
Val (V) 12 4.5%
Pyl (0) 0 0.0%
Sec (U) 0 0.0%
GST-tagged domain peptide 4 mutant (GST-DP4M). Rabbit skeletal
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Sequence:
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID
GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV
DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD WLY M D P M C L  DAFPKLVCFK
KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LEVLFQGPLG SLIQAGKGEA
LRIRAILCSL VPLDDLVGII SLPLQIP
* Underlined is DP4M sequence 
Number of amino acids: 267 
Molecular weight: 30633.8 
Theoretical pi: 5.75
A m in o  a c i d  
c o m p o s i t i o n :
Ala (A) 13 4 . 9%
Arg (R) 11 4 .1%
Asn (N) 4 1.5%
Asp (D) 20 7 . 5%
Cys (C) 5 1. 9%
Gin (Q) 8 3 . 0%
Glu (E) 18 6.7%
Gly (G) 19 7 .1%
His (H) 6 2.2%
H e (I) 19 7 .1%
Leu (L) 38 14 .2%
Lys (K) 22 8.2%
Met (M) 9 3 .4%
Phe (F) 10 3 . 7%
Pro (P) 17 6.4%
Ser (S) 12 4 . 5%
Thr (T) 6 2.2%
Trp (W) 4 1. 5%
Tyr (Y) 14 5.2%
Val (V) 12 4 . 5%
Pyl (0) 0 0 . 0%
Sec (U) 0 0 . 0%
Central domain peptide 10 sequence (DPc10). Human cardiac
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Sequence:
GPLGSGFCPD HKAAMVLFLD RVYGIEVQDF LLHLLEVGFL P
Number of amino acids: 41 
Molecular weight: 4515.3 
Theoretical pi: 4.80
A m in o  a c i d  
c o m p o s i t i o n :
Ala (A) 2 4 . 9%
Arg (R) 1 2.4%
Asn (N) 0 0 . 0%
Asp (D) 3 7.3%
Cys (C) 1 2.4%
Gin (Q) 1 2.4%
Glu (E) 2 4.9%
Gly (G) 5 12 .2%
His (H) 2 4.9%
H e (I) 1 2.4%
Leu (L) 8 19 . 5%
Lys (K) 1 2.4%
Met (M) 1 2.4%
Phe (F) 4 9.8%
Pro (P) 3 7.3%
Ser (S) 1 2.4%
Thr (T) 0 0 . 0%
Trp (W) 0 0.0%
Tyr (Y) 1 2.4%
Val (V) 4 9.8%
Pyl (0) 0 0 . 0%
Sec (U) 0 0.0%
Central domain peptide 10 mutant (DPclOM). Human cardiac
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Sequence:
GPLGSGFCPD HKAAMVLFLD SVYGIEVQDF LLHLLEVGFL P 
Number of amino acids: 41 
Molecular weight: 4446.2 
Theoretical pi: 4.42
A m in o  a c i d  
c o m p o s i t i o n :
Ala (A) 2 4 . 9%
Arg (R) 0 0.0%
Asn (N) 0 0.0%
Asp (D) 3 7.3%
Cys (C) 1 2.4%
Gin (Q) 1 2.4%
Glu (E) 2 4 . 9%
Gly (G) 5 12 .2%
His (H) 2 4 . 9%
H e (I) 1 2.4%
Leu (L) 8 19.5%
Lys (K) 1 2.4%
Met (M) 1 2.4%
Phe (F) 4 9 . 8%
Pro (P) 3 7.3%
Ser (S) 2 4 . 9%
Thr (T) 0 0.0%
Trp (wj 0 0 . 0%
Tyr (Y) 1 2.4%
Val (V) 4 9.8%
Pyl (0) 0 0 . 0%
Sec (U) 0 0.0%
*ln relevant sequences, the GPLGS region (residual from MCS of pGEX-6p-1) is highlighted in 
bold.
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